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Abstract
Bone Morphogenetic Proteins (BMPs) are members of the Transforming Growth 
Factor-P (TGF-B) signalling protein superfamily. BMPs play important and diverse 
roles in cell-cell signalling, including establishing cell fate during the development 
of vertebrate embryos. Their activity is antagonised in vivo by a number of proteins 
such as noggin, which sequester BMP ligands, preventing them from binding to 
BMP receptors. This thesis describes studies to establish a binary genetic approach 
combined with a ligand trap system to manipulate BMP signalling in the frog 
embryo. This system has been used to investigate the roles of BMP signalling in 
dorso-ventral patterning of the forebrain in Xenopus tropicalis.
The binary system described utilises a variety of tissue- or region-specific 
gene promoters to drive expression of the GAL4 transcriptional activator. Such 
transgenic "driver" lines can be crossed with a "responder" line in which expression 
of a membrane-tethered fusion protein comprising human Noggin fused to GFP is 
regulated by a synthetic promoter responsive to GAL4 (UAS-flognog).
Transient expression assays confirmed the effectiveness of the "responder" 
line, GAL4 transactivation of UAS-flognog resulted in the expression of Flognog 
and an expansion of neural progenitor tissue, indicated by the X-Sox3 marker. In a 
binary cross with the Otx2-gal4 driver line, targeted GAL4 transactivation lead to a 
decrease in phospho-Smad-1 staining in the anterior CNS and eye in a proportion of 
cross embryos. Such a cross resulted in embryos showing an open neural tube and 
alterations in both Pax6 (dorsal) and X-dll3 (ventral) forebrain markers, further 
indicating the efficacy of the binary, ligand-trap strategy.
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In order to achieve temporal control on the activity of the UAS-flognog 
responder line in the telencephalon, an inducible driver line comprising the Pax6 
promoter driving hormone-inducible GalPR (an inducible chimeric GAL4) was 
created. In binary crosses with a UAS-gfp reporter line, GFP expression was 
detected in the forebrain, hindbrain and spinal cord only in the presence of the 
steroid hormone, RU486. Similarly, a second driver line, N-tubulin-GalPR yielded 
inducible GFP expression in the developing brain, spinal cord and lens tissue in the 
presence of RU486.
In conclusion, these findings are evidence that the binary ligand trap 
approach is functional and can cause targeted knockdown of BMP signalling, 
resulting in alterations in neural development and patterning. Furthermore, using an 
inducible version of this approach, Flognog (or any other target gene) can be 
expressed in the telencephalon in a RU486-inducible manner.
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CHAPTER Is GENERAL INTRODUCTION
1.1 Introduction
The aim of this study was to gain insight into the basic dorsal patterning 
mechanisms that act to define neuronal subdivisions in the vertebrate forebrain. If 
disrupted, these mechanisms are ultimately involved in many disorders, one of which is 
holoproscencephaly (HPE). This disorder is characterised in its most severe form by the 
cerebral hemispheres failing to separate completely into two distinct halves, as well as a 
lack of olfactory bulbs and a common ventricular system. It is the most common 
developmental anomaly of the human forebrain, occurring in 1 in 10,000 live births, 1 in 
250 conceptions. Although this is primarily a deficit in development of the ventral 
midline of the forebrain, dorsal signalling alterations have been implicated in this 
disorder. Understanding the mechanism(s) of dorsal patterning of the forebrain, and its 
possible consequences on other tissues, is therefore essential for the development of 
therapies.
The strategy employed here to investigate these mechanisms was to use stable 
transgenic lines in Xenopus together with a spatio-temporally controlled Ligand trap 
system, containing extracellular negative regulators of signalling molecules. This 
system enabled the roles of signalling pathways involved in neural patterning to be 
studied.
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1.2 Transgenesis in Xenopus
An advance in research has been the development of transgenesis in Xenopus 
(Kroll and Amaya, 1996). This transgenic technique, which is called Restriction 
Enzyme Mediated Integration (REMI) transgenesis, was originally used in X.laevis, and 
involved the incubation of sperm nuclei with linearised plasmid DNA, the subsequent 
incubation in restriction enzyme (the same enzyme used to linearise the plasmid DNA) 
and egg extract (to decondense the sperm chromatin), and this resulted in the enzyme- 
mediated integration of DNA into decondensed sperm nuclei in vitro. The nuclei are 
then transplanted into the unfertilised egg. This approach enabled stable, spatio- 
temporally controlled expression of cloned gene products (dictated by the promoter 
construct) in targeted cells of Xenopus embryos. Although this original technique was 
successful, it was quite demanding and resulted in transgene integration at four to eight 
sites with 5 to 15 plasmid DNA copies. Further modifications of the transgenic 
procedere were then implemented in an attempt to make the technique easier and 
enhance survival of the transgenic embryos (Sparrow et al., 2000; Offield et al., 2000; 
Browder, 2002; Hirsch et al., 2002). To simplify the method of generating transgenic 
Xenopus, restriction enzyme was excluded from the original transgenic procedure to 
minimise damage to the chromosomes (Sparrow et al., 2000). Also, partial sperm 
decondensation by egg extract was omitted from the procedure. These alterations 
resulted in the same or better numbers of viable embryos with the correct transgene 
expression.
The REMI transgenesis method (Kroll and Amaya, 1996) was further 
modified both in X.laevis and in X.tropicalis (Offield et al., 2000). It was identified that
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the major factors involved in survival of early cleavage stage embryos were egg quality 
and the de-jellying procedure and for later stage embryos (after gastrulation) it was the 
amount of egg extract used (and not the use of restriction enzyme). Thus, the 
modifications included the reduction in the amount of egg extract used to decondense 
the sperm nuclei to one sixth of the amount in the original REMI strategy. Also, MOH 
(see Table A) was used as injection buffer in place of sperm dilution buffer (SDB). 
DTT was used to de-jelly rather than cysteine. Eggs were partially de-jellied and a 
lower injection volume was used. These modifications resulted in a higher amount of 
transgenic embryos that survived to tadpole stages, and better overall long-term 
survival. Also, these modifications resulted in transgene integration at a single locus 
most of the time. Subsequently, egg extract was also heated to denature any harmful 
proteins that may lead to defects in development (Browder, 2002). Heated egg extract 
resulted in even better long-term survival.
Hirsch et al. (2002) made a number of modifications to the original transgenic 
procedure by Kroll and Amaya (1996) and used X.tropicalis. These modifications 
enhanced the efficiency of the technique even further. These included the use of oocyte 
extract instead of egg extract, the omittion of the plasmid backbone from the transgene 
DNA, and also a combination of previous modifications, such as a better method for 
preparation of sperm nuclei (Huang et al., 1999), the elimination of restriction enzyme 
from the transgenesis reaction (Sparrow et al., 2000) and the partial de-jellying of eggs. 
It was found that the use of oocyte extract to decondense nuclei was better than heated 
egg extract. When heated egg extract was compared against oocyte extract for survival 
of transgenic embryos, oocyte extract was found to be much more effective at promoting
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viability of transgenic embryos as assayed by a higher percentage of perfect neurulae. 
The alterations that were made to the sperm preparation protocol were to separate 
diploid cell nuclei from haploid sperm nuclei and to use digitonin for membrane 
solubilisation to limit chromosomal damage. Also, when promoter reporter constructs 
with and without vector sequence were assayed for reporter expression, the use of 
transgene DNA without vector sequence was found to produce expression mostly in 
promoter driven areas, whereas embryos transgenic for the promoter reporter contract 
with vector resulted in ectopic expression outside promoter driven areas in the majority 
of embryos. This result indicated that the elimation of vector sequence from the 
transgene DNA was needed to avoid ectopic transgene expression. Additionally, it was 
found that partial de-jellying affords some protection to the embryos by limiting the 
influx of extracellular Ca2+ ions through the hole made by transplantation. All these 
alterations resulted in a higher proportion of normal transgenic embryos that reached 
adulthood compared to the unmodified transgenesis technique (Kroll and Amaya, 1996).
Many different transgenesis techniques have been developed in Xenopus since 
then, including <|)C31 integrase, I-Scel meganuclease-mediated integration and Tol2 
transposon-mediated transgenesis (Allen and Weeks, 2005; Ogino et al., 2006; Hamlet 
et al., 2006). These techniques were developed to increase the amount of normal 
transgenic F0 embryos (Allen and Weeks, 2005; Ogino et al., 2006), and to use for 
insertional mutagenesis techniques and germline transgenesis (Hamlet et al., 2006).
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1.3 Stable Transgenic Lines in Xenopus
Stable transgenic lines can be made and used as in vivo reporters or to 
manipulate gene expression at later stages of development (Offield et al., 2000). 
X.tropicalis has been demonstrated to share similar developmental characteristics to X. 
laevis, allowing staging morphological criteria, probes and techniques to be adapted to 
X.tropicalis (Khokha et al., 2002). Furthermore, many transgenic lines have been made 
in X. tropicalis due to its short generation time (Offield et al., 2000; Hirsch et al., 2002). 
In the transgenics, the reporter transgenes behave as dominant alleles and segregate in 
simple Mendelian ratios. Analysis of these ratios in transgenic progeny can 
occasionally be complicated by the presence of two or more integration sites, however 
one integration site is usual and makes analysis simpler (Hirsch et al., 2002). Every 
transgenic founder (F0) has unique site(s) of integration and different copy numbers 
(and occasionally different numbers of transgene integration sites), as well as defects 
from the transgenic procedure (Hartley et al., 2002). This results in variable transgene 
expression levels and patterns and, sometimes, suppressed transgene expression, due to 
the transgene being hidden in heterochromatin or other position effects. Therefore, it is 
essential to screen through founders to make stable populations containing the same 
transgene integration and expression levels.
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1.4 Transcriptional Binary Systems and Other Techniques for 
Controlled Gene Expression in Xenopus
As transgenesis has been adapted to Xenopus, this has permitted the binary 
GAL4/UAS system, which is widely used in Drosophila, to be used in Xenopus (Fischer 
et al.f 1988; Brand and Perrimon, 1993; Phelps and Brand, 1998; Hartley et al., 2002; 
Chae et al., 2002). The advantage of this system is that it can be used to control gene 
transcription in living animals and it allows spatio-temporal manipulation of gene 
expression. This makes possible conditional manipulation of gene function at later 
stages of development, and avoids the lethality and pleiotropy associated with 
manipulation of gene function, including transgene expression on its own, or expression 
of lethal genes at early stages of development by other techniques, such as 
microinjection. The system is based on the generation and use of two distinct transgenic 
lines. One line is a transcriptional activator, which contains the coding sequence for the 
yeast transcriptional activator, GAL4, driven by a temporally and/or spatially regulated 
promoter element, and the other line is the effector, which carries the gene of interest 
fused to the target sequence of GAL4, upstream activating sequence (UAS). Upon a 
cross of the two lines, in the resulting progeny, there is transcription of target gene in 
cells expressing GAL4 and any phenotypic consequences can be studied (Brand and 
Perrimon, 1993).
The ability to express a gene in a directed fashion is a useful means of 
analysing its role in development. By targeted mis-expression of genes, the GAL4/UAS 
system can be used to investigate processes, such as cell fate alterations, cell-cell 
signalling and in vivo analysis of embryos or phenotypes. The system also offers
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flexibility to transgenesis, as already characterised GAL4 or UAS lines can be used in 
numerous combinations to assess different biological processes. Furthermore, the 
GalPR/UAS inducible mis-expression technique has been used in Xenopus (Wang et al., 
1994; Chae et al, 2002), and this allows temporal (including inducible), as well as 
spatial control over mis-expression. GalPR is a chimeric protein containing a ligand- 
binding domain for a steroid analogue, RU486, the DNA binding domain of GAL4, and 
the transactivation domain from VP16. In a cross of a promoter-GalPR transactivator to 
a UAS-target gene effector, upon binding of RU486 to GalPR, GalPR escapes 
cytoplasmic sequestration, allowing translocation of the complex to bind UAS motif, 
and to activate transcription of target genes (Chae et al, 2002). This approach permits 
RU486-inducible, tissue-specific transgene expression. By manipulating the RU486 
concentration, the transgene expression level may be manipulated, thus allowing 
correlation of transgene expression levels with the induced biological response.
In addition to the above techniques for controlled gene expression, use of 
other methods to knock down expression or activity of specific genes have been 
investigated. Recent studies using gene silencing in Xenopus laevis by DNA vector- 
based RNA interference and transgenesis has demonstrated that transgene-driven RNAi 
could specifically and stably inhibit protein expression from a GFP transgenic line at 
later stages of development (Li and Rohrer, 2006). However, this technique is 
complicated by the problem that RNAi did not completely inhibit GFP expression, 
suggesting that it is not a good technique for strong knock-down of gene function. This 
emphasises the importance of finding the right knockdown technique for loss-of- 
function experiments.
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1.5 Neural Morphology in Xenopus
I.5.1 Early Neural Morphogenesis
The beginning of the neural plate can be distinguished morphologically by the 
differentiation of the sensorial layer of the dorsal ectoderm (neuroectoderm), as it begins 
to elongate and form columnar epithelium (in cells lateral to the dorsal midline) (at stage
II.5, mid-gastrula) (Hausen and Riebesell, 1991). Cells are transformed into a latero- 
medial organisation in the neural plate and the midline of the neural plate is occupied by 
the floorplate. There is no sharp boundary between neuroectoderm and lateral 
epidermal ectoderm. The forebrain arises from the anterior neuroectoderm.
By stage 12.5 to 13 the neural plate has segregated and becomes 
morphologically distinct as a thickened layer of neuroepithelial cells (several cell layers 
thick) (Fig. 1.1) (Hausen and Riebesell, 1991). These cells are the embryonic precursor 
of the brain. The neuroepithelium has been specified as prosencephalic tissue. 
Subsequently, this specified tissue undergoes a process known as transformation, 
whereby the tissue is specified along the A-P axis into mesencephalic, rhombencephalic 
and spinal cord tissues (Nieuwkoop, 1952). There are more cell proliferation and 
morphogenetic movements (Hartenstein, 1993) and then, assisted by the formation of 
medial and lateral hinge points during neurulation, the neural plate rolls up and by stage 
20 forms a dorsal hollow neural tube (Nieuwkoop and Faber, 1994). As neural tube 
formation progresses, a group of superficial cells lateral to the bottle cells (bottle-shaped 
cells derived from epithelial cells that form the neural groove) form the roof plate, a 
medial group of dorsal midline glial cells, which is later covered by lateral ectoderm
27
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Figure 1.1 Xenopus Neural Developent and BMP expression
A. Pictures depict whole Xenopus embryos and the development time to the respective stages at 25 degrees Celsius for X.tropicalis (Khokha et al., 2002), 
from left to right, dorsal view of early neurula (Stage 13), anterior and then dorsal view of late neurula (Stage 19), lateral and then dorsal view of tailbud 
embryos (at Stages 24 and 25 respectively). Black arrows point to the proscencephalon (Adapted from Nieuwkoop and Faber, 1994). B. Picture on left 
of prosencephalic (pr) neural plate depicting the location of expression of BMPs in the non-neural ectoderm. Picture on right depicts section through the 
telencephalon of adult Xenopus, indicating the location of expression of BMPs (red) in the roof plate (rp). The dorsal telencephalon consists of the roof 
plate, the medial pallium (MP), the dorsal pallium (DP), lateral pallium (LP), ventral pallium (VP). The ventral telencephalon, the subpallium, consists 
of the lateral ganglionic eminences (LGE) and the medial ganglionic eminences (MGE) (Adapted from 
Shimamura and Rubenstein, 1997; Campbell, 2003). A, anterior; D, dorsal; L, lateral; M, medial; P, posterior; V, ventral; bp, basal plate; ap, alar plate; 
pep, prechordal plate; me and rh, mes-or rhombencephalic; nc, notochord; ec, non-neural ectoderm; anr, anterior neural ridge
migrating medially (Hausen and Riebesell, 1991). The movements of the different 
regions of the neural plate during neural tube closure also reveal a pattern in the medio- 
lateral direction at this stage. Neural tube closure is terminated when the edges of the 
lateral ectoderm fuse to form a continuous cover of ectoderm over the neural tube, 
which completely detaches from the neural tube at stage 21.
1.5.2 Brain Morphogenesis
Xenopus brain contains the same major compartments as other vertebrates. The 
brain has divided into the archencephalic and deuterencephalic region by stage 21 and 
the cephalic flexure in the form of the retro-infundibular fold formation occurs 
(Niewkoop and Faber, 1994). Ventricular formation makes progress and the 
archencephalic ventricle elongates dorso-ventrally, as well as widens. At stage 22, in 
the anterior, there is a series of ring-like constrictions, which mark the boundaries 
between the forebrain, midbrain and hindbrain (pros-, mes-, and rhomb-encephalon). 
The proscencephalon, which is the most anterior region of the CNS, segregates into the 
dorsally positioned telencephalon, telencephalic vesicle and eyes, and the more caudally 
located diencephalon (Rubenstein and Shimamura, 1998). At this stage, the brain 
ventricle is enlarged and the prosencephalon ventricular cavity extends through the 
prospective optic stalk into the eye vesicles, as two symmetrical ventricles at the end of 
the neural tube (Niewkoop and Faber, 1994). The roof plate extends along the A-P axis 
with its rostral extent covering the most posterior dorsal area of the telencephalon. It is 
medially invaginated in between the bulk of the telencephalic tissue, two cerebral 
hemispheres. The roof itself may only be one cell diameter thick and forms part of the
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telencephalic epithelium. There is a rapid further progress of internal organisation of the 
brain that occurs from stage 23 to 28 (Fig. 1.1).
Fate mapping studies have revealed that most of the areas of the brain derive 
from the neural plate, and much of the telencephalon, ventral forebrain, and dorsal brain 
stem derives from the anterior neural ridge in the stage 15 Xenopus embryo (Eagleson 
and Harris, 1990; Shimamura et al., 1995; Eagleson et al., 1995). The lateral and 
dorsal telencephalic primordia are located in the antero-lateral neural plate. The roof 
regions of the brain extend into the corresponding part of the lateral neural ridge. The 
most dorsal neural structure, the pineal gland, is derived from the lateral neural plate and 
partly from the ridge, whilst the ventral brain structures derive from the medial plate. 
The ventral telencephalon is derived from medial anterior neural plate. Also, more 
rostral brain regions derive from more anterior parts of the neural plate than more caudal 
regions. Overlapping regions of the neural plate give rise to overlapping regions of the 
brain, consistent with cell division, but not migration playing a major role in brain 
morphogenesis. The cell movements that do accompany neurulation are patterned 
deformations that do not introduce topological alterations.
1.6 The Role of Inhibition of BMP Signalling in Induction of Neural 
Tissue in Xenopus
The CNS initially develops from the dorso-medial region of the embryonic 
ectoderm, in a process known as neural induction, and requires the active repression of 
BMP (Bone Morphogenetic Protein) signals, which is carried out by the BMP 
antagonists, chordin, noggin and follistatin produced by the embryonic organizer, as
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well as FGF and IGF activity (Pera et al., 2003; Delaune et al., 2005), and other signals 
(Glinka et al., 1997; Piccolo et al., 1999). During gastrulation, these signals from the 
involuting dorsal mesoderm induce the adjacent and overlying ectoderm to become 
neural plate (CNS primordium).
The transforming growth factor-p (TGF-p) superfamily of secreted ligands 
contains a number of structurally-related proteins. BMPs belong to the TGF-p 
superfamily, as do other ligands, such as TGFp’s (TGFp is the original protein from the 
superfamily that was found to be capable of inducing a transformed phenotype in non­
neoplastic cells in culture), GDFs, Nodals and Activins (Miyazawa et al., 2002). BMPs 
were originally identified for their ability to induce ectopic bone formation when 
introduced subcutaneously in mammals (Urist et al., 1979). Since then, BMP signalling 
has been found to be important in regulating many processes such as early embryonic 
patterning, organogenesis, tissue homeostasis, cell fate decisions, cell proliferation, 
differentiation and cell death (Reviewed by Chen et al., 2004; Mehler et al., 1997). In 
some tissues BMP-related ligands are known to be involved in the generation of specific 
cell types (Shah et al., 19%; Lee et al., 1998), but many act in a redundant manner, 
possibly due to similarities in structure and function (Dudley et al., 1997; Solloway et 
al., 1998). BMPs (or inhibition of BMPs) are essential for the development of various 
tissues, including the heart, lung, kidneys, limb cells, the gametes and the nervous 
system (Reviewed by Chen et al., 2004).
The need for BMP inhibition as a major part of the mechanism in neural tissue 
formation was elucidated in a series of studies. In transplantation experiments, tissue 
from the dorsal side of a Xenopus embryo was transplanted to the ventral side, and this
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induced the formation of neural tissue (Spemann and Mangold, 1924). This indicated 
that signals from the tissue on the dorsal side of the embryo are needed to induce neural 
tissue. This dorsal tissue is the Organiser. The Organiser is dorsal blastopore lip tissue, 
which gives rise to notochord and prechordal mesoderm tissue. It is called the 
Organiser because it can induce host’s ventral tissues to change their fate, not only to 
form neural tube, but also somites (dorsal mesodermal tissue). Subsequently, Noggin 
was cloned from a LiCl-dorsalised gastrula cDNA library, and shown to produce ectopic 
neural tissue when expressed on the ventral side of the embryo (Smith and Harland, 
1992; Smith et al., 1993). Also Noggin was found to induce neural fate in dorsal 
ectoderm (Lamb et al., 1993). Further experiments demonstrated that Noggin is a BMP 
antagonist (Zimmerman et al., 19%). Other experiments revealed that embryonic 
ectodermal cells that are exposed to high BMP levels develop as epidermis, whereas 
cells exposed to low BMP levels develop as neural ectoderm (Wilson and Hemmati- 
Brivalou, 1995; Chitnis et al., 1999). Furthermore, the organizer molecules, such as 
Chordin and Noggin, which are expressed in the axial mesoderm, act as competing 
neuralising factors with the epidermalising activity of BMP to pattern the ectoderm 
along the dorso-ventral axis (Sasai et al., 1994; Piccolo et al., 19%). Thus, there is a 
morphogen gradient of BMP signalling that specifies epidermal versus neural fate.
Is there a similar mechanism for neural induction in other vertebrates? In 
zebrafish mutants for the bmp2 and bmp7 or Smad genes, embryos are dorsalised with 
an expansion of the neural plate and have ventral defects, whereas mutants for chrd, 
which encodes a BMP antagonist, result in ventralised embryos with a reduced size of 
the neural plate, but with normal CNS patterning (Schulte-Merker et al., 1997; Hild et
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al., 1999; Kishimoto et al., 1997; Dick et al, 2000). Thus, Chordin is needed for proper 
neural development. It has also been reported in mouse that inhibition of BMP 
signalling has a role in neural induction (Di-Gregorio et al., 2007). Thus inhibition of 
BMP signalling plays a role in neural tissue formation across vertebrates.
1.7 The Bone Morphogenetic Protein (BMP) Signalling Pathway
How do BMPs signal? BMPs act by a cell signalling pathway mechanism. The 
BMP signalling pathway initiates when homo- or heterodimers of BMP ligands bind to 
type II and type I Ser/ Thr kinase receptors and then heterodimerize to form a tetramer 
complex of these receptors (Fig. 1.2) (Shi and Massague, 2003; Heldin et al., 1997). 
The type II receptor phosphorylates a serine or threonine on the type I receptor (GS 
domain) and type I receptor phosphorylates receptor-Smad proteins, Smadl, Smad5 or 
Smad8, at carboxyl-terminal SS(V/M)S consensus motifs and thus activates them 
(Heldin et al., 1997). Activated Smads 1, 5 or 8 bind to the co-factor Smad4 (common 
Smad4) and translocate as a complex to the nucleus where they regulate target gene 
transcription. The oligomeric Smad complexes regulate target gene transcription 
through interaction with various transcription factors and transcriptional coactivators 
and corepressors. The target genes then execute further sequential molecular events 
(Reviewed by Miyazono, 2002; Miyazono et al., 2005).
There are different BMP sub-families based on similarities in structure and 
function (Kawabata et al., 1998), and these include the BMP2/4 sub-group, which 
contains BMP2, BMP4 and the Drosophilia decapentaplegic (dpp) gene product. The
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Figure 1.2 The Bone Morphogenetic Protein Signalling (BMP) Pathway
Diagram illustrates the mechanism of action of BMPs/GDFs and their regulation. BMP 
signalling initiates when homo- or heterodimers of BMP ligands bind to type II and type I 
Ser/ Thr kinase receptors and then heterodimerize to form a complex. The type II receptor 
phosphorylates a Ser or Thr on the type I receptor. The type I receptor phosphorylates 
receptor-Smads, such as Smad-1, at a SS(V/M)S motif. Activated, Smads, such as Smad-1 
bind to the co-Smad, Smad4, and translocate to the nucleus where they regulate transcription 
of target genes, such as Msx-1, Bmprll, BMP4 and Ids (Figure adapted from Altmann and 
Brivanlou (2001)).
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OP-1 sub-group (known as OP-1 sub-group due to its members being closely 
structurally-related to osteogenic protein-1 (OP-1), a protein known to induce bone 
formation (Sampath et al., 1990)), which contains BMP5, BMP6, BMP7 (also known as 
OP-1), BMP8 and Drosophila gbb60A product, and the GDF-5 sub-group which 
contains GDF-5, 6 and 7. BMPs bind to three distinct type I receptors, which include 
ALK2, ALK3/BmprIA, and ALK6/BmprIB and they also bind to three distinct type II 
receptors, which include Bmprll, ActRIIA and ActRIIB (Shi and Massague, 2003; 
Heldin etal., 1997).
Different TGFp superfamily ligands bind with differing affinities to different 
type I and type II receptors and activate signal transduction through the specific 
activation of different members of Smad family proteins (Miyazono, 2002). Most 
BMPs bind to three distinct type II receptors, Bmprll, ActRIIA and ActRIIB. Bmprll is 
specific for BMPs, whereas ActRIIA and ActRIIB are shared by activins and BMPs. Of 
the type I receptors, there is more specificity, BMP2 and BMP4 preferentially bind to 
BmprlA and BmprIB, whereas the OP-1 sub-group bind to ALK-2 and BmprlB. The 
GDF-5 sub-group bind to BmprIB, but not the other type I receptors (Miyazono, 2002). 
The activin/TGFp pathway induces Smad2 and Smad3 signals (Faure et al, 2000). 
Activin cannot induce phosphorylation of Smad-1, but BMP4 and BMP7 can induce 
phosphorylation of Smad2, indicating activation of the activin/TGFp pathway by BMPs. 
Mostly, however, the BMP/Smad-1 and the activin/TGFp pathways only converge by 
the common use of co-Smad and I-Smads. Ligands in the TGFp superfamily are active 
as dimers, and the subunit composition of these molecules can dramatically affect 
signalling activity (Hazama et al., 1995; Suzuki et al., 1997; Nishimatsu and Thomsen,
35
1998). The activity of BMP heterodimers is more potent than homodimers (Suzuki et 
al., 1997; Nishimatsu and Thomsen, 1998).
There are different mechanisms of BMP signalling regulation. BMP signalling 
can be positively regulated by Smads regulating their own activation. Smads can either 
directly or through interactions with other transcription factors bind to regulatory DNA 
sequences and positively regulate BMP genes. For example, these interactions can 
regulate a subset of BMP target genes, the BMP4 synexpression group (Karaulanov et 
al., 2004). The synexpression group is set of genes that share similar expression profiles 
in some biological processes. The promoter elements in this group include, the BMP- 
responsive element, bre7 (which is important for the synexpression), SBEs (Smad 
binding elements) and Smad-cofactor. Consequently, for example, BMP4 can regulate 
expression of the Bmp4 gene, as well as its receptor Bmprll (among other target genes 
too, such as Ids and Msx-1) (Fig. 1.1). BMP signalling can also be negatively regulated 
by various mechanisms. BMP signalling can be inhibited by extracellular antagonists, 
such as Noggin, Chordin, Follistatin and Cerberus, which act by preventing BMPs from 
binding to their receptors (Zimmerman et al., 1996; Miyazono, 2000; Massague and 
Chen, 2000). Moreover, BMP signalling can regulate these antagonists (Gazzerro et al., 
1998; Piccolo et al., 1997), thereby modulating the strength and duration of its own 
signal. Noggin is induced by BMPs in rat osteoblastic cell cultures (Gazzerro et al., 
1998). Also, Xolloid (a BMP1 homolog), a secreted metalloprotease, can activate BMP 
signalling by cleaving Chordin and releasing active BMPs (Piccolo et al., 1997). 
Therefore different parts of the BMP signalling pathway are subjected to either positive 
or negative regulation.
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At different stages of neural development and in different parts of the CNS, 
BMPs act to regulate cell fate, proliferation and differentiation.
1.8 Forebrain Patterning
BMPs (among other molecules) are involved in forebrain patterning during both 
its early and late stages of formation (Shimamura and Rubenstein, 1997; Furuta et al., 
1997). The morphological processes of development after (and during) the initial 
induction of neural tissue involve molecular and cellular activities occurring either in the 
neuroectoderm itself or exerting forces and spatial constraints from the outside. The 
molecular and cellular activites include transcription factors, morphogens (graded 
signals capable of inducing at least two distinct cell types at different concentrations) 
and lateral inhibition mechanism, which are involved in defining the neural precursor 
cell fate and/or neuronal differentiation, as well as pattern. Patterning is the process by 
which cells in separate regions of an embryo become different and is essential for 
establishing the spatial organisation of the developing embryo. Through this and other 
processes cells acquire their fate, and depending on the stage of development and the 
competence of the responding tissue these cell fates can be transformed. Formation of 
forebrain pattern in vertebrate embryos entails the specification of regional cell fates 
along the anterior-posterior (A-P), dorso-ventral (D-V) and left-right (L-R) axes, 
initially during gastrulation (Reviewed by Rubenstein et al., 1998; Altmann and 
Brivanlou, 2001). Two co-ordinated but partly independent patterning mechanisms 
assign positional information along the A-P and D-V axes, with the A-P axis preceding 
D-V axis formation. Patterning occurs during neural induction stages in gastrulation
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through to the formation of the mature forebrain. The location where a particular cell is 
generated sets down its developmental potential. This has been indicated by 
transplantation and grafting experiments, and fate mapping studies, altering the 
orientation of neural tube tissue (Simon et al., 1995; Graff et al., 1989; Eagleson and 
Harris, 1990). For example, in neural tube grafts whereby the dorso-ventral axis was 
inverted and transplanted to a different A-P position along the neuraxis, cell types 
differentiated in a D-V position according to their host rather than the original graft D-V 
axis (Simon et al., 1995). However, the change in cell fate was restricted to the 
repertoire characteristic of their original A-P origin. Thus, at this stage, precursor cells 
had been assigned a fate, but remained multipotent in their choice of specific cell type. 
This experiment indicated that D-V values at this stage were still labile, whereas the A-P 
values were fixed.
During initial development of the forebrain, the anterior neural tissue (forebrain 
and midbrain fate) acquires its unrefined initial regional identity by avoiding exposure to 
caudalising factors, Wnt, FGF and retinoids (Reviewed by Altmann and Brivanlou, 
2001; Cox and Hemmati-Brivanlou, 1995; Lamb and Harland, 1995; Blumberg et al., 
1997). A-P pattern indicated by position-specific gene expression is subsequently 
conferred to the neural plate soon after neural plate formation by the exposure to these 
caudalising factors. In Xenopus the early patterning of the nervous system can be 
visualised by position-specific expression of developmental regulatory genes, such as 
OtxA (forebrain), and Krox20 (hindbrain) (Lamb et al., 1993; Nieto et al., 1992). The 
initial A-P regionalisation and growth also establishes local organising centres, the 
anterior neural ridge, or anterior neural boundary and the midbrain-hindbrain boundary
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(ANR or ANB and MHB) in the neural plate (Shimamura and Rubenstein, 1997; 
Houart et al., 1998; Reviewed by Rhinn and Brand, 2001). The ANR, for example, 
induces the telencephalon and patterns the tissue along the anterior-posterior axis 
(Shimamura and Rubenstein, 1997). Using mouse neural plate explants it was found 
that Fgf8 signals from the ANR to induce Bf-1 expression. Also, signals, such as 
inhibitors of BMPs and Wnts or Shh and TGF(3’s from the prechordal mesendoderm 
have been shown to induce anterior neural fate and also anterior ventral neural fates in 
the neural plate (Kiecker and Niehrs, 2001). Thus, as the forebrain initially forms, 
signalling molecules and transcription factors combine to specify the identity and fate of 
cells in each of its regions. The mechanisms that drive regional patterning (early 
regionalisation of the prosencephalic neural plate) occur by interactions between the 
embryonic germ layers and embryo tissue before neural tube closure. The centres 
further define initial regional pattern and lead to the sub-division of neuronal regions in 
the mature CNS (Shimogori et al., 2004). A-P patterning generates transverse zones 
with differing competence to longitudinal and local inductive signals, this divides the 
anterior brain into subdivisions named prosomeres (adapted from neuromeres) (Puelles, 
1995; Puelles and Rubenstein, 1993). These subdivisions can be recognised according 
to both histological and molecular criteria and correspond to the functional forebrain 
structures in the adult Distinct programs of differentiation are implemented in different 
prosomeres as a result of differential fate specification between and within the 
prosomeres. The diencephalon (the more posterior) includes prosomeres P1-P4, and the 
telencephalon (the more anterior) includes prosomeres P5 and P6.
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In addition to these transverse domains, patterning along the medio-lateral (M-L) 
axis generates longitudinally aligned domains (alar, basal, and floor plate). M-L (and 
then D-V) patterning occurs later than A-P patterning, and is set up by its response to 
inductive signals provided by specialised cellular groups that act as organising centres. 
In Xenopus, these include, vertical signals from different regions of the involuting 
mesendoderm of the organiser, the ADE (anterior dorsal endoderm) and possibly the 
adjacent ADME (anterior dorsal mesendoderm) during gastrulation neural inductive 
processes (Lupo et al., 2002). Signals from these tissues have been reported to be 
responsible for proper dorso-ventral patterning of the telencephalon. When explanted 
neuralised dorsal ectoderm from stage 10.5 embryos was recombined with ADE 
fragments, the stage 30/31 recombined tissue expressed emx-1 (a dorsal telencephalic 
marker), whereas expression of nkx2.1 (a ventral telencephalic marker) was suppressed, 
also when animal caps from chordin mRNA-injected embryos were conjugated with 
ADME explant, at stage 30/31 the recombined tissue was positive for both emx-1 and 
eomes expression (eomes is another dorsal telencephalic marker). These results 
indicated that the ADME was able to co-operate with the action of BMP antagonists and 
lead to the development of the dorsal telencephalon, and also that the ADE may be 
important for dorsal telencephalon specification, but have an inhibitory effect on ventral 
forebrain specification. Additionally, in post-gastrula zebraflsh swirl mutants, that carry 
a mutation in the bmp2b gene, there are alterations in the extent of medial and lateral 
expression domains (alterations in cell fate along the medio-lateral axis) in the neural 
plate in response to differing thresholds of BMP signalling (Barth et al., 1999). This 
indicates that BMP signalling regulates the boundaries of the medio-lateral domains in
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the neural plate. Also, signals underlying the neural plate can regulate the molecular 
properties of the neural plate (Ang et al, 1994). In HNF3p -/- embryos there is a loss of 
organised node and notochord, and this leads to secondary D-V patterning defects of the 
neural tube.
Other experiments have shown that common M-L (V-D) patterning mechanisms 
are found in all CNS regions (Shimamura and Rubenstein, 1997). Shh can regulate 
specification of ventral cell types in forebrain neuroectoderm (Ericson et al., 1995) and 
the sub-division of the forebrain into bi-lateral compartments (Macdonald et al., 1995; 
Chiang et al., 1996). During early regionalisation of the forebrain, along the medio- 
lateral axis of the neural plate, Shh from the prechordal plate regulates the medial plate 
fate, and BMPs from the non-neural ectoderm regulate the patterning (dorsal fates) of 
the lateral neural plate (Fig. 1.2) (Liem et al., 1995; Shimamura and Rubenstein, 1997). 
Anterior neural plate explants were shown to be responsive to BMPs in culture, 
suggesting that BMPs may begin to pattern the forebrain even before neural tube 
closure, and that the neural plate is competent to receive dorsalising fates from BMPs 
(Shimamura and Rubenstein, 1997).
Dorsalising signals from the non-neural ectoderm (epidermis) have been 
suggested to pattern the dorsal side of the forebrain (Shimamura and Rubenstein, 1997). 
This was shown in experiments eliminating the anterior non-neural ectoderm resulting 
in a loss of BF-1 dorsal forebrain marker. This indicated that the anterior ectoderm was 
necessary for BF-1 expression. Furthermore, the specification of dorsal cell fates in the 
neural plate is initiated by cells of the epidermal ectoderm, which flank the neural plate, 
and are subsequently propagated by roof plate cells within the neural tube (Shimamura
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and Rubenstein, 1997; Liem et al., 1995, 1997; Basler et al., 1993; Dickenson et al., 
1995). The roof plate is a dorsal signalling centre that occupies the dorsal midline of the 
developing CNS along its entire A-P axis. Along the D-V axis, cell fate determination 
occurs during and following neural tube closure, and involves the action of two 
opposing signalling pathways: SHH ventrally from the notochord and prechordal plate 
and BMP/GDF dorsally from the boundary of the neural and non-neural ectoderm and 
later from the roof plate (Reviewed by Liu and Niswander, 2005). Thus, BMP 
signalling is involved in medio-lateral, and then D-V patterning.
Patterning along the D-V axis of the neuraxis is generated by two processes: the 
assignment of regional identity and sub-division of these regions into discrete domains 
of gene expression (and subsequently assigning cell fate) (Briscoe et al., 2000; Ericson 
et al., 1996; Pierani et al., 1999). In the neural tube, there is a broad expression of 
regional identity developmental regulators, which suggests that these genes act to 
restrict potential fates adopted by cells within that region (Briscoe et al., 2000). These 
regional identity genes include for example Pax6, Nkx2.2, Nkx6.1 or Dbx2. At later 
stages these regions give rise to many different classes of differentiated neurons, 
suggesting that these regions are subdivided into discrete cell populations. The 
differentiated neuron subtypes include, for example, motor neurons (MN). The 
overlapping and individual expression of specific combinations of developmental 
regulators within a given region has been shown to generate the discrete populations. 
Even though the regionalisation and sub-division can be viewed as two distinct 
processes, there is overlap between the two processes, as the Pax gene family has been 
shown to contribute to dorsal identity and sub-divide a population of intermediate cells
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into two distinct populations in the neural tube (Mansouri and Grass, 1998; Pierani et 
al., 1999). Thus, the D-V patterning mechanisms in the neural tube generate discrete 
subdivisions set up by the differential expression of regionally expressed genes.
The M-L and D-V organisation of the neural plate and neural tube is 
characterised molecularly with several genes located at different positions along the D- 
V or M-L axis, such as, Dbx, Msx-1, Nkx2.2, Pax3, Pax6, Pax7, Shh, Wnt-1, Wnt3 and 
Wnt3a, some of which extend all along the neuraxis into the prosencephalon, for 
example, Pax6, Msx-1, Shh and Nkx2.1 (Shimamura et al., 1995). This continuation of 
expression of molecular markers from the spinal cord through to the forebrain provides 
evidence for the continuation of longitudinal properties from the spinal cord into the 
forebrain. These gene expression patterns can provide a read out and a link to the basic 
mechanisms of the inductive processes that generate regional specification within the 
developing CNS.
Furthermore, the conservation of the markers in zebrafish (Barth and Wilson, 
1995) and across other non-mammalian vertebrates including Xenopus (Bachy et al., 
2001, 2002) supports the notion that there is a conservation of some patterning 
mechanisms, and allows these other vertebrates to be used for analysis of such 
processes. Thus, the regionalisation of the anterior neural tube and forebrain in Xenopus 
has begun to be dissected due to the discovery of these conserved transcription factors 
which are involved in patterning (Papalopulu and Kintner, 1993; Bachy et al., 2002; 
Bachy et al., 2001; Brox et al., 2003; Brox et al., 2004; Medina et al., 2005). The 
telencephalon of Xenopus shows the same major organisation of prosomeres, and other 
divisions (pallium and subpallium), characterised by differential expression of the same
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regulatory genes (x-DU3, x-Nkx2.1, x-Emxl, x-Pax6, x-Eomes, x-Tbr-1, x-dll4, x-Nkx2.1, 
x-Lhx5 and xLhx7), as in mouse (Bachy et al., 2001; Brox et al., 2003; Brox et al., 
2004; Papalopulu and Kintner, 1993; Medina et al., 2005; Bulfone et al., 1993, 1999). 
Based on these observations, this has led to the proposal that the proscencephalon is 
functionally and structurally conserved in all vertebrates. However, there are some 
differences in forebrain expression in Xenopus compared to mouse. There are 
divergences in the LIM-homeodomain expression code (for Lkxl/5 and Lhx2/9) in 
Xenopus telencephalon compared to mouse (Bachy et al., 2001). LIM-homeodomain 
expression marks regional specification, as well as axonal projection patterns and 
neurotransmitter phenotypes (Jessell, 2000). These differences could reflect 
divergences in cell types, connectivity and size of telencephalon (being small in 
Xenopus in comparison to mouse and other vertebrates). Hence, Xenopus may not 
contain all the same functional telencephalic domains as higher vertebrates. However, 
despite these major differences in size and morphology, Xenopus telencephalon is sub­
divided into distinct progenitor domains along the dorso-ventral axis, and these are 
marked by the restricted expression of transcriptional regulators.
By analysis of the regionally restricted markers along the D-V axis, the 
telencephalon in Xenopus and other vertebrates was found to be divided along the D-V 
axis into two major subdivisions, the pallium which gives rise to the cortex (the dorsal 
telencephalon) and the sub-pallium which gives rise to the basal ganglia (part of the 
amygdala, part of the septum, the bed of the stria terminalis, the extended amygdala and 
the corticopetal cholinergic neurons) (Bachy et al., 2002; Medina et al., 2005). The 
prospective basal ganglia is in the most anterior position and the pallium in a more
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caudal and dorsal position. The basic organization of telencephalic subdivisions is 
conserved during embryogenesis in all vertebrates. The pallium in Xenopus is divided 
into four regions, the medial pallium (future hippocampus), the dorsal pallium (or 
isocortex), the lateral pallium (future olfactory cortex and part of the amygdala) and the 
ventral pallium (the claustrum and another part of the amygdala) (Fig. 1.1) (Bachy et al., 
2002). The subpallium contains three regions, the lateral and medial ganglionic 
eminences (lge and mge) (that gives rise to the striatum and the pallidum) and the 
telencephalic stalk (the future septum and cholinergic nuclei). The lateral regions of the 
developing pallium become the hippocampal field and neocortex in higher vertebrates, 
but only the hippocampal field in Xenopus. Although Xenopus does not contain all the 
functional forebrain domains such as neocortex, the presence of the major D-V 
subdivisions may allow analysis of major D-V patterning events. It should be noted that 
there is some disagreement on where the D-V and A-P axes are positioned within the 
developing prosencephalon. Studies have suggested that both axes become colinear at 
the anterior margin of the neural plate; thus the A-P and D-V axes become 
indistinguishable most anteriorly (Barth et al., 1999; Rubenstein et al., 1998). Later, 
once the primordia are specified, proliferation, differentiation and migration occur in 
cells of the forebrain. The telencephalon develops in a modular manner whereby 
progenitor cells from different modules, such as the dorsal midline and cortical hem, 
develop independently prior to the mixing of their progeny in the mature cerebral cortex. 
In the telencephalon cells migrate ventro-dorsally across the pallio-subpallial boundary, 
from the ganglionic eminences into the cortex and other parts of the pallium (Chapouton
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et al., 1999). The outcome of these processes is functionally distinct structures in the 
telencephalon.
Thus, there is a precise organisation and formation of the appropriate numbers 
and types of differentiated neurons along the A-P and D-V axes in the forebrain. This 
organisation requires several signalling molecules and transcription factors. BMP 
ligands are the major signals involved in dorsal pattern formation.
1.9 BMP Expression
BMP genes are maternally encoded and are differentially regulated after 
fertilisation (Nishimatsu et al., 1992). The expression of BMP2 and BMP4 (and BMP?) 
in ectodermal and neural tissue was analysed in Xenopus laevis embryos by whole 
mount in situ hybridisation (Hemmati-Brivanlou and Thomson, 1995; Hawley et al., 
1995). During blastula stages all BMP expression is localised to the ventral side of the 
embryo. Subsequently, in the late blastula and mid-gastrula (stage 11), BMP2 is 
expressed in the embryonic ectoderm and throughout the marginal zone. In the stage 18 
neurula, BMP2 is expressed in anterior ventral patch of mesoderm and ectoderm, BMP2 
expression then diminishes in the ectoderm, and BMP2 continues to be expressed in the 
anterior neural folds as they close at the top of the embryo. At stages 18 to 22, BMP2 is 
expressed in the neural folds. By tailbud through to hatching tadpole stages, BMP2 is 
expressed in a variety of structures in the brain, pineal gland, inner portions of the 
forebrain ventricle and head. Forebrain sites of expression are also bilaterally 
symmetrical. These dynamic patterns of expression suggest that BMP2 performs 
multiple functions in early development.
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BMP4 is expressed in animal cap ectoderm in the late blastula (Hemmati- 
Brivanlou and Thomson, 1995). During gastrulation BMP4 expression is gradually 
excluded from the dorsal ectoderm, in a region that is the prospective neural plate. At 
the end of gastrulation and through neurula stages, BMP4 is expressed in ventral- 
posterior regions of the embryo and in the epidermis. At the junction between the neural 
plate and epidermis, the staining in the epidermis is amplified and there is a sharp 
delimitation of expression where the neural crest forms. BMP4 is expressed in the non- 
neural ectoderm up to the boundary with the anterior neural plate (Fig. 1.2). 
Furthermore, at neural plate stages, BMP4 and BMP7 are also expressed in the 
prechordal mesoderm underlying the rostral-most neural plate (Hawley et al., 1995; 
Hartley et al., 2001). Expression of BMP4 and BMP7 is particularly strong underlying 
the medial part of the anterior neural plate, fading off to the lateral sides. When the 
neural folds are closing there is a lack of expression in the neural plate and neural folds. 
BMP4 is expressed at the edge of the neural plate and this corresponds to cells that will 
form the roof plate of the closed neural tube. The anterior limit of BMP4 expression in 
the roof plate of the just closed neural tube was not indicated. However, by stage 24 
there are small patches of BMP4 expression in the anterior spinal cord and across the top 
of the head. Thus, in Xenopus either BMP2 or BMP4 are expressed in the neural folds 
during neurula stages, and then in the dorsal neural tube, as well as dorsal surface 
ectoderm and the forebrain. Furthermore, the expression of BMP2 and BMP4 in 
X.tropicalis in these regions is very similar to X.laevis expression (Knochel et al. 2001).
Another BMP of the GDF5 subgroup, GDF6 (Growth and differentiation factor 
6) is also expressed during Xenopus neurulation at the edges of the neural plate, within
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the neural plate and eye fields (Chang and Hemmati-Brivanlou, 1999). After neural 
tube closure, GDF6 is expressed in the neural tube, and in the retina expression becomes 
restricted to the dorsal side. Therefore, GDF6 ligand may be involved in neural 
development in Xenopus.
An important issue regarding the function of BMPs in early development is 
whether the protein is present at the relevant tissue and place. There is no evidence for 
direct detection of BMP proteins, due to a lack of BMP antibodies. However, BMP 
activity was measured in the neurula and tailbud stage Xenopus embryo by 
immunostaining for phospho-Smadl (Kurata et al., 2001; Wawersik et al., 2005). It 
was found that, at early neurula stage, no phospho-Smad-1 was detected in the entire 
neural plate. At stage 14, as the neural fold developed, the signal began to be detectable 
in the sensorial layer beneath the neural fold. At stage 17, the phospho-Smad-1 staining 
was observed in the eye primordial, including optic vesicle and overlying ectoderm. 
Upon neural tube closure, the phospho-Smad-1-positive cells appeared to move to the 
dorsal part of the forming neural tube and neural crest. The anterior limit of phospho- 
Smad-1 staining in the dorsal neural tube is not indicated. However, at stage 20, it is 
known that phospho-Smad-1 staining localises to the dorsal neural tube in regions above 
the notochord. At tailbud stage, it was observed that phospho-Smad-1 staining was 
found in the dorsal part of the neural tube. Thus BMP signalling activity is located in a 
similar location as the expression of its ligands.
The expression of BMPs (2, 4, 7) and BMP signalling components in the 
developing neural folds, epidermal ectoderm, dorsal surface ectoderm, dorsal neural 
tube and forebrain in Xenopus and other vertebrates (Fig 1.2) (Furura et al., 1997; Liem
48
et al., 1995; Faure et al., 2002) during neurulation, neural tube and tailbud stages (in 
Xenopus) support the hypothesis that BMPs have a role in dorsal patterning. It is likely 
that there is a co-operative BMP signalling mechanism.
1.10 Dorsal Patterning and BMPs
1.10.1 Dorsal Patterning in the Spinal Cord
In the spinal cord, distinct populations of neural progenitor cells exist in defined 
locations along the dorso-ventral (D-V) axis (Helms and Johnson, 2003; Briscoe and 
Ericson, 2001). The relative position along the D-V axis of the progenitor cells in the 
neural tube dictate the neural subtype that will be generated. Neural crest, commissural 
neurons and some groups of sensory neurons are formed dorsally (namely dorsal 
interneurons, d ll-6), whereas motor neurons (MN) and some intemeurons are formed 
ventrally (ventral intemeurons V0-3).
In loss-of-function studies, genetic ablation or loss of the roof plate, in mice, 
reveals that non-autonomous signals from the roof plate are essential for dorsal 
intemeuron (IN) differentiation (Lee et al. 2000; Millonig et al., 2000). In Gdf7-DTA 
ablated mice the dorsal Pax7 domain is reduced, while the ventral Pax6 domain 
expands, and Mat hi and Ngn expressing progenitor cells are absent, as are their 
respective neuronal populations, dorsal intemeurons dll and dI2 in the dorsal third of 
the neural tube (Lee et al., 2000). Concomitantly, dorsal neural progenitors expressed 
Mashl, a gene that is normally expressed in the progenitors in the intermediate region of 
the neural tube, and there was an expansion of more ventral dI3 cell types throughout 
the dorsal third of the neural tube including the dorsal midline. Furthermore, in the
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dreher mouse mutant, the roof plate defects as a result of a loss of Lmxla transcription 
factor results in a reduction of dll intemeurons (Millonig et al., 2000). These 
experiments support the idea that the roof plate is required in a non-autonomous manner 
for inducing dorsal neuronal cell types (and pattern) in the spinal cord. The differences 
in the severity of their effects on dorsal neural gene expression are possibly due to 
residual roof plate signal, differences in the timing of roof plate ablation or due to 
alteration of surrounding tissue, which express TGFp ligands and other factors. A role 
for BMPs as the signal from the roof plate is speculated due to the high abundance of 
BMP expression in the roof plate.
Gain-of-function and loss-of-function analysis, and gene expression profiles 
support the idea that early lateral and later dorsal signalling in the caudal neural tube is 
regulated by BMPs (Liem et al., 1995, 1997; Lee et al., 1998; Basler et al., 1993; Lee 
and Jessell, 1999; Jessell, 2000; Briscoe and Ericson, 2001). The differentiation of 
dorsal cells types is initiated at the neural plate stage by BMPs in the epidermal 
ectoderm (epidermis) (Liem et al., 1995). Subsequently, the epidermis (then surface 
ectoderm), containing BMP4, 5, 7 and dorsalin-1, establishes neural crest and a 
secondary signalling centre by inducing BMP4 expression in the roof plate cells of the 
neural tube (Chizhikov and Millen, 2004; Liu et al., 2004; Lee et al., 2000; Liem et al., 
1995, 1997; Lee et al., 1998; Basler et al., 1993). The roof plate subsequently 
expresses multiple BMPs {BMP 4, 5, 7) and other TGF(3 signals, Gdf7, activin and 
dorsalin. The specification of distinct neuronal progenitor cell domains at defined 
positions (pattern) and the dorsal specification of dorsal and intermediate intemeurons in 
the dorsal neural tube (and then the spinal cord) depends on BMP signalling from the
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dorsal midline organising centre (Lee and Jessell, 1999; Liem et al., 1995, 1997; 
Jessell, 2000; Briscoe and Ericson, 2001). BMP4 protein from the roof plate acts as a 
morphogen, and induces a cascade (or gradient) of TGF-P proteins (BMP4, BMP7, 
dorsalin and activin) in adjacent cells (Liem et al., 1995, 1997, 2000; Basler et al., 
1993). Different sets of cells are exposed to different concentrations of TGF-p proteins 
at different times, the most dorsal being exposed to more factors at higher 
concentrations and at earlier times. This sets up regional-specific expression of 
homeobox genes. Then, the temporal and concentration gradients of the TGF-/3
proteins induce different types of transcription factors, basic helix-loop-helix (bHLH) 
and homeodomain genes, in cells at different distances from the roof plate, thereby 
giving them different identities.
The the gain-of-function evidence for this chain of events include, firstly that, 
BMP4 and BMP7 (and other members of the TGFp family) can induce dorsal markers 
such as Pax3 and Msx, and dorsal neuronal subtypes when cultured with chick 
intermediate neural plate explants or ventral neural explants (Liem et al., 1995, 1997). 
Also, exposure of intermediate explants to low concentrations of BMP4 induced dI2 
neurons and no dll, whereas high concentrations of BMP4 induced many dll, but only 
some dI2 neurons. The changes in expression of developmental regulators expressed in 
the neural plate and dorsal neural tube in response to BMPs suggests that dorsal 
patterning of the neural plate then the neural tube is mediated by BMPs; BMPs are 
sufficient to induce early dorsal identity and dorsal neuronal subtypes in the neural plate 
then neural tube. Other in vivo evidence to support a role for thresholds of BMP 
signalling setting the expression boundaries of dorsal regulators is shown by in ovo
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electroporation studies. BMP signalling activation is sufficient to alter dorsal and 
intermediate pattern in the neural tube. When constitutively activated BMP receptor 
(Bmprla or Bmprlb) was electroporated or virally transfected into the chick neural tube 
after neural tube closure from different expression constructs, this produced different 
BMP expression levels, and lead to the transformation of ventrally located cell types to 
dorsal cell types (Timmer et al., 2002). Pax7, which is expressed dorsally in the neural 
tube, was ectopically expressed ventrally. Pax6, which is expressed in the intermediate 
region of the neural tube, was reduced at low levels of BMP signalling, exhibited a 
ventral shift of Pax6 at moderate levels of BMP signalling, and at high levels of BMP 
signal Pax6 was repressed. Also, intermediate neural tube progenitor genes (Dbxl, 2) 
were repressed by BMP signalling. These alterations in progenitor specification genes 
in turn altered neuronal specification genes and finally neuronal subtypes. For example, 
the decrease in Dbxl, 2 correlated with a reduction of intemeurons.
Thus, BMP signalling regulates the expression boundaries of homeobox proteins 
Pax6, Dbx2 and Msxl to generate precursor populations with distinct developmental 
potential. Within the resulting populations, thresholds of BMP act to set expression 
domain boundaries of developmental regulators of the homeobox (in the intermediate 
cells) and basic helix-loop-helix (bHLH) families (in the dorsal cells), ultimately leading 
to the generation of a diversity of differentiated neural cell types.
Direct targeted disruption in mouse of BMPs or their receptors in the dorsal 
midline has either been hampered by early lethality, as is the case for BMP2, BMP4, 
BmprlA and Bmprll null mutants (Winnier et al., 1995; Zhang and Bradley, 1996; 
Mishina et al., 1995; Beppu et al., 2000) or functional overlap of mutations in BMPS, 6,
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7 or BmprIB mutants leading to no neural phenotype (Kingsley et al., 1992; Dudley et 
al., 1995; Luo et al., 1995; Solloway et al., 1998; Yi et al., 2000). Smad 4 null mice 
also die before E7.5 with gastrulation defects and an abnormal visceral mesoderm, and 
separate Smadl and Smad5 null mutants also die with defects in various tissues (Sirard 
et al., 1998; Lechleider et al., 2001; Chang et al., 1999). However, other loss-of- 
function studies do indicate a requirement of BMPs for dorsal cell fate in the neural tube 
(spinal cord) (Wine-Lee et al., 2004; Liem et al., 1997; Chesnutt et al., 2004; Lee et 
al., 1998). Deletion of both BmprlA and BmprIB using a conditional Brn3a-Cre allele, 
results in the loss of dll, Math-1 sensory intemeurons (dorsal-most neurons), and a 
decrease and dorsal shift in dl2 neurons (dorsal neurons just ventral to dll neurons) 
(Wine-Lee et al., 2004). This indicates that a loss of BMP signalling results in spinal 
cord patterning defects. The defects may involve later stages of neurogenic precursor 
maintenance because there is a loss of pre-existing roof plate and dll/dl2 dorsal 
precursor identity. As there was no spinal cord patterning defects in knockouts of either 
Bmprla or Bmprlb alone, the phenotype in these double mutants indicate that there is 
receptor redundancy in the maintanence of dorsal cell identity.
Other studies have found that the secretion of BMPs and other TGFj3’s by the 
epidermal ectoderm, and the roof plate are required for the induction of dorsal 
intemeurons (Liem et al., 1997). BMP4, 7 and activin induction of dorsal neuronal 
subtypes in neural plate explants is blocked in the presence of BMP inhibitors, Noggin 
and Follistatin, demonstrating a requirement for BMPs in the induction of dorsal 
neurons. Recently, it has been found, using mis-expression of Noggin in the spinal 
cord, that loss of BMP signalling causes loss of Math-1+ dll intemeuron, and
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concurrent expansion of dI2-4 population towards the roof plate (Chesnutt et al., 2004). 
Furthermore, the roof plate was lost via Noggin overexpression in some embryos, 
indicating the requirement of BMP signalling in roof plate maintanence. Also, in Gdf7 
mutant mice, only a specific subset of dll intemeurons are affected (Lee et al., 1998). 
As there was only an alteration in dll intemeurons this suggested that functions of 
BMPs/GDFs in patterning the neural tube is divided between different BMP/GDF genes 
and is not part of a general combinatorial cascade. Other studies have found that Id 
proteins that are induced by BMP can repress transcription of Mash-1 and neurogenin, 
which is induced by basic HLH heterodimers, resulting in the inhibition of neurogenesis 
(Nakashima et al., 2001). Based on all these findings it is established that BMPs act as 
morphogens differentially regulating cell fate in the neural tube (and spinal cord). The 
different effects on dorsal intemeuron populations, dI2 to dI4, such as a decrease and 
shift, an expansion or no effect, from a loss of BMP signalling, may be due to the 
different techniques and areas of knockdown or knock out, or due to qualitative 
differences in the effects of different TGFp signals. However, the fact that not all dorsal 
intemeurons are affected by roof plate ablation or loss of BMP signalling indicates that 
there must be additional inputs into dorsal patterning.
Originating from mesodermal derivatives, studies in mouse and chick have 
shown Shh induces ventral intemeuron and motor neuron progenitor cells by a 
concentration-dependent secretion from the notochord and floor plate (Roelink et al., 
1995; Briscoe et al., 1999; Ericson et al., 1996, 1997; Marti et al., 1995). The case 
being such, it is the interaction of inductive factors derived from both mesodermal (Shh) 
and ectodermal (BMP) tissues that flank the neural plate and neural tube that initiate the
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specification of neural cell types. This is supported by results in chick showing that 
neural plate explants can lose their dorsal identity throughout neural plate stages by the 
exposure to notochord or SHH (Liem et al., 1995), meaning cells in the lateral plate are 
not committed to dorsal fates prior to neural tube closure. Then, in the spinal neural 
tube, activation of the SHH pathway can transform dorsal tissue to a ventral fate 
(Epstein et al., 19%; Hynes et al., 2000; Roelink et al., 1995). Conversely, the 
activation of BMP pathway in chick intermediate neural plate explants can dorsalize 
SHH-induced explants (Liem et al., 2000). Also, if notochord is removed or if 
signalling from the notochord is blocked, there is an expansion of two dorsal markers, 
Msxl and Pax3, indicating that the cells of the neural plate can adopt a dorsal fate 
(Goulding et al., 1993; Liem et al., 1995).
Moreover, BMP/GDF signalling dorsally, combined with SHH signalling 
ventrally, acts to define the differential expression domain boundaries of additional 
genes Pax7, Msx2, Pax6 and GUI, 2, 3. This interaction in the neural tube is further 
controlled by the action of secreted Noggin. BMP signalling is regulated by Noggin, 
which is expressed in the mesodermal cell types that flank the ventral neural tube, such 
as the notochord, as well as in the roof plate along the entire A-P axis (Liem et al., 2000; 
McMahon et al., 1998; Shimamura et al., 1995). The inhibition of the BMP/GDF 
ligands by Noggin is required for the proper formation of ventral cell types in the 
presence of normal Shh signalling (McMahon et al., 1998). In Noggin mutants, dorsal 
neural tube patterning is unaltered, however, ventral neural tube patterning was altered, 
indicated by a failure of motor neurons and ventral intemeurons to develop.
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Other factors also play a role in the establisment of neurons in defined positions 
in the neural tube (spinal cord). In chick, the expression of Bmp2, 7 and Bmprlb in the 
ventral neural tube, suggests a role for BMP signalling in ventral patterning. Also, the 
expression of several BMPs in nested domains in the epidermal ectoderm and the dorsal 
neural tube may suggest that different combinations of BMP hetero-dimers act through 
different sub-classes of BMP receptors to confer qualitatively or quantitatively distinct 
inductive activities. In addition to BMPs, the roof plate produces other secreted 
proteins, such as Wnts and Ephrins, and other TGFp proteins, which act to specify 
several classes of adjacent dorsal intemeurons (Reviewed by Lee and Jessell, 1999 and 
Nakamoto, 2000). The roles of the Wnts and Ephrins have not been assessed here. 
BMP signalling acts together with Wnt and Shh pathways to co-ordinate patterning and 
proliferation of cells.
1.10.2 Dorsal Patterning in the Forebrain
In contrast to more caudal CNS regions, the forebrain undergoes dramatic 
morphological changes during its development. In Xenopus, the posterior telencephalic 
and diencephalic roof curves around with the cephalic flexure at around stage 24. Only 
at later stages does the dorsal midline become hidden between two cerebral hemispheres 
as they expand. It may be that patterning is not the same in the forebrain as in the neural 
tube because there are these substantial cell movements (Eagleson and Harris, 1990), as 
well as differences in the competence of forebrain tissue to respond to inducing signals 
(Shimamura and Rubenstein, 1997). However, the identification of regionally expressed 
genes in defined patterns in the forebrain along the D-V axis suggest that the
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mechanisms of D-V patterning in the forebrain may be similar to more posterior regions 
of the CNS (Shimamura and Rubenstein, 1997; Shimamura et al., 1995; Bachy et al., 
2001; Brox et al., 2003; Brox et al., 2004; Papalopulu and Kintner, 1993; Medina et 
al., 2005).
In addition to their earlier roles during neural plate formation, BMP signalling 
has later roles in dorsal patterning of the forebrain (Furuta et al., 1997; Golden et al., 
1999; Monuki et al., 2001; Cheng et al., 2006). There are several BMPs expressed in 
and surrounding the dorsal telencephalon in mouse and chick (Furuta et al., 1997; 
Golden et al., 1999). The roof plate at the level of the forebrain (up to and including the 
dorso-medial telencephalon) co-expresses multiple Bmp genes of the Bmp2/4 and 60A 
subgroups, Bmp2 and Bmp4, and Bmp5, 6 and Bmp7. Studies using explant cultures 
indicate that BMPs are sufficient to alter forebrain patterning (Furuta et al., 1997; 
Golden et al., 1999; Monuki et al., 2001). Exogenous recombinant BMP4 or BMP5 
soaked beads were implanted into the rostral neural tube of the chicken forebrain and 
assayed by in situ hybridisation for forebrain patterning markers (Golden et al., 1999). 
The resulting embryos either maintained dorsal forebrain markers Pax6, Otxl, Wnt-1, 
Wnt-3a, Wnt5b, Wnt-7a or up-regulated one dorsal forebrain marker Wnt4, whereas 
there was a loss or marked reduction of ventral forebrain markers (Pax2, Nkx2.1, Dlx-2, 
Shh). The embyos showed a loss of basal telencephalon that resulted in 
holoprosencephaly (a single cerebral hemisphere), cyclopia (a single midline eye), a loss 
of ventral midline structures and cranio-facial defects. This experiment suggests that 
BMPs are sufficient to induce some aspects of dorsal pattern in chick forebrain explants,
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and supports a local and global participation of BMPs in dorso-ventral patterning of the 
telencephalon, similar to the mechanisms of BMPs in the caudal neural tube.
In mouse it has been demonstrated that BMPs can regulate lateral telencephalic 
(cortical progenitor) gene expression. Application of exogenous BMP2 and 4 peptides 
to telencephalon explants induced Lhx2 expression at low concentrations and repressed 
Lhx2 expression at high BMP concentrations (Monuki et al., 2001). Thus cortical 
progenitor tissue expression can be differentially regulated by the concentration of BMP 
it receives. In other studies, application of exogenous BMP4 and BMP2 to explants 
from lateral telencephalic neuroectoderm induced Msx-1 expression, inhibed Bf-1 (also 
known as FoxGl) expression, inhibited cell proliferation and increased apoptosis 
(Furuta et al., 1997). Therefore, BMPs can induce roof plate genes, whereas repress 
genes expressed in the dorsal lateral forebrain. Both these studies support a role of 
BMPs in dorsal telencephalon development. Thus, BMPs can regulate midline fate, as 
well as dorsal forebrain molecular pattern. Conversely, a later study in chick 
telencephalic explants has indicated that BMP4 is not able to induce dorsal specific 
markers, although other BMPs were not assessed (Gunhaga et al., 2003). Furthermore, 
in another study, by increasing BMP signalling via in ovo electroporation of BMPRIa 
and BMPRJb into the embryonic chick forebrain, this resulted in alterations in the 
expression of patterning genes in the diencephalon (Lim et al., 2005). This study 
indicated that BMP signalling is sufficient to alter diencephalic patterning.
Clarifying the precise role of BMPs in vivo has proven difficult due to the large 
number of TGF|3 ligands expressed in neural tissue, suggesting functional redundancy. 
Attempts to directly assess the role of BMPs in patterning of the dorsal telencephalon
58
with mouse knockouts have failed for various reasons including expression outside 
neural tissue (Winnier et al., 1995; Zhang and Bradley, 1996; Mishina et al., 1995; 
Kingsley et al., 1992; Dudley et al., 1995; Luo et al., 1995; Solloway et al., 1998; Yi 
et al., 2000; Bachiller et al., 2000; Anderson et al., 2002).
In other loss of function studies it has been found that BMP signalling has a role 
in dorsal midline development (Hebert et al., 2002) and in eye, craniofacial and neural 
tube development (Lim et al., 2005). It has been found that BMP signalling is required 
for induction and patterning of the dorsal telencephalic midline (Hebert et al., 2002), and 
this role for BMP signalling has also been supported by other studies (Panchision et al.,
2001). Both of these studies indicated that BMP signalling has a role in development 
(including specification) of the choroid plexus (epithelium), which is the most dorsal 
structure of the telencephalon. In addition, it has been found that BMP signalling is 
necessary for eye and craniofacial development, as well as neural tube closure. 
However, both of these studies lack any D-V patterning alteration in the forebrain in 
response to a decrease in BMP signalling. Thus they do not support the role of BMPs in 
patterning of the forebrain in a concentration-dependent manner (Monuki et al., 2001; 
Golden et al., 1999). The reasons for a lack of D-V patterning alteration in the 
telencephalon may be due to functional redundancy between BMP receptors, leaving 
residual BMP signalling. In the studies by Hebert et al. (2002) explanted telencephalic 
tissue from the BMPRIa-deficient mouse was still responsive to BMP treatment, and 
this may have been because BMPRIb was still present throughout the telencephalon 
possibly compensating for the loss of BMPRIa. Futhermore, even though both BMPRIa 
and BMPRIb were knocked down in the studies by Lim et al. (2005), other studies have
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shown that BMP signalling can still occur in the absence of these two receptors, by 
signalling through other receptors, such as Alkl and Alk2 (Chen and Massague, 1999; 
Ebendal et al., 1999). Other reasons for a lack of telencephalic patterning phenotype 
may be because BMP signalling could have patterned the cortex prior to FoxGl-Cre 
mediated deletion of BMPRIa (Hebert et al., 2002) or prior to the dominant negative 
knockdown (Lim et al., 2005). Furthermore, the dorsal telencephalon could be specified 
by other factors either independently or in co-ordination with residual BMP signaling.
In roof plate ablation studies, it has been found that the roof plate is required in a 
non cell-autonomous manner for both induction of the telencephalic dorsal midline and 
for patterning of the dorsal telencephalon (Monuki et al., 2001; Cheng et al., 2006). A 
role for BMP signalling in patterning of the dorsal telencephalon was implied because 
there was a reduction and alteration in the gradient of Phospho-Smad-1 staining in the 
roof plate ablated mutant telencephalon, and also because the roof plate expresses many 
BMPs (Cheng et al., 2006; Monuki et al., 2001). These studies have indicted that BMP 
signalling plays a role in dorsal telencephalic patterning, however they are not evidence 
for a direct role for BMP signalling in dorsal telencephalic patterning. Other studies 
have found a direct role for both BMP and Wnt signalling in the regulation of Emx2 (a 
dorsal telencephalic gene) (Theil et al., 2002). An enhancer for the Emx2 gene was 
identified, and it contained binding sites for Smad and Tcf proteins, which are mediators 
of BMP and Wnt signalling respectively. They found that activation of both BMP and 
Wnt signalling pathways lead to ectopic activation of the Emx2 enhancer. This study 
indicated that BMP signalling could be redundant with Wnt signalling in the 
specification of dorsal telencephalic cell fates.
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Ultimately, the role of BMP signalling in modifying dorsal telencephalon 
patterning cannot be assessed alone due to the possibility of cross-talk with other 
signalling pathways. Recent data indicates that there is a co-ordination between 
patterning centres in the forebrain whereby ventrally derived Shh promotes and 
maintains Fgf8, Fgf8 then regulates a balance of dorsally-derived Bmp and Wnt 
signalling, which then regulates telencephalic growth and patterning (Storm et al., 
2006). The paleocortex, which is the olfactory cortex located at the interface of the 
dorsal and ventral telencephalon, is specified in mice in which dorsal telencephalic 
patterning is severely disrupted (Vyas et al., 2003). Therefore, this suggests that signals, 
other than BMPs, may specify this region. These may include, retinoids, which have 
been found to regulate dorso-ventral patterning of the forebrain (Halilagic et al., 2007). 
In vitamin-A-deficient quail embryos there is a reduced and caudally shifted Pax6 
expression domain in the telencephalon. Also, Gli, a transcriptional mediator of Shh 
signalling, is involved in dorsal-ventral telencephalic patterning, possibly indicating 
another co-ordinating signal. Eventually, the downstream effects of BMP and/ or Wnt 
signalling in the dorsal telencephalon involves the combinatorial actions of transcription 
factors such as Emxl, 2 and L/uc2, which function to specify and expand the medial and 
dorsal pallium. Therefore, the correct identity of D-V pattern relies on the 
superimposition of several genetic pathways.
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1.11 Aims
The objectives of the studies described in this thesis were to establish whether a 
binary transgenic approach combining GAL4/UAS with a novel “Ligand Trap” 
knockdown strategy could be used to knockdown signalling pathways involved in 
development. In particular, the binary ligand trap approach was used to assess whether 
knockdown of BMP signalling in a targeted manner could be achieved, and then, 
secondly, to address the role of BMP signalling in forebrain development
An effector line containing Flognog, a membrane tagged noggin GFP fusion 
protein, downstream of UAS, was used to antagonise BMPs and GDFs (BMP2, BMP4, 
BMP5, BMP6, BMP7 (slightly) and GDF6) in a cell-autonomous manner and hence 
knockdown BMP signalling by preventing BMPs/GDFs from binding to their receptors 
(Zimmerman et at, 1996; Chang and Hemmati-Brivanlou, 1999). In crosses of this 
effector line to the neural-tissue transactivator, Otx2-gal4, Flognog could be expressed 
in the anterior CNS and hence used to knockdown BMP signalling in the anterior CNS.
In a cross of Otx2-gal4 to UAS-flognog, the roles of BMP signalling in neural 
patterning and differentiation could be investigated.
Finally, a Pax6-GalPR transactivator tool to drive Flognog target gene 
expression in the telencephalon in a hormone-inducible manner was used. This could be 
used to study the roles of BMP signalling in forebrain development at any stage 
throughout early embryogenesis after gastrulation.
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CHAPTER 2: EXPERIMENTAL PROCEDURES
Table B Abbreviations for Reagents and Materials Used
MMR 0.1M NaCl, 2.0mM KC1, ImM MgS04,2mM CaCl2, 
5mM HEPES (pH7.8) (pH7.4)
SDB Sperm Dilution Buffer (Sive et al., 2000)
MEMFA 0.1M MOPS, 2mM EGTA, ImM MgS04, 10% 
formaldehyde
RU486 (Mifepristone, C^HasNOj) Progesterone receptor 
antagonist
X-Gal 5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside
IX PBS 137mM NaCl, 2.7mM KC1,4.3mM Na2HP04.7H20, 
1.4mM KH2P04
NBT/ BCIP Nitro blue tetrazolium chloride/ 5-Bromo-4-chloro-3- 
indolyl phosphate, toluidine salt
BM purple NBT/BCIP ready-to-use solution
GS Goat Serum
DMSO Dimethyl sulfoxide
2X Sample buffer 125 mM Tris pH 6.8,4% SDS, 10% glycerol, 0.006% 
bromophenol blue, 1.8% p-mercaptoethanol
SDS Sodium dodecyl sulphate
PVDF polyvinylidene difluoride (membrane)
TBS lOmM Tris pH8, 150mM NaCl
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TBST lOmM Tris pH8, 150mM NaCl, 0.2% Tween 20
BSA Bovine Serum Albumin
IX SDS Running buffer 25mM Tris, 250mM Glycine, 0.1% (w/v) SDS
Transfer buffer (IX) lOmM CAPS pHl 1.0,10% Methanol
2.1 Embryo Manipulations
2.1.1 Ovulation, in vitro Fertilisation, Natural Matings, Rearing of Embryos and 
Embryo Collection and Staging
Ovulation of adult X. tropicalis (Cambridge or NASCO), in vitro fertilisation of eggs, 
natural matings, rearing of embryos and embryo collection were conducted as described 
by http://tropicalis.berkeley.edu/home and 
http://www.nimr.mrc.ac.uk/devbiol/zimmerman/protocols.
Fertilised eggs were de-jellied in 2.5% cysteine in 0.05X MMR, pH8.0 for 3-6 minutes. 
Embryos were incubated at 22°C or 25°C in 0.05X MMR with 100p,g/ml gentamicin 
sulfate and staged according to morphological criteria described in Niewkoop and Faber, 
1967, 1994 (Nieuwkoop and Faber staging is applicable to X.tropicalis (Khokha et al., 
2002)). For raising embryos, after 3-4 days embryos were gradually transferred from 
0.05X MMR with lOOpg/ml gentamicin sulfate to ELGA water and raised according to 
standard husbandry procedures for X.tropicalis described in the above websites.
2.1.2 Transgenesis by Oocyte Extract-Mediated Integration
Oocyte extract-mediated integration transgenesis by nuclear transplantation into 
unfertilised eggs was carried out as described by Hirsch et al. (2002). Briefly, sperm
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nuclei are incubated with linearised transgene DNA construct in sperm dilution buffer 
(SDB) for five minutes. Then, Xenopus oocyte extract and SDB are added to the 
reaction and incubated for a further fifteen minutes. The reaction is then diluted in SDB 
and subsequently transplanted by microinjection into unfertilised eggs. This results in 
fertilisation. Pax6-GalPR and N-tubulin-GalPR hormone-inducible transgenics were 
made by this method. The Pax6-GalPR and N-tubulin-GalPR constructs were linearised 
with Sfil and used directly in the transgenesis reaction as described above (see section
2.2.1 for construct generation).
2.1.3 Generation of Transgenic Lines and Use in Transgenic Crosses 
All transgenic frog stocks were made by crossing Otx2-gal4, N-tubulin-gal4, Rx-gal4, 
Pax6-GalPR or UAS-flognog transgenic founders with wild-type frogs (either NASCO 
or Cambridge) (see section 2.2.1 for construct generation). The Pax6-GalPR line was 
raised by Zimmerman, L. All different types of transactivator transgene had a 
secondary reporter cassette containing y-crystallin promoter (Offield et al., 2000) 
upstream of ECFP. The different UAS effector transgenes both had a secondary 
reporter cassette containing CAR promoter upstream of RFP (Mohun et al., 1986).
A detailed comparison of the promoter-GAL4 driven expression patterns to both 
the respective promoters and endogenous gene expression patterns are described in the 
results. Otx2-gal4 was used for expression of UAS-transgenes in the anterior 
neuroectoderm; N-tubulin-gal4 was used for expression of i/AS-transgenes in the 
primary neurons; Rx-gal4 was used for expression of UAS-transgenes in the retina and 
early anterior forebrain; Pax6-galPR was used for RU486-inducible expression of UAS-
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transgenes in telencephalon (amoung other CNS regions). UAS-flognog, which encodes 
Flognog, a GFP tagged version of human Noggin was used to block BMP signalling in 
tissues directed by GAL4; UAS-ECFP (enhanced cyan fluorescent protein) was used as 
a f/AS-reporter in tissues directed by GALA.
Otx2-gal4, N-tubulin-gal4 or Rx-gal4 transgenic lines or founders, or Pax6- 
GalPR FO were subsequently crossed with UAS-gfp or UAS-flognog transgenic frogs to 
yield double-transgenic embryos. All crosses were between heterozygous parents unless 
otherwise stated. Homozygous UAS-gfp reporters were used in some cases. Reporter 
cassettes, y-crystallin driving ECFP and CAR driving RFP, were used to determine the 
transgenic content of the embryo, chi-square test was used to analyse the probability of 
a significant deviation from Mendelian segregation ratios in embryos displaying reporter 
cassette transgene expression.
When determination of the transgenic content of the individual embryo was 
needed, embryos were monitored in individual well dishes over time until reporter 
cassette transgene could be easily visualised.
2.1.4 RU486-inducible Pax6-GalPR Transactivator Cross and Drug Treatment 
RU486 (mifepristone) (BIOMOL) was dissolved in DMSO at 25mg/ml concentration. 
Final concentration was 0.5pM RU486. To test the ability of Pax6-GalPR transgenic to 
transactivate UAS transgenes in a spatially-restricted and conditional manner, embryos 
from a cross of Pax6-GalPR to either UAS-gfp or UAS-flognog were sorted at the 2 to 4- 
cell stage, and subsequently incubated in either 0.5pM RU486 or DMSO alone control. 
Embryos were then raised at 25°C and monitored for the presence of GFP by
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fluorescence microscopy until tadpole stages. Embryos from the crosses were also fixed 
at neural plate and neural tube stages and analysed by whole-mount in situ hybridisation.
2.1.5 Photomicrography
All GFP and RFP were observed by epifluorescence using a standard fluorescence 
stereo-microscope with GFP2 (and GFP1) and RFP filter sets, respectively. Photos 
were taken with a camera assembled on the microscope. In time-course experiments, 
fluorescence was observed in individual live embryos that were separated in well dishes. 
Embryos were monitored by fluorescence until the transgenic identity of the transgenic 
embryos could be observed by the expression of their reporter cassette transgene, either 
CAR-RFP (Mohun et al., 1986) or y-crystallin-ECFP (Offield et al., 2000).
Whole-mount in situ hybridisation images were obtained using a stereo- 
microscope fitted with a camera. Images were altered for brightness and contrast in 
Adobe Photoshop.
2.1.6 Microinjection of Synthetic mRNA
Template for GALA was linearised with Notl (SP6), Flognog (1950bp) with Notl (SP6), 
Noggin (800bp) with Notl (SP6), BMP4 (1104bp) with Asp718 (SP6), FLAG-Smad-1 
(SP6) and LacZ with Xbal (SP6). Then capped mRNA for these genes were synthesised 
in vitro using the mMESSAGE mMACHINE SP6 or T7 kit (Ambion). Synthesised 
mRNAs were injected in a 2nl volume into specific blastomeres of early dividing 
embryos, as stated in the results. Embryos were injected in 3% Ficoll in 0.1XMMR and 
lOOpg/ml gentamicin sulfate, and subsequently incubated in 0.1XMMR and lOOpg/ml
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gentamicin sulfate until collection and use for analysis. In the Sox3 assay, the width of 
the injected side and uninjected side of the embryo was measured for each embryo. A 
paired student’s t-test was used to test whether there was any significant variation in 
width on the injected side compared to uninjected side of the embryo.
2.1.7 X-Gal Staining
For, tracing the injection site in microinjection experiments, embryos were injected with 
LacZ mRNA (50pg) into specific blastomeres as indicated in the results. Embryos were 
then incubated as above, and upon collection were fixed in MEMFA for 1 hour. X-Gal 
staining for P-galactosidase activity was carried out as described by Amaya et al. 
(1993).
2.1.8 Whole-mount in situ Hybridisation
IMAGE and X. tropicalis EST library clones were obtained from HGMP MRC 
Geneservice. Antisense digoxygenin (DIG)-labelled RNA probes were synthesised (see 
section 2.2.2) and whole-mount in situ hybridisation was performed as described by 
Harland (1991) and Sive et al. (2000), using either BM purple or NBT/BCIP as the 
chromogenic substrate (Roche).
2.1.9 Immunohistochemistry
Anti-Phospho-Smad 1/5/8 (Cell Signalling Technology) and anti-GFP (Molecular 
probes, A ll 122) antibodies were used for immunohistochemical analysis. The vitelline 
membrane was removed from embryos. Embryos were fixed in MEMFA for 1 hr, then
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washed four times in PBS containing 0.1% Triton (PBT) for 10 minutes each. For 
Phospho-Smad-1 detection, embryos were digested with DNase 1 for 75 minutes at 37°C. 
DNase buffer contained 66mM Tris pH 7.5, 5mM MgCl2, ImM P-Mercaptoethanol, 
50U/ml DNase 1 (Promega). Embryos were then washed in PBT four times for five 
minutes each, and subsequently blocked for 1 hr in 10% goat serum (GS) (in PBS) 
containing 1% Triton. Embryos were then incubated in Phospho-Smad-1/5/8 antibody 
at 1:50 dilution in 10% GS (in PBS) containing 1% DMSO and 1% Triton, at 4°C 
overnight. The embryos were washed in PBT five times for lhr. Then embryos were 
then incubated in AlexaFluor-488-coupled goat anti-rabbit fluorescent secondary 
antibody at a 1:500 dilution in 10% goat serum (in PBS) containing 1% Triton 
overnight. Embryos were washed in PBT for 2 to 3 hrs, then phototed. The same 
strategy as above was used for Flognog (GFP) detection, except PBS containing 0.1% 
Triton was used for washing and antibody incubation (also no DMSO was used in 
antibody incubation), the DNAse digestion step was omitted, and the primary antibody 
used was anti-GFP (Molecular probes, A ll 122).
2.1.10 Histology
Embryos were processed by whole-mount in situ hybridisation, then vibratome 
sectioned. NBT/BCIP (Roche) was used as the chromogenic substrate when embryos 
were sectioned. Embryos were embedded in 2% agarose, and 25pm sections were 
taken. Sections were collected onto slides, dried, mounted in 70% glycerol and then 
photos were taken on a Zeiss microscope fitted with an Axiocam camera.
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2.1.11 Western Blot
Anti-Phospho-Smad-1 (Ser463/465) (Upstate), anti-GFP (Molecular probes, A ll 122), 
anti-a-tubulin (DM1A) (Sigma) and Anti-FLAG-M2 peroxidase conjugate (Sigma, 
A8592) antibodies were used for western analysis. Embryos were individually snap- 
frozen at the stages indicated in the results and transferred to -80°C. Embryos were 
homogenized in Phospho-extraction buffer (Novagen) containing protease inhibitors, 
EDTA-free mini-complete tablets (Roche); yolk was then extracted with an equal 
volume of 1,1,2-trichloro-l, 2, 2-trifluoroethane (Fluka). Lysates were centrifuged at 
14,000g for 3 minutes at 4°C, suspended in twice their volume 2X Sample buffer and 
boiled for 3 minutes. Samples (one whole embryo per sample) were separated by 10% 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to PVDF 
membrane. Blots were blocked in 5% BSA in TBS for 1 hr. Blots were transferred to 
primary antibody (dilutions were: anti-phospho-Smad-1 at 1:250, anti-GFP at 1:1000, 
anti-a-tubulin at 1:5000) in 5% BSA (0.1% Tween) and incubated overnight at 4°C. 
Following primary antibody incubation blots were washed in TBST (0.1% Tween), and 
subsequently incubated in their respective secondary antibody (either ECL Rabbit IgG, 
HRP-linked F(ab’ )2 Fragment (Amersham Biosciences) for the Phospho-Smad-1 and the 
GFP antibodies or ECL Mouse IgG, HRP-linked Whole Ab (Amersham Biosciences) 
for the a-tubulin antibody) for lhr at RT. Blots were washed in TBST (0.1% Tween) 
and developed with chemiluminescent reagents (PIERCE). Blots were scanned and 
images were adjusted for brightness and contrast in Adobe Photoshop.
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2.2 Molecular Biology Techniques
2.2.1 Constructs
pCS2-gal4 was generated by inserting the 3694bp GALA coding sequence from pGaTB 
(Brand and Perrimon, 1993) digested with BamHl and Spel into pCS2 digested with 
BamHI and Xbal. Pax6-GalPR was generated by inserting a fragment containing the 
3.6kb Pax6 promoter (Hartley et al., 2001), from Pax6-gal4 (from Hartley, K) digested 
with Sail, then blunted with Klenow (Promega), then digested with Sfil into GalPRBicB 
(see below) digested with Eco47III then Sfil. GalPRBicB was generated by inserting the 
1.7kb GalPR coding sequence from pGL-VP (Wang et al., 1994) digested with BamHI, 
then blunted as above, then digested with Asp718 into pBicB vector {BicB containing 
the y-crystallin promoter upstream from ECFP coding sequence, Zimmerman L, Price 
B) that was digested with Notl, then blunted as above, then digested with Asp718. 
Pax6-GalPR was linearised with Sfil for transgenesis. N-tubulin-GalPR was generated 
by inserting the 1.7kb GalPR coding sequence from pGL-VP digested with BamHI, then 
blunted as above, then digested with Asp718, into a construct containing N-tubulin and 
BicB digested with Sail, then blunted as above, then digested with Asp718 (N-tubulin- 
gal4, Zimmerman L, Price B). N-tubulin-GalPR was linearised with Sfil for 
transgenesis. pKS.GAIA was generated by inserting the 3694bp GALA coding sequence 
from pGaTB (Brand and Perrimon, 1993) digested with Sail and Hindlll into pKS+ 
digested with Sail and Hindlll. Molecular biology techniques were carried out as 
described in Sambrook et al. (1989).
Constructs used in transgenic founders (lines) contained either GALA or GalPR 
coding sequences downstream from the specified promoter for transactivators, or
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Flognog downstream from GAM responsive elements, UAS and the hsp70 minimal 
promoter for effectors. There was a secondary reporter cassette in these constructs, 
transactivator transgenes contained y-crystallin-ECFP and effector transgenes contained 
CAR-RFP. These constructs are Otx-2-gal4BicB (Zimmerman L, Price B), N-tubulin- 
gal4BicB (Zimmerman L, Price B), Rx-gal4BicB (Zimmerman L, Price B), Pax-6- 
galPRBicB (constructed by myself) and UAST-flognogBic3 (constructed by Zimmerman 
L, Flognog Dionne, M and Harland, R) or UAS-gfpBicl, Biel has a cassette containing 
the cardiac actin promoter upstream of RFP (Zimmerman L, Price B). The promoters in 
these constructs are 2000bp fragment of the Xenopus laevis Otx2 promoter (Blitz and 
Cho, 1995), the Xenopus laevis 1.8kb N-tubulin promoter (neural-specific 0-tubulin 
promoter) (Richter et al., 1988), a 2200bp proximal fragment from the Xenopus 
tropicalis Rx gene (Chae et al., 2002; Hirsch et al., 2002), proximal 3500bp from the 
Xenopus laevis Pax6 promoter (Hartley et al., 2001), 2.2kb Xenopus laevis y-crystallin 
promoter (Smolich et al., 1993), Xenopus laevis CAR (cardiac actin) promoter (Mohun 
et al., 1986).
2.2.2 Table of Templates for Antisense RNA Probes
Gene Linearisation site RNA polymerase
IMAGE or Xenopus tropicalis 
EST ID or Reference
GFP BamHI T7 pCS2.GFP (Mohun, T)
GALA Eco47III T7 pKS.GAM (constructed myself)
x-Sox3 EcoRl T7 Genbank ID #BG512766
Pax6 Nsil T7 IMAGE 6992220
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X-dll3 EcoRl T7 Burd, G (University of Arizona)
2.2.3 Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)
Total RNA was isolated from 20 pooled Otx-2-gal4 X WT cross embryos, each at the 
stages specified in the results, by lysis in Trizol (Invitrogen) and subsequent isolation as 
described by Invitrogen. RNA was quantified on an agarose gel and 0.5-1.0pg of each 
was used for subsequent cDNA synthesis reaction. cDNA were made using 
Superscript™ First-Strand cDNA synthesis reverse transcriptase kit according to the 
protocol described by Invitrogen. cDNA was used directly in PCR reaction for GAL4 
and EFla. The oligonucleotide primers used were, for GAL4 (F:5*- 
CATGCGATATTTGCCGACTT-3 ’; R:5 ’ -GCTGTCTCAATGTTAGAGGC-3 ’) and for 
E Fla  (F:5’-CAG ATT GGT GCT GGA TAT GC-3’; R: 5'-ACT GCC TTG ATG ACT 
CCT AG-31). The PCR reaction mix included, IX PCR buffer (Abgene), 1.5mM MgCl2, 
0.2mM dNTPs, 0.05 Units/pl Taq, 0.5pM Forward primer, 0.5pM Reverse primer, 
l.Ong/pl DNA up to 10ml with dH20. The PCR amplification protocol was carried out 
as described by http://tropmap.biology.uh.edu/PCRprotocol.html. and was as follows, 
initial denaturing at 94°C for 4 min, denaturing 94°C for 1 min, annealing 58°C for 1 
min, elongation at 72°C for 1 min, for 30 cycles, then final elongation 72°C for 5 min. 
PCR products were analysed on a 1.5% agarose gel.
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CHAPTER 3: TRANSACTIVATOR CHARACTERISATION
3.1 Aim and Introduction
The transactivator transgenes contain the yeast transcriptional activator, GALA, under 
the control of neural promoters Otx-2 (Blitz and Cho, 1995; Pannese et al., 1995), N- 
tubulin (Richter et al., 1988) or the retinal tissue-specific promoter, Rx (Hirsch et al., 
2002) (Fig 3. IB). Using GFP reporter transgenic lines, these promoters have been 
previously characterised in Xenopus tropicalis, and spatial expression patterns similar, 
but not identical, to that of the endogenous gene were observed (Hirsch et al., 2002). 
The exact gene expression profile of these promoters remains unclear. Hence, due to a 
lack of precise gene expression profile data for these promoters and due to variable 
GAL4 driven expression, the aims were to define whether these transactivators were 
able to transactivate a UAS-gfp reporter, and to define the exact timing and location of 
promoter driven transactivation of target gene expression at stages during development 
of the forebrain. In a screen, founder transactivator transgenics were crossed to UAS-gfp 
reporter transgenic lines. The strength and location of transactivation was monitored 
and compared for each founder. Once a founder was identified that could transactivate 
in the correct tissue-specific manner for its respective promoter, stable lines were 
generated.
3.1.1 Xenopus Tissue-Specific Promoters
The use of tissue-specific promoters allows transcription to be limited to a subset of 
cells, but is restricted by the limited numbers of cloned and characterised promoters.
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Fortunately, most identified promoters display no difference in the pattern of GFP 
expression between X. laevis and X.tropicalis in GFP reporter lines (Offield et al., 
2000). The Xenopus Otx2 promoter is among these characterised promoters (Hirsch et 
al., 2002). It has been shown to drive transgene expression in a similar pattern to the 
expression of the Xotx2 gene. The Xotx2 (.Xenopus Otx2) gene is homologous to the 
Drosophila gene Orthodenticle and is expressed in anterior neuroectoderm, including 
the eye and forebrain (Panesse et al., 1995). Xotx2 is expressed at blastula stages. 
Subsequently, Xotx2 is strongly expressed in the anterior mesendoderm (and in cells of 
the Spemann’s organizer) at the onset of gastrulation (stage 10+), and in the prospective 
anterior neuroectoderm as gastrulation proceeds. In the late gastrula embryo (stage 12), 
Xotx2 expression is in a region of columnar cells, which constitute the future brain, and 
also in a region anterior to the columnar cells. At open neural plate stages, Xotx2 
expression is confined to cells of anterior dorsal regions and ectodermal expression 
overlaps the anterior border of the neural plate. At stage 18, Xotx2 is expressed in the 
anterior-most part of the ectodermal derivatives, which includes the brain anlage (Kablar 
et al., 1996). Xotx2 expression persists in the anterior regions of the newly closed neural 
tube. Also, expression persists weakly in the cement gland anlage until early tailbud 
stages. At stage 23, when the encephalon is sub-divided into three vesicles, there is 
expression in the whole forebrain and midbrain regions, as well as prospective ventral 
diencephalon. Xotx2 is also expressed in the lamina terminalis at the base of the 
forebrain (the most anterior part of the vertebrate neuraxis) and prospective anterior 
commissure at stage 23.
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The central nervous system expression in a GFP reporter line for the Xenopus 
Otx2 promoter (Otx2-gfp) seems to generally recapitulate the expression seen in 
prospective anterior CNS cells (Hirsch et al., 2002). GFP was detected in the anterior 
neuroectoderm and sensorial ectoderm by stage 19 and expression persisted in these 
regions throughout development. The apparent delay of transgene expression may have 
been caused by embryonic pigmentation or by growth at 25°C, which can reduce levels 
of fluorescence in transgenic embryos. GFP expression was also detected at stage 10.5- 
11 in the prechordal mesoderm, and persisted in this region until stage 35-36. This 
maintainence of expression in the notochord tissue is unlike the endogenous expression 
pattern. Presumably 2kb of the Otx-2 promoter does not include the regulatory elements 
responsible for turning off expression in this area.
There are also other characterised promoters, some of which include, y- 
crystallin, Pax-6, Xenopus neural-specific fi-tubulin (N-tubulin) and Rx, and these 
promoters have been shown to drive transgene expression in Xenopus in the lens, CNS, 
primary neurons and retina respectively (Offield et al., 2000; Hartley et al., 2001; Paul 
Krieg, unpublished). Moreover, this expression is reproducible in X. tropicalis (Hirsch 
et al., 2002; this thesis). The y-crystallin and Pax6 promoters driving GFP have been 
bred to homozygosity. The second filial generations (F2) of tadpoles from the Pax6- 
GFP line have been shown to display a consistent pattern of GFP expression (Hirsch et 
al., 2002). The Rx promoter was originally cloned from X. tropicalis (Hirsch et al.,
2002). Rx-GFP transgene expression is reported to be similar to that of the endogenous 
Rx gene. GFP expression was first detected in the presumptive eye fields in the anterior 
neural plate. Expression continued in the eye field throughout neurulation and tadpole
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stages and low level Rx transgene expression was also detected in the forebrain. 
Xenopus neural-specific /3-tubulin {N-tubulin) promoter has been reported to drive the 
expression of a reporter gene in the primary neurons of transgenic lines (Paul Krieg, 
unpublished).
The spatio-temporal expression pattern from the Pax6 promoter was analysed in 
more detail. In the Pax-6-GFP transgenic line it was found, via direct observation of 
GFP fluorescence or by whole-mount in situ hybridisation to GFP RNA, that expression 
is first detected at the beginning of neurulation (stage 12.5), indicating for this promoter 
that the expression is temporally correct. However, further analysis of the GFP RNA 
pattern revealed that there were differences in expression driven from the Pax-6-GFP 
transgene compared to endogenous Pax-6 expression. Differences in transgene 
expression compared to their endogenous counterpart expression has also been 
demonstrated from other Xenopus promoters, such as the noggin promoter, where 
expression was located to fusing neural tube instead of notochord cells (Geng et al.,
2003). These studies indicate that these characterised promoters can recapitulate spatio- 
temporal expression patterns of the endogenous genes to some extent, but others can 
drive expression in different areas.
3.1.2 GAL4/UAS Transgene Driven Expression in Xenopus
Analysis of the spatio-temporal profile of target gene expression in binary crosses has 
been assessed (Hartley et al., 2001; Hartley et al., 2002). In a cross of a CMV-gal4 
transactivator to a UAS-gfp reporter, there was ubiquitous GFP expression in a 
proportion of the FI embryos. GFP fluorescence was observed from mid-late neurula
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stages, indicating a time delay between the accumulation of GAL4 protein and its 
transactivation of GFP. The Pax-6 promoter was used to make a Pax-6-gal4 transgenic 
transactivator and in a binary cross with a UAS-gfp reporter tissue-specific expression of 
GFP was observed in a proportion of the FI embryos. GFP fluorescence was observed 
at stage 25, mainly in the eye primordia, whereas GFP mRNA was detected at stage 20 
by in situ hybridisation in prospective eye, hindbrain and spinal cord regions. They 
show that the expression of GFP mRNA correlated with the expression of Gal4 mRNA, 
and with expression of GFP mRNA in embryos transgenic for the Pax-6 promoter 
driving GFP. They conclude that there is spatially and temporally controlled 
transactivation of the reporter, GFP, in a cross of founder activator and effector lines, 
using the GALA system in Xenopus. An obvious limitation of these binary crosses is 
that there are delays in target gene expression and hence alterations in the promoter 
driven expression pattern. These studies indicate that the analysis of the exact spatio- 
temporal expression profile of transgene driven expression is needed to interpret the 
effects of gene manipulation using this system.
3.2 Results
3.2.1 Germline Transmission of Otx2-gal4, N-tubulin-gal4 and Rx-gaI4 Transgenes 
Germline transmission rate of transgenes was estimated in progeny from founder 
transactivators to identify lines with one stably expressed transgene integration site. To 
facilitate identification of the transactivator transgenics, each transactivator type 
transgene contained a secondary reporter cassette, y-crystallin-ECFP (Fig. 3.IB).
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Figure 3.1 Germline Transmission of Otx2~gal4, N-tubulin-gal4 and Rx-gal4 Transgenes
A. GFP fluorescence microscopy images illustrating lateral (i, iii, v, vi, viii, x) and dorsal (ii, iv, 
vii, ix) views of stage 40-42 FI tadpoles from a cross of either Otx2-gal4 (i, ii, vi, vii), N- 
tubulin-gal4 (iii, iv, viii, ix) or Rx-gal4 founders (v, x) to heterozygous UAS-gfp line, i-v show 
ECFP in the lens of the eye driven from the y-crystallin promoter. ECFP expression is in 
embryos only carrying the GAL4 transgene, as assessed by the absence of RFP in the somites 
from the CAR-RFP reporter cassette, vi-x show no ECFP in the lens. B. Diagram of 
transactivator construct in transactivator lines. The yeast transcriptional activator, GAL4 is 
under the control of either the Otx-2 (X. laevis), N-tubulin (X. laevis) or Rx {X. tropicalis) 
promoters. A secondary reporter cassette containing y-crystallin promoter linked to ECFP is 
placed downstream of the GAL4 transactivator transgene. C. Table I illustrates the numbers of 
embryos displaying GFP in the lens in the Otx2-gal4 (T165), N-tubulin-gal4 (T104) and Rx-gal4 
(T196 and T191) transactivator founder crosses to a homozygous UAS-gfp line. It illustrates the 
percentage of GFP+ embryos (containing GFP in the lens and RFP in the somites) and their 
estimated transgene integration number, which is based on statistical analysis of the segregation 
ratios in each cross. The expected segregation ratios and P values are indicated, and the P 
values, based on chi-square test, were P>0.05 in all crosses. Each of the tabulated values, GFP+ 
and GFP-, represent numbers obtained from counting GFP expressors and no GFP-expressors 
from one cross. It should be noted that transactivator transgenics drive expression of the UAS- 
gfp reporter in the eye, therefore GFP in the lens may result from combined transactivator driven 
GFP expression with y-crystallin reporter transgene ECFP expression. (T165, T104, T196, T191 
refer to the nomenclature used for the lines subsequently raised from these founders after further 
analysis).
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Figure 3.1
Otx2-gal4 X UAS-gfp N-tubulin-gal4X UAS-gfp Rx-gal4 X UAS-gfp
Otx-2
Ntubulin
Rx
kanamycin vector
GAL4 SV40pA y-crystallin 
promoter
ECFP SV40pA
GFP detection in the lens in Otx2-gal4 y-crystallin-GFP, N-tubulin-gal4 y-crystallin-GFP 
and Rx-gal4 y-crystallin-GFP F1 embryos
Transactivator
(Line) GFP+ GFP-
Total
Sample
Number
% GFP+ 
embryos P
Expected
Segregation
Ratio
Predicted
Integration
number
Otx2-gal4
(T165) 31 28 59 53 0.70 1:1 1
N-tubulin-gal4
(T104) 37 45 82 45 0.38 1:1 1
Rx-gal4
(T196) 65 169 234 27 1
Rx-gal4
(T191) 157 82 239 65 2
TABLE I
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Embryos could be easily scored for GFP fluorescence in their lens from stage 30 
onwards (Offield et al., 2000).
The Otx2-gal4 founder was tested for its germline transmission rate of 
transgenes by a cross to a UAS-gfp line. It was found that 31/59 (53%) FI embryos 
contained GFP fluorescence in the lens of their eyes (Fig. 3.1 A, C Table I). The GFP 
fluorescence appeared to be detected throughout the lens. If one transgene integration 
had integrated before the first cell division, only half of the embryos were expected to 
carry one copy of the transgene. Thus, as ~50% of the FI embryos were GFP 
expressors, this may indicate that one integration event occurred during the transgenic 
procedure, most likely at a very early stage of development resulting in a non-mosaic 
germline (Fig. 3.1C Table I). One transgene integration site was ideal as it makes 
subsequent binary crosses easier to interpret.
N-tubulin-gal4 founders were also tested for germline transmission rate of 
transgenes by a cross to a UAS-gfp line. An N-tubulin-gal4 founder was found to 
contain GFP in the lens in 37/82 (45%) FI embryos (Fig. 3.1 A, C Table I). This 
suggested that this founder contained one transgene integration site (Fig. 3.1C Table I).
Three Rx-gal4 founders were tested for their germline transmission rate of 
transgenes by a cross to a UAS-gfp line. One founder was found to contain GFP in the 
lens in 65/234 (27%) FI embryos (Fig. 3.1 A, C Table I). A germline transmission rate 
of 27% GFP expression in offspring from founder is near the 25% expected Mendelian 
ratio for a transgene integrated at a single locus from a founder that was half-transgenic 
(such that the transgene integration had incorporated at the 2-cell stage). This may 
indicate that there had been a single transgene integration event in this founder. It could
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also indicate that multiple integrations had occurred. Southern blot analysis on FI 
embryos will determine the number of transgene integrations. The two other Rx-gal4 
founders were found to transmit their transgene to produce 157/239 (65%) and 340/655 
(52%) FI embryos containing GFP in the lens, respectively. More than 50% of 
offspring exhibiting GFP expression from a founder indicates that multiple insertions 
into different chromosomes occurred in its germline. This may suggest that there were 
multiple integration sites for the Rx-gal4 T191 founder (Fig. 3.1C Table I). The value of 
52% (340/655, P>0.05, P=0.33) expression in the progeny is close to the expected ratio 
for one integration site, suggesting that the Rx-gal4 T63L1 founder contained one 
transgene integration site.
3.2.2 Onset and Location of Expression from Transactivator Transgenics 
To determine the onset of transcription from the promoter in the transactivator 
transgenics, the onset and pattern of GAL4 mRNA expression was assessed. The GAL4 
expression pattern was also assessed in comparison to the promoters’ respective 
endogenous gene expression pattern to identify the location of promoter driven GAL4 
expression. Embryos from a cross of either Otx2-gal4, N-tubulin-gal4, or Rx-gal4 
founders (FO) to WT were analysed either by whole-mount in situ hybridisation for 
GAL4 and the appropriate endogenous mRNA expression or by RT-PCR for GAL4 
expression.
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3.2.2.1 Otx2-gal4 Transactivator
RT-PCR for GALA expression was performed on embryos from an outcross of the Otx2- 
gal4 transactivator to WT at a series of time-points from the onset of expression of the 
endogenous Xotx2 gene. GALA was expressed from blastula stages (stage 9.5) and 
expression was maintained throughout gastrula and neurula stages (stages 11, 13 and 17) 
(Fig 3.2A). These results suggest that the Otx2-gal4 transactivator can drive expression 
from early stages of development, most likely from MBT (when zygotic transcription 
begins), consistent with the onset of the endogenous Xotx2 gene (Pannese et al., 1995). 
Subsequently, promoter driven GALA expression is maintained throughout neurula 
stages.
3.2.2.2 N-tubulin-gaM Transactivator
GALA is expressed at stage 13 in two stripes in the posterior-most region of the neural 
plate in 14/28 (50%) N-tubulin-gal4 X WT FI cross embryos (from the N-tubulin-gal4 
founder suggested to contain one transgene integration site) (Fig. 3.2B i, iv). At this 
stage there is no GALA expression in the anterior neural plate (Fig 3.2B iv). 
Endogenous N-tubulin is expressed in three stripes along the neural plate corresponding 
to the three types of primary neurons located along the medio-lateral axis (Oschwald et 
al., 1991) (Fig 3.2B iii). GALA mRNA expression therefore does not completely 
recapitulate N-Tubulin endogenous gene expression, most likely being restricted to the 
posterior-most prospective ventral primary neurons at stage 13. The reasons for the 
altered GALA expression may be due to a lack of all the regulatory elements in the N- 
tubulin promoter fragment, causing only part of the endogenous gene expression. Also,
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Figure 3.2 Onset of Expression from Otx2-gal4, N-tubulin-gal4 and Rx-gal4 
Transactivators
A. Gal4 mRNA expression starts at mid-blastula stages in Otx-2-gal4 X WT cross embryos. RT- 
PCR on FI embryos from an outcross of Otx2-gal4 transactivator displaying that Gal4 mRNA 
expression is transcribed from blastula stages and throughout gastrula and neurula stages. RNA 
was made from embryos at the stages 9.5, 11, 13 and 17 as indicated. EF-la was used as a 
control. B. Images represent dorsal views of embryos from a cross of N-tubulin-gal4 or Xrx- 
gal4 to WT that were analysed by whole-mount in situ hybridisation for Gal4 mRNA and their 
respective endogenous mRNA. Images iv and v are dorso-anterior views. Gal4 mRNA is 
expressed in the posterior neural tube in two stripes closest to the prospective ventral midline in 
N-tubulin-gal4 X WT cross embryos (i, iv). Endogenous N-tubulin mRNA expression at this 
stage is throughout the primary neurons of the neural plate (iii). Gal4 mRNA is expressed in 
putative forebrain (prospective retinal fields) in the anterior neural plate in stage 13 Xrx-gal4 X 
WT cross embryos (vi). Endogenous Xrx is expressed in a uniform field in the anterior neural 
plate of a stage 14 Xenopus embryo (image depicts an anterior view) (Mathers et al., 1997). ii, 
v, vii represent sibling embryos from N-tubulin-gal4 and Rx-gal4 crosses respectively (indicated 
by panels) displaying no Gal4 mRNA expression.
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the GALA mRNA expression pattern may not indicate the onset of the N-tubulin 
promoter as endogenous N-tubulin expression initiates at blastula stages (Oschwald et 
al., 1991).
3.2.2.3 Rx-gal4 Transactivator
GALA was expressed from stage 13 in the anterior neural plate in Rx-gal4 X WT FI cross 
embryos (from the Rx-gal4 half-transgenic founder suggested to contain one transgene 
integration site) (Fig 3.2B vi). Endogenous Xrx is expressed in the anterior neural plate 
of early neurulae, in a domain localised to the putative eye field (Mathers et al., 1997). 
Endogenous Xrx expression domain subsequently splits into two fields that give rise to 
the optic cups, which is the primordial of the retina at neural tube and tailbud stages. 
Thus, the domain of GAL4 expression most likely corresponds to putative forebrain. 
This result also suggests that the Rx-gal4 transactivator initiates transcription at the 
beginning of neurulation, consistent with the onset of endogenous Xrx mRNA.
All these transactivator lines were then sequentially tested for their ability to 
transactivate a UAS-gfp reporter.
3.2.3 Anterior CNS Tissue-Specific Transactivation of GFP in a Cross of Otx2-Gal4 
Transactivator to UAS-gfp Reporter
To determine whether the Otx2-gal4 transactivator could efficiently transactivate GFP 
from a UAS-gfp reporter, embryos from a cross of Otx2-gal4 X UAS-gfp (homozygous 
reporter) were analysed in vivo for GFP fluorescence. The transgenes that each embryo 
contained were established partly by using the detection of RFP in the somites from the 
CAR-RFP reporter (CAR, cardiac actin, Mohun et al., 1986) in the UAS-gfp reporter.
86
The transgenic identity could not be predicted from ECFP detection in the lens from the 
y-crystallin-ECFP reporter, due to Otx2 promoter driven co-expression in the lens. It 
was expected that two quarters of the progeny would carry one locus of each transgene.
GFP fluorescence was detected from stage 19 (neural tube stage) in anterior 
neural tube tissue in Otx2-gal4 X UAS-gfp cross embryos, whereas no GFP fluorescence 
was detected in UAS-gfp sibling control embryos (Fig 3.3A, K, N). GFP fluorescence 
was subsequently detected in the developing forebrain and midbrain (and the cement 
gland) at stages 23 to 36 in Otx2-gal4 X UAS-gfp cross embryos, whereas there was no 
GFP detected in UAS-gfp single transgenic embryos (Figure 3.3B, C, E, L, M, N). Due 
to time lags before GFP visibility, growth at 25°C reducing transgene fluorescence 
expression, leading to a delay in GFP detection, the stability of GFP for up to 24hrs or 
high pigmentation in Xenopus, which can cause a lack of ability to visualise GFP 
(Clontech; Amsterdam et al., 1996; Li et al., 1998; Hirsch et al., 2002), GFP 
fluorescence detection cannot be used to accurately determine the location of target gene 
expression at a particular stage of development because it may reflect an earlier 
expression profile. Nevertheless, GFP detection can be used to determine qualitatively 
if expression is driven in a tissue-specific manner. It should be noted that the y- 
crystallin promoter from the transactivator transgene can drive expression in the 
hindbrain at stage 19, as well as ectopic expression in the forebrain (Offield et al., 
2000). Thus, although it cannot be ruled out that part of the GFP fluorescence observed 
in the forebrain and hindbrain is due to the y-crystallin promoter, the GFP observed in 
the midbrain must be due to Otx2-gal4 transactivator driven expression. Furthermore, 
while GFP may not detect the real timing and location of expression of target gene for
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Figure 3.3 GFP is Transactivated by GAL4 in the Anterior CNS and Eye in Otx2-gaI4 X 
UAS-gfp Cross Embryos
Images are fluorescence microscopy photos of embryos from a cross of Otx-2-gal4 
transactivator to UAS-gfp reporter. All images are dorso-anterior views of the embryos, except 
images E, I, J are lateral images. White arrows point to developing anterior CNS tissue. GFP 
fluorescence is detected at stage 17 in the anterior neural tube (A). Then GFP is detected at 
early tailbud stage in the anterior CNS region (B). By stage 36, GFP can be seen in the brain 
and eye (and cement gland) (C). GFP is in the brain and eye at stage 39 (E) (and ECFP is co­
expressed in the lens from the y-crystallin reporter). Images D and I are the respective images 
for C and E and illustrate RFP in the somites from the CAR-RFP reporter in UAS-gfp. F-H, J are 
the respective brightfield images for A-C, E. No GFP is detected at stage 17 (K), early tailbud 
(L) and stage 36 (M) in a UAS-gfp single transgenic embryo (N). The genotype is predicted by 
the presence of RFP in the somites from the CAR-RFP reporter (K, L, M, N). O-Q are the 
respective brightfield images for K-M.
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the above reasons, and the stages displaying strong GFP are not for subsequent analysis, 
the data suggests that the Otx2-gal4 transactivator can transactivate expression from a 
UAS-gfp reporter in a tissue-specific manner.
3.2.4 Target Gene, GFP, is Expressed in the Anterior Neural plate and Anterior 
Neural Tube in Otx2-gal4 X UAS-gfp Cross Embryos
To establish if the Otx2-gal4 transactivator could transactivate GFP from a UAS-gfp 
reporter during neurula stages, western blot analysis was used to detect the target 
reporter protein, GFP, in Otx2-gal4 X UAS-gfp cross embryos during neurula stages.
A GFP signal (at ~27kDa) was detected in Otx2-gal4 X UAS-gfp cross embryos 
at stage 12.5 and at stage 19 (Fig. 3.4B). The detection of GFP at stage 12.5 indicates 
that the Otx2-gal4 transactivator can transactivate UAS-gfp GFP to protein levels during 
late gastrulation/ early neurula stages. At stage 19, it is not possible to distinguish 
whether the detection of GFP is due to Otx2-gal4 transactivator driven expression or due 
to y-crystallin promoter driven expression.
To further examine if the Otx2-gal4 transactivator could drive expression in the 
anterior CNS anlage, the location of Otx2-gal4 transactivator driven target gene 
expression was analysed by whole-mount in situ hybridisation for GFP RNA in 
embryos from the Otx2-gal4 X UAS-gfp cross.
GFP was expressed broadly throughout the anterior neural plate at stage 13 (Fig. 
3.4Ai). Whether or not there was earlier GFP expression in prospective neuroectoderm 
was not assessed. Subsequently, GFP was expressed in a broad domain at the anterior 
of the neural tube at stage 19 (Fig. 3.4A iii). The GFP expression at stage 19 is likely to
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Figure 3.4 GFP is expressed in the anterior neural plate and anterior neural tube 
(and other anterior-most regions) in Otx2-gal4 X UAS-gfp cross embryos
A. Images depict embryos from a cross o f Otx-2-gal4 X  UAS-gfp (i-iv) analysed by 
whole-mount in situ hybridisation for GFP  (i-iv). Images are whole-mount dorsal views 
(i, ii) or anterior views (iii, iv). GFP  is expressed in the anterior neural plate o f stage 13 
embryos, as well as other anterior regions (i), and then in the anterior neural tube and 
other anterior regions at stage 19 (iii). No GFP  is expressed in sibling control embryos 
(ii, iv). B. Lysates o f single embryos from a cross o f Otx-2-gal4 X  UAS-gfp made at the 
stages indicated, stage 12.5 (St 12.5) and stage 19 (St 19), and used for western blot 
analysis. A single embryo was loaded per lane. GFP is detected at stage 12.5 (n=12) and 
stage 19 (n=12) in Otx2-gal4 X  UAS-gfp cross embryos, a-tubulin signal indicates load­
ing o f samples. Images represent a typical signal in one embryo for its stage o f develop­
ment.
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be due to Otx2-gal4 transactivator driven expression, because in other GAL4 
transactivator crosses that do not drive expression in the forebrain at stage 19 (Fig. 3.7b 
C), there is no GFP expressed in the forebrain from y-crystallin promoter driven GFP 
expression. At these stages endogenous Xotx2 is expressed in a defined domain of 
ectodermal cells in the anterior dorsal regions (including neural plate), as well as 
stomodeal-hypophyseal and cement gland (Pannese et al., 1995). Therefore, in 
comparison with the published Xotx2 expression patterns, these results indicate that 
there is a difference in the Otx2-gal4 transactivator driven UAS-gfp target gene 
expression to the endogenous pattern. Nevertheless, the even distribution of reporter 
GFP transgene expression within the anterior neural tissue indicates that there is a non­
mosaic targeted mis-expression of target gene from the Otx2-gal4 transactivator. In 
another cross of the Otx2-gal4 founder to a heterozygous UAS-gfp reporter line, GFP 
was expressed consistently in the anterior neural tissue, as above, in 10/41 (24%) FI 
embryos. Although it was not confirmed that GFP expression was due to the presence 
of both Otx2-gal4 transactivator and UAS-gfp effector transgenes, GFP was expressed in 
approximately one quarter of the mating embryos. This indicated that expression was 
close to Mendelian ratios, and thus supported that GFP expression was due to embryos 
containing both Otx2-gal4 transactivator and UAS-gfp effector transgenes.
Embryos from a cross of Otx2-gal4 X UAS-gfp were further analysed by 
vibratome sectioning after whole-mount in situ hybridisation for GFP RNA. GFP 
expression was seen within the dorsal-anterior region of the embryo in ectodermal 
tissues (Fig. 3.5A-E). GFP expression was seen in the brain and eye anlage, as well as 
the epithelial layer of neuroectoderm. These results indicate that GAL4 expressed from
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Figure 3.5 GFP is expressed in the anterior brain and eye anlage (and other ectodermal 
tissue derivatives) in Otx2-gal4 X UAS-gfp cross embryos
I. A picture to illustrate a para-sagital section of a stage 17 Xenopus embryo. The brain and eye 
anlage, and epithelial layer of the neuroectoderm are indicated by the black lines (Hausen and 
Riebesell, 1991). n. Images represent stage 17 embryos from a cross of Otx2-gal4 X  UAS-gfp 
analysed by whole-mount in situ hybridisation for GFP and subsequently sagitally sectioned. 
Dorsal is at the top and anterior is at the left. Both A to E and F-I represent a stack of sections 
from the para-sagittal plane (left) to sagittal plane (right) through a representative GFP express­
ing embryo (A-E) and a sibling, non-GFP expressing embryo (F-I). A-E GFP expression is in 
the brain and eye anlage, as well as the epithelial layer of neuroectoderm. Black arrows point to 
the brain and eye anlage expression. F-I display background staining in a a sibling, non-GFP 
expressing embryo in the epithelial layers surrounding the embryos. Scale bar 50pm. Axes 
are indicated and are the same for the section picture in I and the images in II.
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the Otx-2 promoter is capable of activating transcription from UAS-gfp in anterior CNS 
cells. (It should be noted that BM purple was used as the substrate for alkaline 
phosphatase. BM purple can give two shades of blue stain with abundantly expressed 
RNA’s. Both the dark purple and the turquoise stain represent real staining).
These results suggest that an Otx-2-gal4 X UAS-target gene cross would be 
useful to analyse neural development, as a UAS-target gene reporter protein is detected 
from stage 12.5 onwards during neural development and target gene is expressed within 
developing CNS tissue. Therefore, a viable Otx2-gal4 FI heterozygous transactivator 
population (line T165/T191) was produced. Individual frogs from the Otx2-gal4 FI 
population were then outcrossed, and all frogs tested stably expressed their transgene in 
the F2 Otx2-gal4 population, confirming that the Otx2-gal4 transgene is stably 
expressed. Furthermore, progeny from crosses of either Otx2-gal4 founder transgenic or 
all Otx2-gal4 FI line frogs to UAS-gfp reporter transgenics produced the same 
transactivation of the GFP reporter.
3.2.5 Neural or Retinal Tissue-Specific Transactivation of GFP in a Cross of either 
N-tubulin-gal4 or Rx-gal4 to UAS-gfp Reporter
3.2.5.1 N-tubuUn-gaM X UAS-gfp Cross
The three N-tubulin-gal4 founders were compared for their ability to transactivate a 
UAS-gfp reporter. The founders were crossed to a UAS-gfp reporter and the FI embryos 
from these crosses were monitored for GFP fluorescence. In order to predict the 
transgenic identity of sibling embryos, individual embryos were grown in individual
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wells and monitored for their reporter cassette expression. By stage 40, secondary 
reporter cassettes containing CAR driving RFP in the heart and somites were visible.
In N-tubulin-gal4 X UAS-gfp cross embryos from the N-tubulin-gal4 F0 4 
founder there was no GFP in the nervous system (Fig 3.6 D-F, D’-F’). This indicated no 
transactivation for this line. In N-tubulin-gal4 X UAS-gfp cross embryos for another 
founder, N-tubulin-gal4 P0 5, there was strong GFP in the pharyngeal arches together 
with background GFP throughout the embryo and some GFP along the spinal cord (Fig 
3.6 G-I, G’-I’), implying ectopic transactivation outside the promoter-driven expression 
domain, possibly due to a leaky promoter construct. In N-tubulin-gal4 X UAS-gfp cross 
embryos from one N-tubulin-gal4 F0 3 founder there was relatively strong CNS-specific 
GFP fluorescence (including along the spinal cord), with minimal background 
fluorescence (Fig. 3.6 A-C, A’-C’), indicating for this founder that there was CNS-tissue 
specific transactivation of GFP from UAS-gfp reporter. Consequently, due to the CNS- 
specific transactivation, this N-tubulin-gal4 line (FO 3) was chosen for further analysis. 
Spinal cord or neural tube GFP fluorescence was evident from stage 23 in N-tubulin- 
gal4 X UAS-gfp cross embryos (Fig. 3.7B). GFP is maintained along the spinal cord 
throughout tailbud stages in N-tubulin-gal4 X UAS-gfp cross embryos (Fig. 3.7G). Only 
by late tailbud stages can GFP expression be seen to be reaching more rostral areas (Fig. 
3.7C). By stage 40 and stage 42 there is GFP expression in the brain (Fig. 3.7E, D). No 
GFP was detected in sibling UAS-gfp single transgenic embryos (Fig 3.7K, P, L-N).
To analyse the exact location of transactivation of GFP target gene, in situ 
hybridisation for GFP RNA was performed. GFP expression was evident from stage 13 
in two stripes in the posterior-most neural plate domain (Fig. 3.7b A), analogous to the
95
Figure 3.6 Different Areas of GFP Transactivation in Crosses between Different N-tubulin- 
gal4 Founders and a UAS-gfp Reporter
Fluorescence microscopy images of N-tubulin-gal4 X UAS-gfp cross embryos from three 
different N-tubulin-gal4 founders FO 3, FO 4 and FO 5. Images are taken at three sets of stages 
26-28,28-34, 38-39, see box above column. Panels on left indicate the founder that each image 
represents; images are of the same embryo from each different founder monitored over time. 
There was CNS tissue-specific GFP (A-C, see white arrows), no observable GFP in the anterior 
CNS (D-F) or non-specific GFP (G-I, see arrow), with expression located in areas just anterior 
and posterior to the eye (H) in N-tubulin-gal4 X UAS-gfp cross embryos from the three different 
founders FO 3, FO 4 and FO 5. In G-I, in addition to the high levels of non-specific GFP speckles 
throughout the embryo, there is also a lack of GFP in the CNS (although some GFP is still 
present in the anterior spinal cord (G, see arrow)). A*-I’ are the brightfield images for A-I 
respectively.
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Figure 3.7 GFP is Transactivated by GAL4 in the CNS in N-tubulin-gal4 X UAS-GFP 
Cross Embryos
Images depict fluorescence microscopy images or brightfield, as indicated. Images A, F, J, O, 
G, P, L, D, I, M, R are dorsal views, all the remaining images are lateral views. GFP is detected 
in the developing nervous system at stage 23 to stage 42 in N-tubulin-gal4 X UAS-gfp cross 
embryos (B, G, C, D, E white arrows point to nervous system). No GFP is detected at 
equivalent stages in a UAS-gfp single transgenic embryo (K, P, L, M, N). No GFP is detected 
during neurula stages in N-tubulin-gal4 X UAS-gfp cross embryo (A, same embryo as D) or 
UAS-gfp single transgenic embryos (J). F, H, I and O, Q, R are the brightfield images for A, C, 
D and J, L, M respectively. Images A, C, D represent the same embryo. Images J, L M 
represent the same embryo. GFP fluorescence was observed using with the GFP2 filter set, 
except images B, G, L, Q, which were observed with the GFP1 filter set.
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Figure 3.7b GFP is Expressed in the CNS in N-tubulin-gal4 X UAS-gJp Cross Embryos 
Images depict embryos analysed by whole-mount in situ hybridisation for GFP or endogenous 
N-tubulin. GFP is expressed in developing primary neurons in the posterior neural plate (A, B), 
neural tube (C, red asterisk illustrates the level of the prospective anterior brain) and spinal cord 
(D) in N-tubulin-gal4 X UAS-gJp cross embryos (see black arrow). GFP is also expressed in 
hindbrain regions, which is an artifact from y-crystallin driven ECFP (C, D). Sibling N-tubulin- 
gal4 X UAS-gJp cross embryos do not express GFP (B’\  D”), but illustrate background staining. 
Endogenous N-tubulin is expressed in developing primary neurons throughout the neural plate 
(and lateral ectoderm) (A’, B’), neural tube and brain (C’) and spinal cord and brain (D’) in N- 
tubulin-gal4 X UAS-gJp cross embryos.
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GAL4 RNA expression pattern (Fig. 3.2B i, iv). There appeared to be no time lag 
between GAL4 transactivation of GFP in this posterior domain. Again, analogous to the 
GAL4 expression pattern for this promoter, the expression domain of target gene 
expression, GFP, is not located in the anterior neural plate of the stage 13 embryo (Fig. 
3.7b A). GFP continued to be expressed in posterior neural tube areas thoughout 
neurula stages (Fig. 3.7b B). At stage 20, GFP expression extends along the neural 
tube, however there is still no expression in the anterior prospective brain region (Fig. 
3.7b C). Even by stage 25 there is no anterior brain GFP expression (Fig. 3.7b D). 
Ectopic speckles of GFP expression were evident on the yolk tissue in N-tubulin-gal4 X  
UAS-gfp cross embryos (Figs. 3.7C; 3.7b C, D). This is not seen in single transgenic 
sibling embryos (Figs. 3.7L; 3.7b D”), therefore could be due to slight non-specificity of 
GAL4 transactivation from this N-tubulin-gal4 founder. There were 11/24 (46%) of N- 
tubulin-gal4 X UAS-gfp (homozygous UAS-gfp reporter) cross embryos displaying GFP 
expression. Endogenous N-tubulin was expressed in the primary neurons throughout the 
neural plate, neural tube and brain (Fig. 3.7b A’, B \ C \ D’). GFP expression was in 
parts of the endogenous N-tubulin expression domain in posterior CNS regions, 
however GFP expression was not expressed in the same anterior CNS expression 
domains of endogenous N-tubulin.
A heterozgous FI population (T104) was produced from the N-tubulin-gal4 F0 3 
by outcross to WT frog. Eight frogs were raised in this FI population. Individual frogs 
were tested for stable expression of their transgene, and all individual frogs tested were 
able to transactivate GFP when crossed to a UAS-gfp reporter. In three different crosses 
of N-tubulin-gal4 heterozygous FI frogs to a homozygous UAS-gfp reporter, there were
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119/305 (56%), 112/348, (49%) and 161/441 (53%) cross embryos containing CNS- 
specific GFP respectively. This data suggests that the N-tubulin-gal4 transgene has a 
stable transgene expression through generations and high transactivation efficiency.
3.2.5.2 Rx-gal4 X UAS-gfp Cross
The Rx-gal4 founder transactivators were tested for their ability to transactivate 
expression of GFP from a UAS-gfp reporter. GFP fluorescence was detected in the eye 
fields in early tailbud stage Rx-gal4 X UAS-gfp cross embryos from Rx-gal4 (T196) 
founder (Fig. 3.8A, D). GFP fluorescence can be seen in the retina surrounding the lens 
by stage 39 in Rx-gal4 X UAS-gfp cross embryos (Fig. 3.8E, E” ). No GFP fluorescence 
was observed in a sibling UAS-gfp control embryo (Fig. 3.8F-H, H”). In another cross 
of Rx-gal4 X UAS-gfp from Rx-gal4 (T196), GFP was detected throughout the retina at 
stage 35/36 embryos (Fig. 3.8B, C). These results indicate that Rx-gal4 founder (T196) 
can transactivate GFP from a UAS-gfp reporter in a retinal tissue-specific manner.
In contrast, no GFP fluorescence was found in the eye fields in embryos from a 
cross of founder Rx-gal4 (T191) to a heterozygous UAS-gfp reporter (Fig 3.9B, C). 
Also, no GFP was detected in Rx-gal4 sibling single transgenic embryos (Fig 3.9J, K, 
L). However, using in situ hybridisation for GFP RNA, GFP expression could be 
detected in anterior neural plate in prospective eye fields at stage 13 (Figure 3.90). 
Subsequently, through neurula stages, GFP target gene expression is maintained in eye 
anlage (Fig 3.9P). This supports that Rx-gal4 founder (T191) can transactivate in a 
retinal tissue-specific manner, and that transactivation of expression from UAS-gfp does 
occur from the beginning of neural plate stages for the Rx-gal4 founder (T191), even
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Figure 3.8 GFP is Detected in Retinal Fields in Rx-gaM X UAS-gfp Cross Embryos
Fluorescence microscopy images of FI embryos from a Rx-gal4 FO (T196 line) cross to UAS-gfp 
effector. GFP is detected in the fields that give rise to the retina throughout early tailbud stages 
in Rx-gal4 X UAS-gfp cross embryo (A, D, E (represents ECFP in lens from y-crystallin reporter 
and Rx promoter driven GFP) (E” represents detection of RFP in the somites in embryo E, at 
stage 39)). B, C GFP can be seen in the retina in another embryo from the Rx-gal4 X UAS-gfp 
cross at stage 35/36 (line T196). No GFP in a UAS-gfp single transgenic sibling control (F, G, 
H, H, H” represents RFP in the somites from embryo H, at stage 39). B \ C \ D \ E \ H’ 
represent the brightfield images for B, C, D, E, H respectively.
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Figure 3.9 GFP Transcript, but not GFP Protein is Detected in Fields that give Rise to the 
Retina in Rx-gal4 X UAS-gfp Cross Embryos from another Founder
Images depict fluorescence microscopy, brightfield or whole-mount in situ hybridisation for 
GFP photos, as indicated, for embryos from a Rx-gal4 X UAS-gfp cross (T191 line). GFP is not 
detected in the developing retina in a Rx-gal4 X UAS-gfp cross embryos (A, B, C, (D, H 
indicating ECFP in lens from the y-crystallin reporter and Rx promoter driven GFP and RFP in 
the somites respectively to suggest that the embryo is double transgenic)). No GFP is detected 
in a Rx-gal4 sibling single transgenic embryo (I, J, (K, L ECFP in lens from the y-crystallin 
reporter and no RFP in somites suggests that the embryo is a Rx-gal4 single transgenic)). E, F, 
G, M, N are brightfield images to stage embryos of A, B, C, M, N respectively. O-P GFP is 
expressed in developing retina through neurula stages (13-16).
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Figure 
3.9
Brightfield Brightfield
though there is no apparent transactivation of GFP. Viable heterozygous FI stable lines 
were expanded from both Rx-gal4 founders (T196 and T191).
Otx2-gal4, N-tubulin-gal4 and Rx-gal4 lines were viable and displayed normal 
morphology (Figs. 3.3; 3.7; 3.8; 3.9), suggesting that expression of the GAM 
transcription factor and UAS target gene expression throughout the specific tissues from 
the respective promoters is not deleterious in itself.
BMP signalling has a role in neural patterning at early stages of neural 
development (Barth et al., 1999). In order to test the binary approach it was necessary 
to use a transactivator that drove target gene expression during early stages of anterior 
neural development. The N-tubulin-gal4 transactivator did not drive target gene 
expression in the anterior CNS during neurula or tailbud stages. The Otx-2-gal4 
transactivator was chosen for further characterisation due to its anterior neural plate 
expression.
3.3 Discussion
GALA transactivator lines have been established. The analysis of the GAL4 
transactivator lines containing different characterised promoters, Otx2, N-tubulin and 
Rxt has indicated that their spatio-temporal expression patterns of GALA and UAS target 
gene, resembles that of their respective characterised promoters. Although, there are 
time delays in target gene expression, as expected for this approach. Thus, using these 
transactivator lines, UAS target genes, of genes that may otherwise be lethal or multi­
functional, may be mis-expressed in the tissues directed from these promoters, and the 
effects of gene function in these areas can be assessed at later stages of development.
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3.3.1 Prospective Anterior CNS-targeted Reporter Gene Expression
Analysis of the transactivator line, Otx-2-gal4, by crosses, has established that it can be 
used as part of a two-part Gal4/UAS system for targeting gene expression to specific 
tissues in the developing anterior CNS (Fig. 3.3; 3.4; 3.5). The role of neural 
development and GAL4-mediated expression in this targeted mis-expression is 
discussed.
The expression of GAL4 transcripts in early blastula and gastrula, as well as the 
detection of GFP protein in late gastrula Otx-2-gal4 X UAS-gfp cross embryos, suggests 
that there is a minimal time-lag between accumulation of GAL4, its transactivation of 
the UAS-gfp effector, and the resulting accumulation of GFP. The anterior CNS is 
initially specified during gastrulation, at which point target gene product is made (Fig. 
3.4B). Target gene expression is detected throughout the neural plate; expression is in 
antero-lateral and lateral regions of the neural plate in regions which give rise to the 
telencephalon and dorsal neural structures, such as the pineal gland (Eagleson and 
Harris, 1990). Target gene expression in more medial regions of the neural plate is in 
regions which give rise to ventral brain structures. At later stages, when the neural tube 
has closed, target gene expression is still localised to the anterior of the embryo in brain 
anlage. Previous studies mis-expressing developmental regulatory genes within neural 
tissue during early stages of its development have found severe malformations in neural 
development (Hartley et al., 2002). Thus, mis-expression of developmental regulatory 
genes, in crosses of the Otx2-gal4 transactivator to UAS-target gene effectors 
(containing target genes such as Flognog), has the potential to interfere with forebrain 
development.
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At all stages of development assessed, the GALA and GFP mRNA expression 
pattern is distinct from the endogenous Otx-2 expression pattern (Fig. 3.4; 3.5). The 
reasons why transgene-mediated expression is not the same as endogenous expression 
may be due to transgene position effects, whereby the genomic site of integration affects 
reporter expression, with the same cis-acting sequences resulting in different subsets of 
the “correct” expression pattern. Alternatively, it may be due to the Otx2 promoter 
fragment not containing all the necessary regulatory elements to mimic the endogenous 
gene; it has been reported that the Otx2 promoter may not contain the necessary 
elements to down-regulate expression in the prechordal mesoderm (Hirsch et al., 2002). 
Also, GAL4-mediated expression may cause time lags in expression. Time lags may 
result from the synthesis and accumulation of GAM. Thus, GAM can distort the 
temporal control of expression in two ways. Firstly, there may be a delay before GAM 
reaches levels sufficient to activate the UAS-gene. UAS-target gene expression will 
then lag behind the start of promoter GALA transcription. This may result in the 
expression pattern in a later embryo resembling an earlier expression pattern. Secondly, 
GAM expression may carry on long after the endogenous expression has ceased, due to 
the stability of GAM protein, GAM protein will still be present and driving UAS-gene 
expression after cessation of promoter-ga/4 transcription (Phelps and Brand, 1998). 
Studies illustrating GAM-mediated delays have reported that GALA RNA is transcribed 
within 15 minutes after temperature-mediated induction from a hsp70:Gal4 activator. 
Then, GALA RNA decays rapidly by 90 minutes, depending on the duration of 
heatshock from the promoter, and subsequently GAM protein was detectable 1.5 hours 
after heat shock and persisted for at least 13 hours (Scheer et al., 2002). Other GAM-
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mediated problems include, GAL4 specificity; GAM transactivator lines can drive 
expression in other cells (Phelps and Brand, 1998). Also GAM can be variable, which 
can lead to variable phenotypes, which are difficult to interpret. These artifacts have to 
be taken into account when analysing the effects of a GAM/UAS cross. Thus, in the 
Otx2-gal4 reporter cross, the altered target gene expression pattern from endogenous 
Otx2 expression in the Otx2-gal4 X UAS-gfp cross (Fig. 3.4; 3.5) (Blitz and Cho, 1995) 
may be due to a lack of regulatory elements in the Otx2 promoter (Hirsch et al., 2002). 
The target gene expression (Fig. 3.3) resembles the expression seen from the Otx-2-gfp 
transgene line (Hirsch et al., 2002), therefore positional effect is not affecting expression 
in the Otx-2-gal4 line. Due to the altered expression profile from altered regulatory 
elements in the Otx2 promoter, it is hard to assess whether GAM-mediated delays have 
altered the expression profile in the Otx2-gal4 transactivator reporter cross, however this 
is likely to be a factor in the target gene expression profile. The expression patterns here 
do not indicate that there are problems with GAM expression variability because GFP 
was expressed consistently throughout the respective tissues for the Otx2 promoter.
The pattern of target gene expression from the N-tubulin-gal4 transactivator 
crosses are not recapitulating their endogenous expression patterns in primary neurons 
(Fig. 3.2; 3.6; 3.7; 3.7b) (Oschwald et al., 1991). Previous characterisation has shown 
that the N-tubulin promoter (neural specific beta-tubulin promoter) is expressed in 
primary neurons, as expected for this promoter (Kroll and Amaya, 1996; Richter et al., 
1988). Thus altered promoter elements from the endogenous gene may not be a reason 
for the altered transgene expression from this promoter. Position effects could be a 
reason for the differences in expression (Brand and Perrimon, 1993). Also, the target
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gene expression pattern in the N-tubulin-gal4 transactivator crosses resembles an earlier 
expression profile for the promoter but in an older embryo (Fig. 3.7). The altered target 
gene expression pattern appears to gradually appear in N-tubulin domains over time, in a 
similar manner to the Otx2-gal4 reporter cross. Thus, in addition to possible position 
effects modifying the N-tubulin promoter fragment, this delayed target gene expression 
may be due to a GAL4-mediated delay; GAL4 accumulation over time causing a time 
lag in reporter transgene driven expression.
In all transactivator type reporter crosses the levels of GFP target gene mis- 
expression were strong enough to produce detectable protein (Fig. 3.3; 3.7; 3.8). There 
is a high level transactivation here, which has the potential to be useful for the ligand 
trap technique.
Note that in figures 3.6, 3.7 and 3.7b there are ectopic speckles of GFP 
expression outside promoter driven areas in embryos from crosses of transactivators to 
reporters. As the ectopic GFP is only observed in double transgenic embryos and not in 
sibling control embryos, this indicates that the promoters may drive ectopic expression 
outside the promoter driven area. As this ectopic expression was mostly confined to 
yolk areas it should not be a problem.
3.3.2 Differences in Transactivation between Stable Lines
Fig. 3.8; 3.9 illustrates differences in retinal GFP expression between Rx-gal4 
transactivator lines; the Rx-gal4 T196 line appeared to produce GFP whereas Rx-gal4 
T191 line did not display GFP. The Rx-gal4 T196 line is the optimum line to use, as it 
appears to transactivate functional target gene protein (GFP). One might speculate that
112
the reason for such differences in transactivation could be due to transgene copy 
numbers, e.g. the Rx-gal4 T196 line may contain a higher transgene copy number than 
the Rx-gal4 T191 line. Thus, the overall levels of GFP via the Rx-gal4 T191 line X 
UAS-gfp cross may not be sufficient to produce visible GFP. As the transgene copy 
number has not been directly established, the copy number is assumed to be anywhere 
between 1 to 15 tandem copies of the plasmid carrying the transgene (Kroll and Amaya, 
1996; Marsh-Armstrong et al., 1999). It would be interesting to determine if this is the 
reason for the differences in transactivation. Other reasons for differences in 
transactivation (variations in expression of GAL4 occurring between activator lines 
containing the same construct) may be caused by the effect of the site of integration on 
the transgene or partial deletions of the transgene. These explanations do not seem 
likely as transgene-mediated expression reflects endogenous gene expression. 
Nevertheless, a Rx-gal4 T196 line has been bred that has strong transactivation during 
retinal determination, and it will be useful to study these processes. It may also be 
useful to breed this Rx-gal4 T196 line to homozygosity.
Fig. 3.6 illustrates differences in the level and location of N-tubulin-gal4 
transactivation of UAS-gfp reporter from different N-tubulin-gal4 founders. One 
possible explanation for these transactivation differences is the transgene position. 
Depending on the position of the N-tubulin-gal4 transgene integration site, it may be 
inhibited possibly by being buried in heterochromatin, thus resulting in a lack of 
transcription and a lack of transactivation from this integration site; or, transgene 
expression may be modified in other ways from its surroundings in the chromosome by 
“position effects”. The action of genomic enhancers adjacent to the site(s) of transgene
113
insertion may perturb the transcriptional activity of the N-tubulin promoter, resulting in 
an altered expression pattern from the promoter.
3.3.3 Other Roles for Different GAL4 Transactivator Types with Useful Spatio- 
Temporal Expression Patterns
The characterised GAL4 transactivator lines do not have useful expression patterns to 
investigate dorsal telencephalon patterning. This is due to either too early, i.e. the Otx2- 
gal4 transactivator (Fig. 3.3; 3.4; 3.5) or too late, i.e. the N-tubulin-gal4 transactivator 
(Fig. 3.7), target gene expression during CNS development to assess initial dorsal 
patterning, which occurs during and after neural tube closure. Nevertheless, the GAL4 
transactivator lines provide a way to drive the expression of developmentally important 
genes within restricted domains in the embryo. Lines have been developed that express 
GAL4 in different spatio-temporal patterns that will be useful to investigate other 
biological questions (Fig 3.6; 3.7; 3.8; 3.9). Xrx gene expression is important in early 
eye determination (Mathers et al., 1997). Sectional analysis will verify the precise 
location of transactivation of the prospective retinal field of target gene expression seen 
in these Rx-gal4 X UAS-gfp crosses (Fig. 3.7 O, P). The use of the Xrx-gal4T196 
transactivator line together with UAS-reporters (i.z.UAS-gfp) will allow expression to be 
visualised when retinal determination is occurring. Alternatively, Rx-gal4 transactivator 
lines can be used in conjunction with UAS lines containing developmentally important 
genes to investigate their effects during retinal determination.
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The N-tubulin-gal4 transactivator line may be useful for studying processes of 
differentiation and re-organisation of identified neurones during neurogenesis 
(Oschwald et al., 1991).
All of these established transactivator lines can be used to induce expression of 
many different transgenes with a reproducible timing and pattern of expression, for 
example, using the UAS-HIP (UAS fused to Hedgehog Interacting Protein, personal 
communication) to trap secreted SHH, this may be useful to investigate unanswered 
questions in ventral CNS patterning.
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CHAPTER 4: EFFECTOR CHARACTERISATION
4.1 Aim and Introduction
The effector transgene, UAS-flognog, contains five tandem repeats of the GAL4-binding 
motif UAS (Upstream Activation Sequence) along with the hsp70 minimal promoter 
from pUAST (Brand and Perrimon, 1993) linked to “ Flognog ” (Fig. 4.1). Flognog is a 
membrane-tethered fusion protein containing human Noggin fused to intracellular EGFP 
(Clontech) via a rat CD2 transmembrane domain. Noggin is an extracellular BMP 
antagonist and preferentially binds to BMP2 and 4 (and also binds other GDF5 subgroup 
BMPs, such as GDF6) (Zimmerman et al., 1996; Chang and Hemmati-Brivanlou, 
1999). Noggin cannot bind BMP7 efficiently in in vitro binding assays, however, it 
might still experience some binding in vivo (Zimmerman et al., 1996). This high 
affinity binding between noggin and BMPs prevents BMPs binding to their cognate cell 
surface receptors, and blocks BMP signalling. Although Flognog has been reported to 
dorsalize frog embryos and fluoresce (Dionne and Harland, per. comm.); it has not been 
established directly whether Flognog can block BMP signalling alone, as well as in the 
UAS-flognog transgenic line. Moreover, it has not been established whether the ligand 
trap can function in this binary system. Establishing this is therefore essential for the 
interpretation of any phenotype obtained in binary crosses. The UAS-flognog founders 
were screened for both their ability to block BMP signalling and for an optimum 
transgene integration site, in terms of copy numbers and position in the genome. Once a 
functional effector was identified, effector stable lines were generated, allowing a stable 
population containing uniform levels of transgene expression.
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5XUAS TATA human noggin Rat EGFP SV40pA Cardiac Actin RFP SV40pA 
hsp70 CD2 promoter
kanamycin vector
Figure 4.1 UAS-Flognog Effector Construct
A diagram of UAS-flognog effector construct. The 2-kb Flognog cDNA is placed under five 
repeats of the GAL4-responsive UAS. Flognog contains membrane-tethered human noggin 
fused to intracellular GFP (Dionne & Harland). A secondary reporter cassette containing 
Cardiac Actin promoter (Mohun et al., 1986) linked to RFP is placed down 
stream of flognog.
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4.1.1 Noggin and BMP Signalling
BMP signalling blocks the ectoderm’s ability to adopt a neural fate. An important role 
of neural inducers is to define an area of the ectoderm in which the anti-neural activity 
of the BMPs is antagonised. By blocking BMP signalling, Noggin therefore acts as a 
neural inducer. Neural inducers influence the fate of the ectoderm by planar or vertical 
signalling. Additionally, studies have demonstrated that Noggin mRNA injections into 
Xenopus dorsal equatorial region can cause an expansion of the neural plate, as indicated 
by Sox2 expression in Xenopus whole embryo (Huang et al, 2007). It was unknown 
whether Flognog could perform this same function, therefore an aim was to determine 
whether Flognog misexpression in the Xenopus dorsal equatorial region could increase 
neural progenitor tissue.
Other studies have demonstrated that levels of BMP signalling can be monitored 
in Xenopus using phospho-specific antibodies directed against the carboxyl-terminal 
region of the transcription factor Smadl, a downstream effector of BMP signalling 
(Reversade et al., 2005; Faure et al., 2000; Kurata et al., 2001). For example, a block 
in BMP signalling using BMP2/4/7 morpholinos or a dominant negative BMPRIA 
receptor leads to a loss of Smad-1 phosphorylation (Kuroda et al., 2005; Reversade et 
al., 2005). Therefore, another aim was to determine if Flognog can act in a similar 
manner to block Smad-1 phosphorylation.
4.1.2 Demonstration of Efficiency of UAS-target Gene in Effector Transgenics 
UAS-target gene effector transgenics have been characterised by determining whether 
the target gene transcript is transcribed (transactivated) and whether target protein
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product can be detected (Brand and Perrimon, 1993). Recently, the GAL4/UAS system 
has been demonstrated to be effective in Xenopus (Hartley et al., 2002; Chae et al., 
2002). Founders containing a reporter/ effector construct (UAS-gfp) were tested by 
GALA mRNA injections into progeny from an outcross of the UAS-gfp transgenic. 
Transactivation of the effector gene GFP was observed by fluorescence microscopy in 
embryos containing UAS-gfp. To test whether transactivation of the UAS-gfp effector 
could be achieved in a temporally and spatially controlled fashion, effector lines 
containing UAS-gfp were crossed to activator lines expressing GAL4 in a tissue-specific 
manner. Tissue-specific GFP expression was observed in a proportion of the FI 
embryos from this mating (Hartley et al., 2002).
The aim of the studies described in this chapter was to determine whether Flognog is 
functional in the UAS-flognog transgenic embryos (or lines). Then, subsequently, raise 
the most efficient UAS-flognog effector line for use in experimental crosses with 
suitable driver lines.
4.2 Results
4.2.1 Germline Transmission of UAS-flognog Transgene and its Responsiveness to 
GAL4
In order to identify a stable effector transgenic line, four independent UAS-flognog 
effector founders were crossed to WT frogs and tested for germline transmission rate 
and responsiveness of the UAS-flognog transgene to GAL4. Initially, the FI progeny
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were analysed for the expression of RFP in the somites driven from the CAR-RFP 
reporter. The RFP was detected throughout the somites, demonstrating that these 
transgenes were fully expressed (Fig 4.2i (A, C, I, K)). The expression was consistent 
with that obtained from RFP pattern in the somites from the CAR-RFP reporter in 
another reporter line, UAS-gfp. The FI progeny from crosses of UAS-flognog founders 
X WT were assessed for their number of expressors. It was observed that 28/58 (48%) 
embryos from T139 line, 137/286 (48%) embryos from the T201 line, 26/107 (24%) 
embryos from T14L2 and 117/187 (63%) embryos from T14L1 express RFP in their 
somites (Fig. 4.2ii Table II). Table II shows the number of embryos expressing RFP 
and the transgene integration number as predicted by Mendelian segregation ratios. 
Two UAS-flognog lines displayed RFP in approximately 50% of their embryos, 
suggesting both founders contain one transgene integration site (P>0.05, Table II), and 
that the integration event in these founder animals occurred at a very early stage of 
development resulting in a non-mosaic germline. One UAS-flognog line, T14L2, 
displayed transgene expression from CAR-RFP in 24% of its embryos. A germline 
transmission rate of 24% RFP expression in offspring from this founder is near the 
expected Mendelian ratio for a transgene integrated at a single locus from a founder that 
was half-transgenic (such that the transgene had incorporated at the 2-cell stage). Thus, 
this may indicate that there had been a single transgene integration event in this founder. 
The other UAS-flognog founder T14L1 had a high number of expressors, indicating 
multiple integrations in the founder.
To investigate whether the effector lines were functional (responsive to GAL4), 
GAL4 mRNA was injected unilaterally into one blastomere of two-cell stage FI progeny
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Figure 4.2 RFP is Detected in the Somites in UAS-flognog Lines
i. Images show stage 40 tadpole embryos from a cross between UAS-flognog transgenics 
(T139 and T201) and WT frogs. A, B, E, F, I, J, M, N are dorsal images. C, D, G, H, K, L, 
O, P are lateral images. A, C, I, K illustrate RFP throughout the somites driven from the 
CAR-RFP reporter. E, G, M, O illustrate sibling embryos displaying no RFP. B, D, F, H, J, 
N, L, P are their respective brightfield images, ii. Different founder UAS-flognog 
transgenics were crossed to WT. Table II illustrates the numbers and percentages of the FI 
embryos displaying RFP in the somites; and the transgene integration number as predicted 
from the chi-square test. The expected segregation ratios for both the UAS-flognogT 13 9 
and T201 line were 1:1, and the P values were P>0.05 in all crosses. The values in the table 
represent data collected from one experiment (one cross for each founder). In a second 
cross for founder (T14L2) to WT, 9/29 (31%) FI embryos displayed RFP in the somites.
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Figure 4.2
Brightfield Brightfield
RFP expression in UAS-flognog CAR-RFP F1 embryos
E ffe c to r
L ine RFP+ RFP-
%  RFP+ 
e m b ry o s
P
E s tim a te d  
N u m b e r  o f  
I n te g r a t io n s
T139 28 30 48 0.79 1
T201 137 149 48 0.48 1
T14n2 26 81 24 - -
Tl4n1 117 70 63 - -
Table II
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from crosses between UAS-flognog founders and WT. Subsequently, embryos were 
analysed at neurula stages for Flognog expression, as indicated by in situ hybridisation 
for GFP transcripts. After injection with GAL4 mRNA, all lines tested showed uni­
lateral expression of Flognog (GFP) (Fig. 4.3B i, ii, iii, iv). The unilateral Flognog 
expression indicates that the UAS-flognog transgene is specifically transactivated by 
GALA This suggests that GAL4 is sufficient to activate transcription from the UAS- 
flognog transgene in all UAS-flognog lines tested.
At 80pg GALA mRNA, 8/18 (44%) embryos for the UAS-flognog T139 line and 
25/133 (19%) embryos for the UAS-flognog T201 line expressed Flognog (Table III). At 
20pg GALA mRNA there is no induction of Flognog expression in the UAS-flognog 
T139 line, whereas Flognog is expressed in 28/96 (29%) embryos in the UAS-flognog 
T201 line (Table III). At 5pg GALA mRNA there was no visible Flognog expression for 
either line. This data illustrates that there is transcription of Flognog via GAL4 
transactivation of the UAS-flognog lines and that UAS-flognog requires in the region of 
20 to 80pg GAL4 mRNA to initiate transcription. The low percentages expressing 
Flognog suggest that not all of the embryos containing the UAS-flognog transgene are 
expressing Flognog. It should be noted that, in some cases, total amounts of embryos 
analysed for each condition is amalgamated data from parallel experiments that were not 
carried out in the same experiment (Table III).
This data confirms that UAS-flognog transgene is stably expressed in FI 
populations from both founders. Both UAS-flognog T139 and T201 lines are 
heterozygous viable, and since both showed expression from the transgene via GAL4 
transactivation, both are potentially useful. Hence, FI animals were raised from each
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/
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Figure 4.3 Flognog mRNA is expressed uni-laterally in GAL4 mRNA-injected UAS- 
flognog embryos from different UAS-flognog lines
All images are dorsal views o f neurula stage embryos analysed by whole-mount in situ 
hybridisation for GFP (i-iv) or fluorescence microscopy for GFP. i-iv represent uni-lateral 
Flognog mRNA expression in uni-laterally GALA mRNA-injected UAS-flognog X  WT 
cross embryos from four different UAS-flognog founders, T14L1, T14L2, T139 and T201. 
Un-injected side o f the embryo represents a control displaying no 
flognog  expression, v represents detection o f Flognog in embryos injected uni-laterally 
with 50pg Flognog mRNA.
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Cross
(Line)
Type of  
mRNA 
injected  
(P9)
Total 
am ount o f  
em bryos  
analysed
% of em bryos displaying phenotype  
(nu m b er/sam p le) Induced (I )  
Functional 
(F) 
Neither (N)
Flognog
(GFP)
expression
Flognog
(GFP)
detection
Neural 
increase  
Sox3  assay
UAS-flognog  
(T 139 )X  
WT
W a te r 4 7  (N b) N/A N/A 0 (0 /4 7 ) N
g a l4  (8 0 p g )
18 (N a) 
4 2  (N b )
4 4  ( 8 /1 8 ) n o n e 12 ( 5 /4 2 ) I, F
g a l4  (2 0 p g ) 4 7  (N b) 0 n o n e 0  ( 0 /4 7 ) N
g a l4  (5 p g ) 3 0  (N b) 0 n o n e 0 ( 0 / 3 0 ) N
UAS-flognog 
(T 2 0 1 )X  
WT
W a te r 27  (N b) N/A N/A 0 ( 0 / 2 7 ) N
g a l4  (8 0 p g )
133  (N a) 
19 (N b)
19 (2 5 /1 3 3 )
F lognog (GFP) 
(lO O pg g a l4 ) 5 (1 /1 9 ) I , F
g a l4  (2 0 p g ) 9 6  (N a) 
2 0  (N b)
2 9  (2 8 /9 6 ) n o n e 10 (2 /2 0 ) I , F
g a l4  (5 p g ) 19 (N b) 0 n o n e 0  ( 0 /1 9 ) N
WT X WT
n o g g in
( 6 2 .5 p g ) 2 7  (N b) N/A N/A 81  ( 2 2 /2 7 ) F
flo g n o g
(1 2 5 p g ) 3 4  (N b)
Flognog
e x p re s s e d
F lognog
(GFP) 3 8  ( 1 3 /3 4 ) F
W a te r 29  (N b) N/A N/A 0 ( 0 /2 9 ) N
N* Number of embryos analysed for GFP egression NbNumber of embryos analysed for Sox3 expression 
GFP expression data for the T201 line, and box3 expression data for T139 ana T201 lines represents combined 
results from two experiments. All other data represent values from one experiment.
founder. A heterozygous UAS-flognog F2 population was also obtained from the UAS- 
flognog T139 line.
In order to determine whether detection of fluorescence provided a viable assay 
for assessing the presence of Flognog protein, Flognog mRNA injections were carried 
out. Unilateral injection of 50pg Flognog mRNA resulted in unilateral neural plate 
Flognog (GFP) fluorescence, indicating GFP fluorescence can be detected from Flognog 
(Fig 4.3v). The same assay was then used to assess induction of Flognog protein via 
GAL4 mRNA injection into the UAS-flognog line. GFP fluorescence was evident in 
GAL4 mRNA-injected UAS-flognog embryos at lOOpg GALA mRNA, only in the UAS- 
flognog T201 line (Table III). This result suggests that there may be induction of 
protein from this UAS-flognog line. Further to these results, it was necessary to 
investigate whether or not Flognog protein was functioning.
4.2.2 Flognog Function in UAS-flognog Lines
Firstly, to determine the efficacy of Flognog fusion protein, Flognog was tested for its 
neural inducing ability in comparison to Noggin. Noggin and Flognog mRNA were 
injected unilaterally into the dorsal-animal equatorial region of WT embryos to induce a 
neural fate in neighbouring cells. Neural tissue can be identified by the X-Sox3 gene, 
this gene is a member of the HMG-box containing transcription factor family and is 
expressed in a highly restricted pattern in dorsal ectoderm where it marks proliferating 
neural precursor cells (Penzel et al., 1997). Alterations in the amount of neural 
precursor cells in injected embryos were then assessed by in situ hybridisation for x-
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Sox3 expression at neural plates stages, in an assay similar to that employed by Huang et 
al. (2007) to monitor Noggin activity.
In both Noggin and Flognog mRNA-injected embryos there was an expansion in 
domain of neural progenitor tissue in the neural plate on the injected side of the embryo, 
as indicated by x-Sox3 expression, which was not seen in water-injected control 
embryos. Embryos were co-injected with LacZ mRNA to determine the injected side of 
the embryo. The width of the x-Sox3 expression domain was measured, and the injected 
side of the embryo was compared with the contralateral uninjected side. There was 
background variation in the width of x-Sox3 expression domain in water-injected 
control. Therefore, taking this into account, if the width of domain of x-Sox3 expression 
at the mid-point of the anterior-posterior axis was at least two times the width of the un­
injected side, it was classified as an expansion (an increase). Using this criterion, there 
were 22/27 (81%) of Noggin (62.5pg) mRNA-injected embryos displaying an increase 
in neural tissue on the injected side of the embryo, whereas 13/34 (38%) Flognog 
(125pg) mRNA-injected embryos showed an increase on the injected side (Fig 4.4 C, F, 
Table III). As a control for injection, the same measurements were taken for embryos 
injected with LacZ mRNA alone. There were 0/29 (0%) LacZ mRNA-injected embryos 
displaying similar alterations in x-Sox3 expression domain. Therefore, these control 
embryos displayed no increase of neural progenitor tissue in the neural plate on the 
injected side of the embryo. In uninjected embryos, no variation in x-Sox3 expression 
between embryo sides was detected using the two-fold criterion as the threshold. These 
results suggest that Flognog is mimicking the activity of Noggin at inducing neural 
tissue.
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Figure 4.4 Expansion of the neural plate progenitor cells in GALA, Flognog and 
Noggin mRNA-injected UAS-flognog X WT cross or WT embryos
Images are dorsal views of whole-mount in situ hybridisation neural plate stage embryos 
expressing Sox3. A, B indicate embryos from T139 UAS-flognog line X  WT cross, D, E 
indicate embryos from T201 line X WT cross and C, F indicate embryos from a WT 
cross. Embryos from a cross o f UAS-flognog to WT (A, B, D, E) or W T embryos (C, F) 
were injected with 80pg GAL4 mRNA (A, D) or 125pg Flognog mRNA (C) or 62.5pg  
Noggin mRNA (F) or LacZ  mRNA alone (B, E) into one animal dorsal blastomere o f  
8-cell stage embryos and assayed for the extent o f  domain o f neural progenitor cells via 
Sox3 expression. A, D show an expansion o f the neural plate progenitor cells in GALA 
mRNA-injected embryos from both T139 and T201 UAS-flognog lines, indicated by the 
expression o f Sox3 marker. There is no expansion o f neural plate in LacZ  mRNA alone- 
injected control embryos (B, E). C, D show an expansion o f the neural plate progenitor 
cells in both Flognog (125pg) and Noggin  (62.5pg) mRNA-injected embryos, i indicates 
the injected side o f the embryo, as assessed by the presence o f X-Gal staining ((3-Gal 
activity)). X-Gal stained embryos were sorted for left and right and then analysed by in 
situ hybridisation for Sox3 for Flognog and Noggin  mRNA-injected embryos or embryos 
were analysed by in situ hybridisation for Sox3 and then analysed for X-Gal 
stain for UAS-flognog X  WT cross embryos. See Table III for numbers o f embryos 
injected.
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To investigate whether the effector lines were producing functional protein, 
GAL4 mRNA was injected unilaterally into the dorsal-animal equatorial region of 
embryos from a cross of UAS-flognog founders to WT frogs. Then subsequently 
assayed for x-Sox3 expression at neural plate stages.
At neural plate stages, GAL4 mRNA injection into embryos from UAS-flognog 
T139 and T201 lines resulted in a proportion of the embryos displaying an expansion of 
neural progenitor tissue in the neural plate on the injected side of the embryo, as 
indicated by x-Sox3 expression (Fig 4.4 A, D; Table III). This expansion was not seen 
in water-injected control embryos (Fig 4.4 B, E; Table III). Again all embryos were co­
injected with LacZ mRNA to determine the injected side of the embryo and the injected 
side of the embryo was determined by examination of the embryo for X-Gal staining. In 
order to assess the response of the UAS-flognog lines to different doses of GAL4 mRNA, 
it was necessary to define the criteria for what is classified as an increase. The width of 
x-Sox3 expression in the neural plate was measured for all of the embryos. It was 
decided that if the increase in width of domain of Sox3 expression on the injected side, 
at the middle of the anterior-posterior axis, was at least 1.5 times the width of the un­
injected side, it was classified as an increase (expansion). This arbitrary value of 1.5 
fold increase was taken based on the fact that there was a 1.05 to 1.06 mean fold 
increase in water-injected (LacZ mRNA alone) control. At 80pg GAL4 mRNA there 
were 5/42 (12%) embryos for the T139 line and 1/19 (5%) embryos for the T201 line 
displaying an increase in neural progenitor tissue on the injected side of the embryo (Fig 
4.4 A, D, Table III), whereas 0/47 (0%, mean fold increase on injected side was 1.05, 
P=0.54, P>0.05) and 0/27 (0%, mean fold increase on injected side was 1.06, P=0.22,
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P>0.05) water-injected (LacZ mRNA alone) control embryos for the T139 and T201 
lines respectively, displayed an alteration in size of neural progenitor tissue (Fig 4.4 B, 
E, Table III). There was no severe expansion of neural progenitor tissue on one side of 
the embryo compared to the other in uninjected control embryos expressing Sox3. As 
the dosage of GAL4 mRNA was decreased, at 20pg GAL4 mRNA there were 0/47 (0%) 
and 2/20 (10%) embryos for the T139 line and T201 lines displaying an increase in 
neural progenitor tissue on the injected side of the embryo. At 5pg GAL4 mRNA there 
were no drastic alterations of neural progenitor tissue on the injected side of the embryo, 
compared to LacZ mRNA-injected control embryos. These results suggest that GAL4 is 
sufficient to cause an increase the number of neural progenitor cells in the neural plate 
and indirectly suggests that BMP2, 4 and GDF6 signalling can be blocked by 
transactivation of the UAS-flognog transgene in these effector transgenic lines.
To verify that both of the UAS-flognog lines are functional, 80pg GAL4 mRNA 
was injected into the ventral marginal zone to determine whether axis duplication could 
be induced. Noggin mRNA injection into the same site is known to cause axis 
duplication (Fang et al., 2000). It was observed that axis duplication can occur in both 
T139 and T201 UAS-flognog transgenic lines upon injection of GAL4 mRNA, visualised 
by staining for N-tubulin. Axis duplication was not observed in LacZ mRNA alone- 
injected control embryos. Also, Flognog mRNA injections, like those of Noggin 
mRNA, induced secondary axis formation by injection into ventral marginal zone, 
providing further evidence that Flognog can mimic the function of Noggin.
For subsequent analysis, the UAS-flognog T139 line was used.
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4.2.3 Loss of Smad-1 Phosphorylation (Activation) in GAL4 mRNA-injected UAS- 
flognog Embryos
The phosphorylation state of Smad-1 can be used as an indicator of activation or 
inactivation of the BMP/ Smad-1 signalling pathway. Phospho-Smad-1 can be detected 
via western analysis of Xenopus embryo at neurula stage, and the signal is enhanced by 
activation of the BMP signalling pathway with BMP4 (Faure et al., 2000). The size of 
phospho-Smad-1 in Xenopus is approximately 60kDa (Kuroda et al., 2005). To 
determine whether BMP signalling was blocked in UAS-flognog embryos via GAM 
transactivation, embryos from a UAS-flognog X WT cross were co-injected at the 2-cell 
stage into two blastomeres in the vegetal pole with GAL4 and BMP4 mRNA (or BMP4 
mRNA alone), or were un-injected. Injected and un-injected sibling embryos were 
harvested individually at neurula stage for western blot detection with anti-phospho- 
Smadl antibody.
Anti-phospho-Smadl (Ser463/465), raised against a peptide of amino acids 455- 
465 from the C-terminus of human Smadl protein was obtained. This antibody 
recognizes the dual serine phosphorylated Smadl (Ser 463/465) and due to conservation 
of sequence it cross-reacts with Xenopus phospho-Smad-1 (Fig. 4.5A). When GAM is 
co-expressed with BMP4 in UAS-flognog X WT cross embryos, anti-phospho-Smad-1 
antibody reveals a signal at approximately 60kDa in 7 out of 17 embryos (Fig 4.5C). 
Expression of BMP4 in UAS-flognog X WT cross embryos and detection with anti- 
phospho-Smad-1 reveals a signal in all BMP4 mRNA injected embryos, whereas there is 
a faint signal in un-injected sibling embryos, supporting the specificity of the phospho- 
Smadl band. I was unable to detect a Smad-1 signal with a Smad-1 antibody, so I
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Fig. 4.5 Loss of Smad-1 Phosphorylation in GAL4 mRNA-injected UAS-flognog Embryos
A. Diagram of antigen sites and highly conserved carboxyl terminal sequence of Smad-1 
proteins of Xenopus and human. The amino acid sequence of human Smad-1 shown corresponds 
to the sequence of the synthesised phosphopeptides against which anti-phospho-Smad-1 
antibody was raised. The location of the phosphorylated serine residues are highlighted in red.
B. Phospho-Smad-1 size control. Embryos from a cross of UAS-flognog founder to WT were 
either injected with Flag-Smad-1 mRNA (25pg) (FLAG-SMAD-1) or injected with GAM 
mRNA (Non). Lysates from single embryos were loaded one per lane, and detected with either 
a-phospho-Smad-1 or a-Flag. A phospho-Smad-1- signal is detected at approximately 60kDa, 
and a FLAG signal is detected between 45 and 60kDa. C. There is a loss of Smad-1 
phosphorylation in UAS-flognog embryos co-expressing GAL4 and BMP4 from the UAS- 
flognogT 139 line. Embryos from a UAS-flognog X WT cross were co-injected at the 2-cell 
stage into two blastomeres with GAL4 (80pg/embryo) and BMP4 (lOOpg/embryo) mRNA 
(GAL4/ BMP4) or BMP4 mRNA alone (lOOpg/embryo) (BMP4), or were un-injected (Un). 
Injected and un-injected siblings were harvested at neurula stage for western blot detection with 
anti-phospho-Smadl. Individual embryos were lysed and lysate from one embryo was loaded 
per lane. The embryo number is shown, the figure illustrates 17 individual GAL4/BMP4 
embryos, one BMP4 alone embryo and one un-injected embryo. Phospho-smad-1 signal is 
detected in BMP4 alone, and reduced to a residual faint signal in un-injected embryos. Anti-a- 
tubulin indicates loading of samples.
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cannot rule out the possibility of alterations in total Smad-1 protein levels as a reason for 
alterations in phospho-Smad-1 signal. However, anti-a-tubulin reveals a signal in all 
embryos, controlling for loading of samples. Also, there was no variation within 
phospho-Smad-1 signal in BMP4 injected control embryos, suggesting that there may 
not be alterations in total Smad-1. In an independent control experiment, lysates from 
single embryos that were either injected with Flag-Smad-1 mRNA (25pg) (from cDNA 
encoding human Smad-1) or were not injected with Flag-Smad-1 mRNA, were analysed 
by western blot for either phospho-Smad-1 or FLAG antibody. A signal at 60kDa was 
detected in samples detected with phospho-smad-1 antibody (Fig. 4.5B). A signal at 
approximately 55kDa was detected in Flag-Smad-1 mRNA-injected lysates, indicating 
that the size of the endogenous phospho-Smad-1 was at a slightly higher size than 
Smad-1 (Fig. 4.5B). Although I have not demonstrated that the embryos with a loss of 
phospho-Smad-1 signal correspond to the transgenic embryos, the loss of the phospho- 
Smad-1 signal in approximately half of the GAL4 mRNA-injected embryos could 
suggest that GAL4 is sufficient to block endogenous phosphorylation of Smad-1 and 
that BMP/Smad-1 signalling is blocked by transactivation of the UAS-flognog transgene 
in these effector embryos.
4.2.4 Expression Levels of Flognog in Otx2-gal4 X UAS-flognog Binary Cross
Embryos
To analyse the transcription of Flognog and to assess the levels of Flognog in the 
Otx2-gal4 X UAS-flognog binary cross, Otx2-gal4 X UAS-flognog cross embryos, from 
heterozygous frogs, were firstly analysed by in situ hybridisation for GFP mRNA to 
detect Flognog mRNA. Whole-mount analysis of these embryos revealed, at stage 11,
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Flognog is expressed in the neuroectoderm (Fig. 4.6A). At stage 13, Flognog continues 
to be expressed in ectoderm cells of anterior dorsal regions, in the presumptive fore- and 
mid-brain (Fig. 4.6C), in a pattern similar to that reported for endogenous Otx2 
expression (Pannese et al., 1995). Later, Flognog was strongly expressed in the anterior 
neural tube, and prospective eye region at stage 19, as well as throughout the developing 
forebrain and midbrain and eye tissue at stage 24 (Fig. 4.6E, G). Throughout early 
development, although Flognog expression was maintained strongly in some embryos, 
there was variation (in expression seen) in the expression domains. This suggests that 
the expression seen is likely to represent the prolonged expression of Flognog due to 
GAL4-mediated expression, and may indicate that while the mRNA is stable in some 
embryos, the mRNA is not as stable in other embryos. Nevertheless, this data suggests 
that Flognog mRNA is transcribed in the Otx2-gal4 X UAS-flognog binary cross from 
gastrula stages. Furthermore, Flognog was expressed in 15/72 (21%) embryos, 
suggesting that the Otx2-gal4;UAS-flognog double transgenics are viable.
To test if GAL4 can activate UAS-flognog to levels that result in embryonic 
phenotypes, GFP detection can be used as an indication of expression levels of Flognog 
protein in the binary cross. Embryos from a cross of Otx2-gal4 X UAS-flognog, from 
heterozygous frogs, were monitored throughout development from end of gastrulation/ 
beginning of neurulation stage up to tailbud stage by immunohistochemistry using GFP 
antibody. Flognog (GFP) was observed in the anterior neural tube and prospective eye 
regions in stage 19 cross embryos (Fig. 4.61). Flognog (GFP) was not observed in other 
cross embryos at stage 19 (Fig. 4.6J). At stage 25, Flognog (GFP) was confined to the 
anterior CNS (forebrain and midbrain) and eye in 29/119 (24%) cross embryos (Fig
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Figure 4.6 GAL4-dependent Mis-expression of Flognog in a Spatially Restricted Manner in 
Otx2-gal4 X UAS-flognog Cross Embryos from Gastrula to Tailbud Stages
In all panels, images are anterior views and dorsal is to the top. A-H. Flognog mRNA is 
induced in embryos from Otx2-gal4 X UAS-flognog cross. A, C, E, G Flognog is expressed at 
stage 11 in anterior neuroectoderm (A). At stage 13 Flognog is expressed in anterior neural plate 
(C). Flognog is expressed in developing forebrain, midbrain and eye (E, G). B, D, F, H Sibling 
embryos displaying no Flognog expression. Black arrow in G points to forebrain. Red arrow 
points to two dots of expression, which is likely to be due to GFP expression in the hindbrain 
from the y-crystallin reporter. I-L Flognog protein is induced in embryos from the Otx2-gal4 X 
UAS-flognog cross. Immunohistochemistry for a-GFP was used to detect the presence of 
Flognog (GFP), and monitor the levels and location of Flognog. I Flognog is detected in stage 
19, initial neural tube stage embryos in the anterior neural tube and prospective eye region. K 
At stage 25, Flognog is detected in the developing forebrain, midbrain and eye. M-P Brightfield 
images of embryos in I-L respectively.
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4.6K), suggesting Flognog is translated in all binary embryos. Flognog could not be 
seen in the anterior CNS in the remaining 76% of embryos at stage 25 (Fig. 4.6 L). 
Within embryos displaying Flognog there was variation in both the level of Flognog and 
the location of Flognog. Some embryos displayed less or no Flognog in the anterior 
CNS, together with a malformation (possible loss of tissue) of the anterior CNS, but still 
retained Flognog in the eye and midbrain regions in a distorted neural tube. This effect 
may be due to a transformation, loss or alteration in tissue seen in a phenotype in the 
Otx2-gal4;UAS-flognog double transgenic embryos. These results suggest that GAL4 is 
sufficient to induce Flognog in double transgenic embryos by transactivation of UAS- 
flognog in Otx2-gal4 X UAS-flognog cross embryos.
4.2.5 Decrease of Phospho-Smad-1 in Embryos from a Cross of Otx2-gal4 X UAS- 
flognog
To determine whether BMP signalling was blocked in the Otx2-gal4 X UAS-flognog 
binary cross embryos, progeny from a cross of heterozygous Otx2-gal4 cross to 
heterozygous UAS-flognog at tailbud stage were analysed by immunohistochemistry for 
a-phospho-Smad-1.
At early tailbud stage, there was a decrease of phospho-Smad-1 in the anterior 
neural tube and eye region (Fig. 4.7A-C). This decrease was observed in 9/39 (23%) 
cross embryos. Within embryos displaying a decrease, there were slight variations in 
the residual phospho-Smad-1 stain. The remaining embryos displayed no loss of 
phospho-Smad-1 staining in the anterior neural tube and eye region (Fig. 4.7 D, I-L). 
Also, WT controls displayed no loss of phospho-Smad-1 staining in these regions. This 
result suggests that GAL4 is sufficient to reduce phospho-Smad-1, and hence reduce
Figure 4.7
Otx2-gal4 X UAS-flognog
Figure 4.7 Decrease of phospho-Smad-1 in Otx2-gal4 X UAS-flognog cross embryos
Photos represent fluorescence microscopy or brightfield images o f  tailbud stage embryos 
from a cross o f  Otx2-gal4 X  UAS-flognog analysed by whole-mount immunohistochemistry 
for phospho-Smad-1. A-C show a decrease in phospho-Smad-1 staining in the anterior CNS  
and eye in three representative (based on the reduced staining) O tx2-gal4 X  UAS-flognog 
cross embryos. D, I-L show phospho-Smad-1 staining localised to the anterior CNS and eye  
region in other O tx2-gal4 X  UAS-flognog cross embryos. E-H, M-P show their respective 
brightfield images. Images represent data collected from one experiment. There was a 
decrease o f phospho-Smad-1 in 9/39 (23%) embryos.
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BMP signalling, by transactivation of UAS-flognog transgene in a proportion of Otx2- 
gal4 X UAS-flognog binary cross embryos.
Thus, although tailbud stages are relatively late stages to assess the effects of the 
Otx2-gal4 X UAS-flognog cross, these results indicate that transcription via 
transactivation of the UAS-flognog transgene in the Otx-2-gal4 binary cross is induced at 
high enough levels to transcribe Flognog transcript, as well as translate Flognog protein. 
Flognog is, in both in situ hybridisation and immunohistochemistry assays, expressed 
and functioning in ratios close to the expected 25% Mendelian ratio. Hence, illustrating 
full transgene expression and indicating that the ectopic mis-expression of Flognog is 
not lethal, but may cause a phenotype in the anterior CNS.
4.3 Discussion
Stable and functional UAS-flognog effector transgenic lines were established. 
Flognog fusion protein is biologically functional as an inducer of neural tissue and as an 
inhibitor of BMP signalling. The results indicate that, GAL4 transactivation of Flognog 
in embryos from a cross of UAS-flognog to WT leads to an increase in neural tissue in 
these embryos, and also in a proportion of Otx2-gal4 X UAS-flognog cross embryos 
there is a reduction of BMP signalling (Fig. 4.4A, D; Fig. 4.7). This suggests that the 
UAS-flognog line can be used in conjunction with the Otx-2-gal4 transactivator (or any 
other GAL4 transactivator) to reduce BMP signalling in a spatially-restricted manner. 
The transgene expression and its ability to modify the BMP signalling pathway in UAS- 
flognog lines has been analysed in detail and this is outlined below.
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4.3.1 Flognog Transgene Expression
4.3.1.1 Varying Transgene Expression Between UAS-flognog Stable Lines
All UAS-flognog lines tested were able to respond to GAL4 by activating 
transcription of their transgene (target gene) (Hartley et al., 2002; Chae et al., 2002). 
Table III illustrates that UAS-flognog T201 line can be transcribed to express Flognog 
and show phenotypic effects at a lower amount of GAL4 than the UAS-flognog T139 
line. (It does not appear to have a more profound alteration in Sox3 expression at either 
amount of GAM, or compared to the UAS-flognog T139 line). Moreover, it appears 
that there are varying levels of Flognog expression between all the UAS-flognog stable 
lines (Fig. 4.3B i, ii, iii, iv). Dose effects of transgenes have being reported, and this can 
lead to extreme differences in transgene expression levels between lines. It has been 
previously demonstrated that effector lines vary in their response to GAM by 
transactivating the responsive gene to various degrees (Hartley et al., 2002). The 
reasons why there are varying levels of responsiveness between UAS-flognog lines may 
be due to positional effects or copy numbers of the transgene for the different founders 
consistent with findings from Hartley et al. (2002). The copy number may be the reason 
for the extremely weak expression in one UAS-flognog line (Fig. 4.3B iii). There may 
be a low transgene copy number in embryos from the T14L2 founder, whereas the UAS- 
flognog T201 may have the highest transgene copy number. However, this is unknown 
and a Southern blot could be carried out to determine this. The generation of the two 
different UAS-flognog lines may allow modulation of the transgene expression level of 
the UAS-flognog effector.
141
In addition to the differences in the expression level of target gene, there were 
differences in the germline transmission rate from different UAS-flognog founders 
(assayed by CAR-RFP reporter) (Table II). Transgenic founders are hemizygous for the 
transgene and transmit it to 50% of their resulting progeny (Kroll and Amaya, 1996; 
Hirsch et al., 2002). Thus, here there are founders displaying approximately 50% 
expressors in their progeny, whereas other founders displayed other germline 
transmission rates. Germline transmission rate can be altered in cases where the 
founders are half transgenics (indicating that the transgene had integrated after the first 
cell division) or when the transgene had integrated even later (i.e mosaic integration(s) 
in the founder), or when the founders contain multiple transgene integrations. This 
phenomenon has been seen before using the REMI transgenesis method (Hartley et al.,
2001). Lines were expanded from founders containing ~50% expressors in their 
progeny because this suggested that one transgene integration had occured; this allowed 
easier interpretation of the subsequent genotype ratios from the binary crosses. If there 
were multiple integrations, the transgene expression pattern in the founder would result 
from the sum of expression from all of the integrations, which may then segregate in 
subsequent generations, making crosses difficult to interpret. Lines from founders 
containing multiple integrations would require, in some cases, the segregation of 
multiple different insertions at F2 to generate the ideal clonal transgenic populations.
4.3.1.2 Flognog Expression in the Otx-2-gaM X UAS-flognog Binary Cross
The level of GAL4 expression in the Otx2-gal4 X UAS-flognog binary cross is sufficient
to induce Flognog expression in approximately 25% of cross embryos (Fig. 4.6; section
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4.2.4). This may indicate that in the binary cross there is GAL4 transactivation of UAS- 
flognog in all of the embryos containing both transactivator and effector transgenes. 
However, the transient assays illustrate variations in the amount of UAS-flognog X WT 
cross embryos displaying Flognog expression and increased neural tissue (Table III), 
which is not consistent, in some cases, with the UAS-flognog transgenic containing one 
transgene integration site (Fig. 4.2ii). Considering that the amount of mRNA 
transcribed from a transgene is usually lower than in microinjection, this raises the 
question why there are variations in numbers of embryos displaying Flognog 
transcription or neural expansion. Researchers have recorded expression analysis of 
UAS-effector gene expression in response to GAL4 activation by a hsp70 (heatshock) 
promoter. They showed that the amount of target gene expressed depended on the 
duration of heatshock (HS); being lower after 5 minutes than after 15 or 30 minutes HS 
(Scheer et al., 2002). This indicates that the level of target gene expression depends on 
the duration and hence amount of GAL4 being received. This is further suggested by 
GAL4 mRNA injection into a UAS-gfp reporter transgenic line, which produced a 
concentration-dependent increase in GFP fluorescence, indicating that the amount of 
GAL4 can regulate the transgene expression levels (Chae et al., 2002). Other studies 
show that the level of GAL4 directed expression can be varied, but only by exploiting 
position effects between lines or by changing copy number (Phelps and Brand, 1998). 
The threshold amount of GAL4 required to activate UAS-flognog transcription is lower 
than previously reported (Hartley et al., 2002). Thus, the varying responses to GAL4 
within embryos from these transient assays may indicate that GALA has not reached a 
threshold amount of GALA required to activate transcription in all of the transgenic
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embryos. Alternatively, it may be that the transgene position effect is inhibiting 
expression levels (Hartley et al., 2002). However, this is not a likely explanation for the 
UAS-flognog T139 line as Flognog is induced in approximately 25% cross embryos in 
the binary cross (Fig. 4.6). Other reasons for the effects seen may include low sample 
numbers or, for the Sox3 assay, the criteria being too stringent and therefore not 
including all embryos displaying an effect.
Flognog mRNA is expressed from gastrula stages (Fig 4.5 A), as expected from 
the timing of onset of the Otx2 promoter prior to gastrula stages (Fig. 3.2 A). Flognog 
expression is maintained up until tailbud stages (Fig. 4.6 E, G). Flognog protein 
expression can be seen by immunostaining from stage 19 and is maintained until stage 
25, again possibly longer (Fig. 4.6 I, K). Expression analysis of UAS-effector gene 
expression in response to GAL4 activation by a hsp70 heatshock promoter showed that 
target gene RNA was first detectable 1.5h after HS treatment, irrespective of the 
duration of the HS (Scheer et al., 2002). The amount of target gene RNA remained 
constant or even continued to increase after 3 and 17hr. Others have found that GAL4 
may direct expression with a slight time delay (Brand and Perrimon, 1993). (A GAL4 
insertion at the hairy locus can direct expression in a pattern that resembles hairy, an 
hour or so after the onset of stripes of hairy protein expression). Thus, there may be a 
slight delay of an hour or less between Otx2 promoter onset at blastula stages and 
expression of Flognog at gastrula stages (Fig. 3.2; Fig. 4.6A), similar to these previous 
findings. The Flognog transcript may also be more stable than the Gal4 transcript as 
suggested by previous research (Brand and Perrimon, 1993; Scheer et al., 2002) and the
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persistence of Flognog expression may be due to Gal4-directed transcription or due to 
the stability of the GFP portion of Flognog (Heim et al., 1994).
In the binary cross, Flognog was expressed in a spatially restricted manner in 
some embryos, whereas in other embryos expression was altered, in that there was either 
less expression or a lack of expression in specific areas. Flognog expression was seen in 
the anterior neuroectoderm, and subsequently throughout the anterior CNS including the 
forebrain and midbrain, and eyes (Fig. 4.6 A, C, E, G), consistent with the expected 
location of transactivation from the Otx2 promoter (Fig. 3.4). Flognog protein 
expression at late neurula to early tailbud stages likely reflects continued transactivation 
of target gene expression because the Flognog transcript is still present. The variations 
seen in Flognog expression (decreased level or absence) in these areas in some Flognog- 
expressing embryos (putative double transgenic embryos) may be due to a phenotype in 
the binary cross (Fig. 4.6). However, embryos were not genotyped so it is uncertain if 
these embryos are double transgenic. Nevertheless, the Flognog mRNA and protein is 
detected in the Otx2-gal4 X UAS-flognog cross at stages and tissues relevant for 
investigation of early neural differentiation or patterning during morphogenesis of the 
central nervous system.
4.3.2 Flognog Reduces BMP Signalling
The results show that Flognog can induce neural tissue, similar to Noggin in the x-Sox3 
assay (Fig. 4.4, section 4.2.2, Table III). Fig. 4.4 illustrates an expansion of Sox3 
expression domain, indicating an increase in neural progenitor cells (and a parallel shift 
of the neural-epidermal boundary), in the GAL4-transactivated UAS-flognog embryos.
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Studies have shown that Noggin (and blocking BMP signalling) can induce neural tissue 
(Hawley et al., 1995; Huang et al., 2007; Sasai et al., 1998; Reversade et al., 2005). 
Over-expressing mutant forms of BMP4 or BMP7, which block the normal function of 
BMPs in Xenopus, lead to a neural fate, indicated by N-CAM and Otx2 expression in 
animal caps (Hawley et al., 1995). Also, radial injections of BMP4 morpholino into all 
four blastomeres, in Xenopus, can lead to an expanded domain of pan-neural Sox2 
expression in the neural plate (Reversade et al., 2005). Others have shown injection of 
Noggin mRNA into animal blastomere lineages leads to an expansion of neural plate 
progenitor cells (altering the number of neural progenitor cells in the neural plate), 
indicated by x-Sox2 expression (Huang et al., 2007; Sasai et al., 1998). Huang et al. 
(2007) suggest that Noggin signalling from Xenopus animal blastomere lineages 
promotes a neural fate in neighbouring vegetal blastomere lineages. They propose that 
this is due to an early signalling center prior to gastrulation present in early animal- 
dorsal marginal zone lineages (the BCNE center) that secretes Noggin signals to induce 
a neural fate in neighboring vegetal equatorial cells. Conversely, other studies have 
shown that a dominant negative BMP receptor (a truncated BMP receptor lacking the 
intracellular kinase domain) has no effect on embryo pattern when injected into dorsal 
blastomeres (Suzuki et al., 1994), whereas injection into the ventral marginal region 
results in secondary axis formation. The findings here are not consistent with the latter, 
but are consistent with the studies of Huang et al. (2007) indicating cell fate changes 
prior to gastrulation that predispose a neural fate. This suggests that the mechanism for 
the neural expansion is that GAL4-activation and over-expression of Flognog (via its 
effects on BMP signalling) from animal blastomere lineages promotes a neural fate in
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neighbouring vegetal equatorial blastomere lineages. There are most likely other 
signalling pathways that are leading to the expansion of neural tissue as well (Pera et al., 
2003). These results may indicate that BMP 2 and 4 (and GDF6) signalling (the 
BMP/Smad-1 pathway) are blocked by GAL4 transactivation of the UAS-flognog 
transgene in UAS-flognog lines.
Western analysis showed a loss of phosphorylation of Smad-1 in GAL4 
transactivated embryos from a cross of UAS-flognog X WT (Fig. 4.5C). The embryos 
displaying a loss of Smad-1 phosphorylation are assumed to correspond to the 
transgenic embryos, although this has not been demonstrated directly. Blocking 
different components of the BMP signalling pathway individually or in different 
combinations can decrease phospho-Smad-1 signal, and hence decrease or block BMP 
signalling (Reversade et al., 2005; Kuroda et al., 2005; Faure et al., 2000). Blocking 
BMP signalling via a combination of BMP2/4/7 morpholinos (MO) injected into the 
marginal zone of all four blastomeres at the 4-cell stage results in a decrease in phospho- 
Smad-1 signal by western analysis, also, co-injection of MO for BMP4/7 or BMP4 
alone leads to decrease in phospho-Smad-1 signal, although to a lesser degree 
(Reversade et al., 2005; Kuroda et al., 2005). Likewise, expression of a dominant 
negative BMP type I receptor in animal and vegetal poles of two-cell stage embryos 
decreases phospho-Smad-1 signal (Faure et al., 2000). Moreover, cross-talk from other 
signalling pathways is involved in modulating the response of the BMP signalling 
pathway. FGF8 and IGF2 can induce MAPK to phosphorylate Smad-1 in its linker 
region, inhibiting Smad-1 activity and decreasing BMP signalling (Pera et al., 2003). 
Thus, as noggin is known to block BMP signalling (Faure et al., 2000), consistent with
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these other studies, the reason for a loss in phospho-Smad-1 signal could be due to 
Flognog activity, and could indicate that there is a reduction in BMP /Smad-1 signalling 
in these embryos. However, there could be interferences from other signalling 
pathways, such as MAPK activity or the degradation of Smad-1 by the ubiquitin ligase, 
Smurf 1 (Alexandrova and Thomsen, 2006), which act to inhibit Smad-1 activity. 
MAPK activity inhibits Smad-1 activity independent of C-terminal phosphorylation of 
Smad-1, so this is not a likely explanation for alterations in phospho-Smad-1 signal 
(Pera et al., 2003). Another observation was that in the embryos displaying a loss of 
Smad-1 phosphorylation, there was still some residual phospho-Smad-1 signal. A faint 
phospho-Smad-1 signal is also observed in BMP2/4/7 MO knockdown embryos 
(Reversade et al., 2005). This suggests that not all BMP/ Smad-1 signalling is blocked. 
The residual phospho-Smad-1 signal could be due to other BMPs activating the 
BMP/Smad-1 pathway or could indicate that insufficient levels of Flognog (expression) 
were achieved to block BMP/Smadl signalling. This raises the question of whether all 
BMP/Smad-1 signalling will be knocked down enough in the binary cross to produce a 
phenotype. Although other reasons for the alterations, such as variations in levels of 
phospho-Smad-1 signal cannot be ruled out, this data could indicate a reduction in BMP 
signalling in the UAS-flognog embryos, which is consistent with the increase in neural 
tissue seen in the UAS-flognog embryos by the Sox3 assay (Fig. 4.4A).
There was a reduction of phospho-Smad-1 staining in the anterior neural tube 
and eye region in approximately 25% of Otx2-gal4 X UAS-flognog cross embryos (Fig. 
4.7). There was a slight variation in reduction of the phospho-Smad-1 staining, with 
some embryos displaying a loss throughout the embryo, whereas other embryos
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displaying the main loss only in the anterior of the embryo. The ratio of loss of 
phospho-Smad-1 signal is consistent with it occuring in all the presumed double 
transgenic embryos. Blocking BMP signalling can abolish phospho-Smad-1 staining in 
wholemount embryos (Kurata et al., 2001; Faure et al., 2000). Co-injection of 
dominant negative-BMPRIA receptor and BMP4 mRNA into the animal pole blocked 
phospho-Smadl staining in the animal hemisphere in wholemount stage 8.5 embryos, 
whereas in BMP4 mRNA alone injected embryos showed specific nuclear staining in 
the animal hemisphere (Kurata et al., 2001). Moreover, Xenopus embryos injected 
marginally with Noggin mRNA (lOOpg/embryo) or BMP4 mRNA (500pg/embryo), 
abolished endogenous phosphorylation of Smad-1 in noggin-injected embryos, whereas 
the strength and distribution of phospho-Smad-1 signal was enhanced by ectopic 
activation of the BMP signalling pathway, in BMP4 injections (Faure et al., 2000). 
Thus, although Xenopus is not the best system to use for immunohistochemistry due to 
its lack of transparency, as BMP inhibition is known to cause a decrease in phospho- 
Smad-1 (Kurata et al., 2001; Faure et al., 2000), the results here are consistent with a 
decrease of phospho-Smad-1 and hence a block of BMP signalling, in vivo, in binary 
cross embryos. However, alternatively, pigmentation may obscure visualisation of 
fluorescence, and thus may be the reason or contribute to the reason for the reduction in 
phospho-Smad-1 stain. The possible reasons for variations in the loss of stain may be 
due to variations in transgene expression levels and /or a phenotype in the double 
transgenic embryos, or again, a possible lack of visualisation due to pigmentation. It 
would be interesting to carry out a time-course immunohistochemistry for phospho-
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Smad-1 to determine exactly when phospho-Smad-1 staining is reduced in the binary 
cross.
Combined evidence of increase in neural tissue and a decrease of Smad-1 
activation indicate that Flognog from the UAS-flognog line is functional at blocking (or 
knocking down) BMP/ Smad-1 signalling induced by BMP2, BMP4 and GDF6. 
Therefore, the UAS-flognog can be used in combination with a GAL4 transactivator to 
reduce BMP signalling in GAL4 expressing cells.
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CHAPTER 5: ANALYSIS OF NEURAL DEVELOPMENT 
IN BINARY CROSSES
5.1 Aim and Introduction
It remains unclear whether BMP signalling is required in a concentration-gradient- 
dependent manner from the dorsal signalling centre for patterning of the dorsal 
telencephalon. Thus, the aims here were to set up binary crosses to determine if there 
were any alterations in neural patterning, and subsequently to set up a system to 
determine if this gradient of BMP signalling is required for patterning of the dorsal 
telencephalon. This required tools that could manipulate gene expression in neural 
tissue, ideally within the telencephalon, after the initial induction of neural tissue, and 
during formation of the secondary source of BMPs. Previous chapters have 
characterised and established the Otx2-gal4 transactivator line and demonstrated that it 
can be used to mis-express target gene in the forebrain. Also, a UAS-flognog effector 
line has been characterised that can block BMP signalling in a tissue-specific manner. 
Although the Otx2-gal4 transactivator cannot be used to assess the effects of the late 
BMP signalling source on dorsal telencephalic patterning, due to its early onset of 
expression, the Otx-2-gal4 cross to UAS-flognog provided a first system to assess 
whether there were any forebrain patterning alterations by loss of BMP signalling in the 
anterior neuroectoderm. In a second approach, a Pax6-galPR line was established that 
can be used to manipulate the expression of a target gene in the anterior neural plate and 
prospective dorsal forebrain in a hormone-inducible manner. This hormone-inducible 
transactivator allows the late signalling source of BMPs to be manipulated, and thus is a
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more direct way to answer whether a late BMP signalling source acts to pattern the 
dorsal telencephalon.
5.1.1 Dorsal (and Ventral) Markers Confer Identity and Pattern to the Dorsal (and 
Ventral) Telencephalon
In Xenopus, the dorso-ventral axis becomes apparent from neural tube closure (around 
stage 21, Nieuwkoop and Faber, 1994) (Eagleson and Harris, 1990,1995). Hence stages 
from this time are useful to assess dorsal patterning.
Genes conferring positional information are expressed in spatially and 
temporally restricted patterns throughout the nervous system and may be used as stable 
markers of regional identity. Pax6 is a highly conserved transcription factor and is 
essential for the development of the alar plate of the forebrain (e.g. cerebral cortex) (as 
well as eye and other regions of the CNS) (Schmahl et al., 1993; Stoykova et al., 1996). 
Pax6 can be used as a dorsal or lateral marker of the prosencephalon/ prosencephalic 
neural plate. In Xenopus, Pax6 expression is initiated at the end of gastrulation/ 
beginning of neurulation in two lateral stripes, one on either side of the midline, and in a 
crescent at the anterior of the embryo (Hirsch and Harris, 1996). Expression continues 
in the anterior neural plate and the neural ridge, spanning most of the neuroectoderm. 
Pax6 is expressed in lateral (alar) regions of the prosecencephalic neural plate, and is 
excluded from the medial region. The two stripes of expression in the posterior neural 
plate give rise to the ventral-lateral spinal cord and hindbrain. At stage 23, Pax-6 
expression can be seen in the developing telencephalon and diencephalon. Transverse 
sections through the brain show that Pax6 expression occurs throughout the dorso-
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ventral extent of the telencephalon, but becomes restricted in the diencephalon where it 
is confined to presumptive dorsal thalamus. There is a gradient of Pax6 expression 
throughout the dorsal pallium in a [caudo-medial],ow to [rostro-lateral]high gradient, with 
highest levels present in the progenitor cells of the ventral pallium. At stage 32 and 35, 
Pax6 is expressed in the pallium, in the VP (ventral pallium) and LP (lateral pallium) in 
the SVZ (sub-ventricular zone) and MZ (mantle zone), whereas in the DP (dorsal 
pallium) and MP (medial pallium), Pax6 is expressed in the VZ (ventricular zone)/SVZ, 
with an area negative for Pax6 expression in the MZ of the DP. In the diencephalon 
Pax6 is expressed in P3 zone (Bachy et al., 2002). Pax6 is not expressed in the dorsal 
midline itself, possibly due to the high levels of BMPs expressed there (Timmer et al.,
2002). There is evidence to support Pax6 in forebrain regionalisation, where it plays a 
role in specifying dorsal telencephalic character, as well as subdivision or patterning 
(cell fate) decisions of the dorsal telencephalon (Toresson et al., 2000; Yun et al., 
2001). Pax6 mutation leads to a down-regulation or dorsal retraction of the expression 
of pallial markers (Emxl, Ngnl and Ngn2, Tbrl, Tbr2) and the dorsal expansion of 
subpallial gene expression (Gsh2, Mashl, Dlxl, Dlx2, Vaxl, Six3) into the pallium. The 
ventral pallium is partially re-specified to express some molecular characteristics of the 
dorsal LGE. The expression of Pax6 in the lateral alar prosencephalic plate and 
subsequently throughout the developing dorsal forebrain, means that it is co-expressed 
at least in part with the Otx2 promoter driven expression. Furthermore, since Pax6 
expression commences after gastrulation (i.e. after the onset of Otx2-gal4 transactivator 
driven expression) and the fact that Pax6 is a key regulator of forebrain regionalization,
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Pax6 could be a good candidate marker for analysis of lateral (dorsal) patterning in the 
Otx2-ga4 X UAS-flognog cross.
X-dll3, a ventral forebrain marker (which is a conserved gene, orthologous to 
Dlx5 in mouse (Liu et al., 1997)), is expressed from open neural plate stages (stage 16) 
(Papalopulu and Kintner, 1993). At stage 16, X-dll3 expression is evident in the anterior 
transverse rim or border of the neural plate and in the cement gland. At initial neural 
tube stage, Stage 19 (Nieuwkoop and Faber, 1994), X-dll3 is expressed in the anterior 
neural plate boundary in regions fated to become part of the ventral telencephalon, 
ventral diencephalic structures (which are mostly derived from the alar plate) and 
olfactory placodes (Eagleson and Harris, 1990). At stage 32 and 35, x-dll3 has been 
shown to mark the future pallidum arisen from the sub-pallium (in the SVZ and the 
MZ), and forms a sharp boundary, at the pallio-subpallial boundary. Its expression also 
marks the diencephalon (Bachy et al., 2002). The late onset of expression, its distinct 
expression profile, and the overlap with expression of the Otx2 promoter suggests that 
this marker can also be used to assess neural plate/ neural plate boundary (ventral 
forebrain) regional identity and position.
5.1.2 Timing of BMP Signalling Alteration on Dorsal (and Ventral) Forebrain 
Patterning
Gain- or loss-of-function studies, increasing or decreasing BMP signalling at various 
stages throughout nervous system development have been found to cause changes in 
expression of either dorsal (or ventral) forebrain or dorsal nervous system markers
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(Hartley et al., 2001; Hartley et al., 2002; Golden et al., 1999; Hanel et al., 2006). 
Further to these molecular alterations, there are malformations of the brain or head.
Mis-expressing BMP4 in the anterior neuroectoderm from the Xenopus Pax6 
promoter or by BMP4 mRNA injections targeted to the anterior neuroectoderm in 
Xenopus have been reported to cause different effects on expression of the ventral 
forebrain marker, X-dll3 (Hartley et al., 2001). Early BMP4 signalling inhibited the 
expression of this gene in the anterior region of the embryo, whereas late BMP 
signalling after gastrulation resulted in a significant increase in expression. As for the 
dorsal marker, Pax6, an increase in BMP signalling in the anterior neuroectoderm 
resulted in a reduced level of expression and a reduced extent of expression domain of 
Pax6, whereas mis-expressing BMP signalling after gastrulation from the Pax6 
promoter resulted in a slight down-regulation of Pax6 expression. Thus, there are 
different responses of these regional markers (implying different competence of the 
neural tissue) to BMP signalling at different stages of neural development and/or 
different responses of these regional markers due to the levels of BMP misexpression 
the embryo received. In the same study morphological alterations were also observed. 
In the Pax6-BMP4 transgenic embryos there was a suppression of anterior brain and eye 
formation in 90.7% of tailbud stage embryos, compared to in 36% of GFP expressing 
Pax6-GFP transgenic embryos. Also, by BMP4 mRNA injection into the anterior 
neuroectoderm, there was a reduced or entirely absent neural plate. This indicates a 
similar response of the tissue from these two methods, and that increasing BMP 
signalling throughout early neural development results in a decreased neural 
development.
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In another cross, mis-expression of a downstream target of BMP signalling, 
vent-2, by the Pax6 promoter resulted in a microcephalic phenotype, as well as a severe 
ventralization phenotype “bauchstuck” by stage 28 (Hartley et al., 2002). The dorsal 
axis of the embryos was shortened and all head structures were absent. There were 
variations in the severity of the phenotype between lines. When the same Pax6-gal4 
line was crossed to two different UAS-vent-2 lines, a cross from one line produced the 
severe ventralized phenotype, whereas the other line produced the microcephalic 
phenotype. These results illustrate the variability in phenotypes resulting from the use 
of different transgenic lines with different transgene expression levels, hence 
presumably different levels of BMP signalling. Nevertheless, these results show severe 
malformations of anterior neural structures as a result of increases in BMP signalling 
after gastrulation.
Furthermore, in the study by Golden et al. (1999), mentioned before, the 
alterations in dorsal and ventral forebrain markers, as well as the brain and head 
malformations in response to a late source of BMPs, indicate that, at late developmental 
stages BMPs are sufficient to specify dorsal forebrain development, in part, as indicated 
by Wnt4 expression alterations, and that the nervous system is still competent to respond 
to dorsal/ ventral patterning signals. Furthermore, BMPs can cause severe brain 
malformations at these later stages of neural development. However, there was only a 
reduced Pax6 expression in a reduced brain size, and Pax6 expression was maintained. 
It is interesting that there was a no alteration in level of Pax6 expression, consistent with 
only a slight alteration of Pax6 at late stages of neural development in the studies of 
Hartley et al. (2001).
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In loss of function studies, using a GDF6 morpholino to reduce BMP signalling, 
there was an overall reduction in size of embryos by neurula stage (stage 20, Nieuwkoop 
and Faber, 1994), and a reduction in size and shape of the Pax6 expression domain in 
the retina and forebrain. By stage 27 there was a reduced or altered shape of Pax6 
expression in the retina and a marked loss of Pax6 expression in the forebrain (Hanel et 
al., 2006). Thus, implicating a loss of BMP signalling from early stages of neural 
development in retina and forebrain specification at later stages.
These studies have assessed the effects of BMP signalling alterations at different 
stages in forebrain development and have indicated that this can result in different 
changes in expression of forebrain markers depending on the stage of development.
5.1.3 Pax6 Promoter and Hormone-inducible GalPR as a Tool to Investigate Dorsal 
Telencephalon Patterning
The inducible GalPR system allows both temporal and spatial control of gene 
expression. A chimeric regulator (pGL-VP) comprising the ligand-binding domain of 
human progesterone receptor hPRB891 fused to the yeast transcriptional activator 
GAL4 DNA-binding domain and the herpes simplex virus protein VP16 activation 
domain can activate target genes in response to RU486 (Wang et aL, 1994).
The Xenopus Pax-6 promoter drives expression of a GFP reporter in a similar 
but not identical domain to that of endogenous Pax-6 (Hartley et al., 2001). Unlike 
endogenous Pax6 expression (Liu et al., 1997), the transgene driven expression does not 
down-regulate in the medial domain of its anterior-most expression domain during 
neurulation (Hartley et al., 2001). Also, there is a higher level of transgene expression
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in the telencephalon than endogenous Pax6 expression, and there is a lack of strong 
transgene expression in the diencephalon and lens. This suggests that separate elements 
missing from the 3.6kb genomic promoter fragment are required for these expression 
domains. Upon analysis of the Pax6 promoter driven expression in X. tropicalis, it was 
established that Pax6-GFP transgene expression was similar to the Pax6 expression 
profile (Hirsch et al., 2002). Therefore, there are some differences in Pax6 promoter 
driven expression compared to that of the endogenous Pax6 gene (Hirsch and Harris, 
1996). However, the strong Pax6 transgene driven expression in the telencephalon, that 
is presumably outside the dorsal midline (containing high levels of BMPs), indicates 
that the Pax6 promoter in conjunction with other transgene and transgenic tools may be 
used to a investigate the effects of a BMP signalling gradient on dorsal telencephalon 
patterning.
A binary system using Pax6-galPR would be more useful than the Otx-2 
promoter-based approach because its inactivity in the absence of inducer may avoid the 
early effects associated with alterations of BMP signalling during gastrulation. 
Moreover, the Pax6 promoter has restricted expression in the dorsal central nervous 
system in the rostral CNS, allowing more targeted mis-expression to the dorsal 
telencephalon (whereas Otx2 promoter targets expression to ventral domains as well). 
Pax6-galPR induction at late stages of telencephalon development could be used to 
dissect out whether BMP signalling is required for specification of dorsal fate and 
pattern formation in the dorsal telencephalon. Another advantage of using the GalPR is 
that it contains the VP16 transcriptional activation domain, which is capable of driving 
higher levels of transcription compared to GAL4 alone.
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5.2 Results
5.2.1 Open Neural Tube Defects in Otx2-gal4 X  UAS-flognog Cross Embryos 
To determine whether there was any morphological effects caused by inhibiting BMP 
signalling in the prospective anterior CNS (anterior neuroectoderm), embryos from an 
Otx2-gal4 X UAS-flognog cross (both heterozygotes) were analysed over early 
development until tadpole stages for abnormalities. All frog crosses were heterozygous, 
unless otherwise stated.
At neural tube stage a partial open neural tube was observed in Otx2-gal4 X  
UAS-flognog cross embryos, whereas sibling control embryos did not display these 
alterations (Fig. 5.1 A, B alteration, C control). Otx2-gal4 X UAS-gfp cross (n=95) and 
WT (n=54) (Fig. 5. ID) control embryos did not display these alterations either. The 
altered morphology was observed in 68/349 (19%) Otx2-gal4 X UAS-flognog cross 
embryos. Within these embryos displaying the phenotype there were variations in the 
severity of the open neural tube and embryo size. At stage 19 there was a failure of the 
neural tube to fully close (or a partial closure), with some embryos being more open 
than others, as well as some embryos being smaller compared to others. The opening 
focused around the prospective midbrain area of the anterior CNS, with the propective 
anterior CNS area of the neural tube closed. This data could suggest that BMP 
signalling in the anterior neuroectoderm, including neural plate, is required for proper 
closure of the neural tube in a proportion of Otx2-gal4 X UAS-flognog cross embryos.
Double trangenics were viable at least up until stage 42. A proportion of these 
had small heads with eyes closer together (16/115 (14%)). Some Otx2-gal4;UAS- 
flognog double transgenic tadpoles displayed an extended pigmented retinal epithelium
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Stage 19
WT
Figure 5.1 Partial open neural tube in Otx2-gal4 X UAS-flognog 
cross embryos
Images represent fixed stage 19 embryos from a cross o f Otx2-gal4 X  UAS-flognog (A-C) 
or a stage 19 WT embryo (D). A, B illustrate embryos with a partially open neural tube, 
with the anterior o f the neural tube closed. C shows a sibling embryo with a normal 
closed neural tube. D shows a WT embryo with a normal closed neural tube. n=349
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(making the eyes appear as an hourglass shape). This could result from an interference 
of the bi-lateralisation signal from the (ventral) midline structures of the neural plate and 
tube (Reichenbach et al., 1997). The transgenic identity of embryos from the Otx2-gal4 
X UAS-flognog cross were observed as, 65/200 (32.5%) double transgenics (containing 
both the y-crystallin-GFP and CAR-RFP reporters), 47/200 (23.5%) Otx2-gal4 
(containing y-crystallin-GFP), 43/200 (21.5%) UAS-flognog (containing CAR-RFP) and 
45/200 (22.5%) non-transgenic, and did not significantly (P>0.05, P=0.10) deviate from 
Mendelian ratios.
5.2.2 Pax6 Expression is Disrupted in the Otx2-gal4 X  UAS-flognog Cross Embryos 
To further investigate the phenotype, the next step was to determine whether dorsal 
patterning was altered by a loss of BMP signalling in the prospective anterior CNS 
(including in embryos displaying the variably altered open neural tube). Embryos were 
therefore analysed for the dorsal neural marker, Pax6, by whole-mount in situ 
hybridisation. Embryos were analysed both in whole-mount and by vibratome 
sectioning to reveal the dorso-ventral (transverse) axis within the (prospective) forebrain 
tissue. Neural tube and tailbud stages were taken for analysis, as these stages occur 
during and after dorsal patterning has occured, and the dorso-ventral axis is established 
(Eagleson and Harris, 1990). Furthermore, at stage 23 to late tailbud, the dorsal 
telencephalon is already formed and the brain sub-divisions are more distinct by 
morphology, as well as gene expression.
At stage 19, in whole-mount embryos, there was an altered shape, a reduced size 
of domain and a closer together or fused anterior domain of Pax6 expression in 8/54
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(15%) Otx2-gal4 X UAS-flognog cross embryos (Fig. 5.2I-K, sibling displaying no 
alterations M-O). Although WT embryos did not display any alterations in Pax6 
expression (Fig. 5.2A-H), a proportion of Otx2-gal4 X UAS-gfp cross embryos did 
display a reduced size of Pax6 expression domain. The same alterations in Pax6 
expression were observed in Otx2-gal4 X UAS-flognogT201 cross embryos (Fig. 5.2K, 
sibling control displaying no alteration O) as in the Otx2-gal4 X UAS-flognogT139 cross 
embryos, defending that the effects are consistent with the Otx2-gal4 X UAS-flognog 
cross. There were variations in the size of the expression domains. The reduced 
expression domain was more pronounced in the Otx2-gal4 X UAS-flognog T201 cross, 
possibly reflecting a higher level of Flognog transgene expression in this cross. This is 
consistent with the varying severity of phenotypes observed from binary crosses 
employing two different effector lines in previous studies (Hartley et al., 2002). At 
tailbud stage alterations in Pax6 expression were observed in 4/111 (~4%) of Otx2-gal4 
X UAS-flognog cross embryos (Fig. 5.2L, sibling embryo displaying no alteration P). In 
whole-mount embryo analysis, there appeared to be a reduced and/or altered shape of 
Pax6 expression domain in the eye, and transverse sections revealed that there was 
reduced Pax6 expression in the eye. There was normal Pax6 expression throughout the 
forebrain and eye in an Otx2-gal4 sibling single transgenic control embryo. This data 
could suggest that BMP signalling in the anterior neuroectoderm, including neural plate, 
is required for correct specification and patterning of the anterior neural tube in a 
proportion of Otx2-gal4 X UAS-flognog cross embryos. However, there are transgene- 
mediated alterations in Pax6 expression as well, which may contribute to the effects 
seen.
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Figure 5.2 Pax6 is Expressed in the Developing Forebrain of WT Embryos and in an
Altered Shape in Whole-mount Otx2-gal4 X UAS-flognog Cross Embryos
Images show embryos analysed by whole-mount in situ for Pax6 expression. Images are 
anterior views. Pax6 expression in WT embryos (A-H). Pax6 is expressed in two lateral stripes 
one on either side of the midline, and in a crescent at the anterior of the embryo at the end of 
gastrulation/ beginning of neurulation (stage 12.5) (A). Pax-6 is expressed in the anterior neural 
plate in cells that will form the telencephalon and parts of the diencephalon, spanning most of 
the neuroectoderm at stage 14 (B), stage 18 (C), stage 19 (D), stage 19 to 20 (E, F) and stage 21 
(G). Pax-6 is also expressed in the posterior neural plate in two stripes that give rise to the 
ventral-lateral spinal cord and hindbrain. At stage 23, Pax-6 expression can be seen in the 
developing telencephalon and diencephalon, between the prominent domains of expression in 
the eye (H). There is a characteristic lack of expression in the midbrain. I-P illustrates Otx2- 
gal4 X UAS-flognog cross embryos analysed by in situ hybridisation for Pax6. I-K illustrate 
embryos displaying the altered shape and fusion of expression domain in stage 19 Otx2-gal4 X 
UAS-flognog cross embryos. J represents an embryo with a partially closed neural tube. I, J 
show a wider Pax6 expression domain in the neural tube in comparison to sibling controls M, N 
and WT control D. M-0 illustrates normal Pax6 expression in the prospective dorsal forebrain 
and eyes. L represents an altered expression domain of Pax6 in a tailbud stage Otx2-gal4 X 
UAS-flognog cross embryo. P represents normal expression of Pax6 in the eyes and forebrain in 
a sibling Otx2-gal4 X UAS-flognog cross embryo.
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The alterations in Pax6 expression suggest that there may be transformation in 
the identity of other anterior CNS tissue. To understand the alterations in more detail, I 
next asked if there were any other alterations in another regionalised neural gene marker 
in the Otx2-gal4 X UAS-flognog cross embryos.
5.2.3 Expansion and Fusion of Ventral Telencephalon Marker X-dll3 in Otx2-gal4 
X UAS-flognog Cross Embryos
X-dll3 is a ventral telencephalon marker across vertebrates. Stage 19 embryos were 
analysed by in situ hybridisation for X-dll3 expression. This stage was chosen because 
regionalized patterning markers are more distinct in neurulae.
X-dll3 expression was expanded in the anterior neural tube in an area fated to 
become part of the ventral telencephalon and the olfactory placodes (Papalopulu and 
Kintner, 1993) in 6/45 (13%) Otx2-gal4 X UAS-flognog cross embryos (Fig. 5.3A, B (C- 
E sibling controls), n-45). WT control embryos displayed expression in a compact 
domain in the anterior neural tube (Fig. 5.3F, «=45). Also, no alteration from normal x- 
dll3 expression was observed in Otx2-gal4 X UAS-gfp cross embryos («=11). Further 
analysis of embryos with the expanded X-dll3 expression domain revealed that X-dll3 
expression fused across the anterior ridge of the neural tube. The same alterations were 
observed in 11/72 (15%) embryos from an Otx2-gal4 X UAS-flognogT201 cross 
confirming the effects are specific to the Otx2-gal4 X UAS-flognog cross. This result 
could suggest that BMP signalling in the anterior neuroectoderm, including neural plate, 
is required for correct specification and patterning of prospective ventral forebrain 
tissue.
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X-dll3
Figure 5.3 Expansion of X-dll3 expression domain, which marks the 
prospective ventral telencephalon and olfactory placodes, in Otx2-gal4 X 
UAS-flognog cross embryos
Images display anterior views o f Otx2-gal4 X  UAS-flognog cross embryos anal­
ysed by whole-mount in situ hybridisation for X -dlU  (at stage 19). A,B there 
is an expansion in the domain of expression o f X-dll3  in the anterior neural tube 
(see black arrows) in an area fated to become the olfactory placodes and part o f  
the ventral telencephalon in Otx2-gal4 X  UAS-flognog cross embryos. C-F 
displaying compact X-dll3 expression in the anterior neural tube (see white 
arrows) in Otx2-gal4 X  UAS-flognog sibling control embryos (C, D, E) 
or WT embryos (F). n=45.
The resulting morphological and molecular alterations in the Otx2-gal4 X UAS- 
flognog cross may be due to early roles of BMP signalling during gastrulation and/or 
neurulation. In order to investigate the later roles of BMP signalling on dorsal 
telencephalic patterning, a hormone-inducible transactivator, which is expressed in the 
dorsal telencephalon, was generated.
5.2.4 Pax6-GalPR9 Hormone-inducible GAL4 transactivator Activates GFP from a 
UAS-gfp Reporter Only in the Presence of RU486
A Pax6-GalPR construct containing the Xenopus Pax-6 promoter (Hartley at al., 2001) 
and GalPR, a hormone-inducible GAL4 (Wang et al., 1994) was made (Fig. 5.40) 
(Section 2.2.1). Subsequently, using transgenesis as described by Hirsch et al. (2002), a 
Pax6-GalPR FO transactivator transgenic was made. The transgenic founder was 
identified via GFP in the lens due to the reporter y-crystallin-gfp. The transgenic 
tadpole was raised to adulthood (Section 2.1).
The carrier Pax6-GalPR founder was assayed for the germline transmission and 
transactivation potential of Pax6-galPR line by crossing to a homozygous UAS-gfp 
reporter transgenic line. The embryos from this cross were incubated in either 0.5pM 
RU486 or DMSO control from the 4 to 8 cell stage. Embryos were raised in individual 
well dishes to monitor each embryo over time, and assess the transgenic identity at 
tadpole stages. At early neurula stages, GFP was detected via fluorescence microscopy 
in the anterior neural plate in a Pax6-GalPR X UAS-gfp cross embryo incubated in 
0.5pM RU486 (Fig. 5.4A), that at later stages contained ECFP in its lens from the y- 
crystallin promoter in the transactivator transgene and RFP in the somites from the CAR
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Figure 5.4 Pax6-GalPR Hormone-inducible GAL4 Transactivator Activates GFP from a 
UAS-gfp Reporter Only in the Presence of RU486
All images are either GFP fluorescence microscopy (A-D, I-K) or brightfield (E-H, I-N) of 
embryos from a cross of Pax6-GalPR transgenic founder X UAS-gfp reporter frog, incubated in 
either 0.5pM RU486 (A, B, E, F, I, J, L & M) or DMSO alone (C, D, G, H, K & N). GFP is 
throughout the anterior neural plate and along the posterior neural plate at stage 13 in double 
transgenic embryos (expressing RFP in their somites and GFP in their lens) incubated in RU486 
(A, E, I & L). No GFP is detected in stage 13 double transgenic embryos incubated in DMSO 
alone (C, G, K & N). At stage 17, GFP is detected in anterior neural tube, and along the dorsal 
neural tube in double transgenic embryos incubated in RU486 (B, F, J & M). No GFP is 
detected in stage 17 double transgenic embryos incubated in DMSO alone (D, H, K & N). At 
tadpole stage, GFP can be seen in the forebrain (white arrow), hindbrain and retina in double 
transgenic embryos incubated in RU486 (1, L, J & M). No GFP is detected in double transgenic 
embryos incubated in DMSO alone (K & N). A, E, I, L represents an RU486-treated embryo. B, 
F, J, M represents another RU486-treated embryo. C-D, G-H, K, N represents the DMSO 
control embryo. O represents a diagram of the Pax6-GalPR construct used to make the Pax6- 
GalPR FO. It contains GalPR, which is a chimera consisting of the ligand binding domain of the 
human progesterone receptor hPRB891 (PR-LBD), the DNA-binding domain of yeast activator 
GAL4, and the activation domain of herpes simplex virus VP16, downstream from the Xenopus 
Pax6 promoter (Hartley et al., 2001), and upstream of SV40pA. Also, there is a secondary 
cassette, the reporter cassette, which contains GFP downstream of the y-crystallin promoter, and 
upstream of the SV40pA.
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promoter in the effector transgene (Fig. 5.41). No GFP was detected via fluorescence in 
DMSO-treated control embryo (Fig. 5.4C) that, subsequently, contained expression 
from both reporter cassettes at later stages (Fig. 5.4 K). By stage 17, GFP detection was 
more pronounced in the anterior neural plate, and expression was also more evident 
along the neural tube (Fig. 5.4B). Again, no GFP was detected in DMSO-treated 
control embryos (Fig. 5.4D). 50% of the RU486-treated cross embryos displayed GFP 
fluorescence.
Embryos were then allowed to develop to tadpole stages, GFP was detected in 
the forebrain, including the olfactory region of the telencephalon, in the hindbrain, along 
the spinal cord and in the ventral retina (part of the retina that is not covered by 
pigmented epithelium) in the double transgenic embryos (indicated by ECFP in the lens 
and RFP in the somites from the reporter cassettes) (Fig. 5.41, J). In DMSO-treated 
double transgenic embryos, there was no GFP fluorescence (Fig. 5.4K). Control 
embryos included sibling heterozygous and non-transgenic embryos, as well as DMSO- 
treated embryos, and no GFP was detected via fluorescence in any of these. 50% of 
embryos expressed GFP in the lens (through the y-crystallin reporter), suggesting the 
Pax6-GalPR founder could have one integration site. Embryos containing the Pax6- 
GalPR (detected by lens ECFP from the y-crystallin promoter) (and UAS-gfp (detected 
from RFP from the CAR promoter)) transgene(s) displayed normal morphology (Fig. 
5.4L-N).
Embryos were also analysed by in situ hybridisation for GFP at neurula stage. 
GFP was expressed in the anterior neural plate and along the neural plate in 50% of the 
cross embryos (Fig 5.5A), analogous to the location of GFP fluorescence (Fig. 5.4A, B).
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Figure 5.5 GFP is expressed in the anterior and posterior neural plate 
in Pax6-GalPR X UAS-gfp cross embryos induced with RU486; Flog- 
nog is expressed in Pax6-GalPR X  UAS-flognog cross embryos induced 
with RU486
Images show anterior views of embryos from a cross of Pax6-GalPR X 
UAS-gfp (A, C) or UAS-flognog (B, D), either treated from the 4-8-cell 
stage with 0.5pM RU486 (A, B, C) or DMSO (D), or WT embryos (E, F). 
Embryos were analysed by in situ hybridisation for GFP (A, C), Flognog 
(B, D) or Pax6 (E, F). There is anterior and posterior neural plate-specific 
expression of GFP in the Pax6-GalPR X UAS-gfp cross embryos induced 
with RU486, image depicts a stage 17 embryo (A) (red asterisk illustrates 
strong medial expression), background expression in stage 17 sibling 
control (C). Flognog expression is induced in the anterior neural tube and 
hindbrain, whereas it is reduced in the posterior neural tube in Pax6-galPR 
X UAS-flognog stage 19 cross embryos induced with 0.5pM RU486 (B), 
control embryo from stage 19 cross of Pax6-galPR X UAS-flognog incu­
bated in DMSO alone (D). E, F illustrate Pax6 expression in the prospec­
tive eye and forebrain regions in WT embryos at stage 14 (E) or stage 19 
(F).
The GFP expression domain in the anterior medial neural plate and in prospective 
hindbrain regions of the neural plate was expanded compared to Pax6 expression in WT 
embryos (Fig. 5.5E). RU486-induced sibling (Fig. 5.5C) and DMSO-treated Pax6- 
GalPR X UAS-gfp cross control embryos did not express GFP. This result suggests that 
Pax6-GalPR transgenic can transactivate and induce transcription (mRNA) from a UAS- 
gfp reporter transgene in a tissue-specific manner, in the CNS, only in the presence of 
RU486. A stable viable FI population was therefore raised from the Pax6-GalPR 
founder.
5.2.5 Flognog mRNA is Expressed in the Pax6-Ga1PR X  UAS-flognog Cross 
To determine whether Flognog was induced in the Pax6-GalPR (FO) X UAS-flognog 
(heterozygote) binary cross, embryos from the Pax6-GalPR X UAS-flognog cross were 
cultured with 0.5pM RU486 or DMSO alone, and were subsequently analysed both by 
fluorescence microscopy and by in situ hybridisation for GFP.
There was no GFP fluorescence at stages 14 to 19 in Pax6-galPR X UAS- 
flognog cross embryos. However, at neural tube stage, Flognog was expressed across 
the anterior neural tube, and in two patches in the prospective hindbrain region of the 
neural tube, whereas there was less expression in posterior regions of the neural tube in 
Pax6-GalPR X UAS-flognog cross embryos induced with 0.5|xM RU486 (Fig. 5.5B, D). 
In WT embryos, Pax6 is expressed in two uniform stripes along the neural tube 
(Fig5.5F). Flognog expression was evident in 25% of cross embryos. Although 
embryos were not genotyped, it is assumed that the embryos expressing Flognog are 
Pax6-galPR; UAS-flognog double transgenic.
172
5.3 Discussion
The establishment of sub-divisions is an essential step in the formation of neuronal 
patterns and ultimately the functioning of the vertebrate forebrain. It is possible that 
levels of BMP signalling determine distinct sub-divisions along the D-V axis of the 
telencephalon. Gain-of-function studies have demonstrated that BMP signalling is 
sufficient to specify (and pattern) the dorsal forebrain (including the telencephalon) 
(Golden et al., 1999; Monuki et al., 2001), whereas loss-of-function studies have not yet 
established directly whether graded BMP signalling in the dorsal forebrain is required 
for dorsal telencephalic patterning.
Here, the Otx2-gal4 transactivator was crossed to the UAS-flognog effector to 
test if the binary approach can result in alterations of development and developmental 
regulatory genes. The findings here show that BMP signalling is required in the anterior 
neuroectoderm for correct specification of prospective dorsal (or lateral) cell fates 
(patterning) within the prospective anterior CNS. It has been shown that BMP 
signalling can regulate genes that encode homeodomain proteins, which are essential for 
the development and patterning of forebrain structures. Interestingly, the findings here 
also reveal that, in the Otx2-gal4 X UAS-flognog cross, there is an increased prospective 
ventral telencephalon/ olfactory placode/ diencephalic identity; as well as open neural 
tube defects. BMPs have been implicated in both dorsal and ventral specification, 
dorsal patterning, and growth and apoptosis of the forebrain. How BMP signalling (via 
molecular, cellular and tissue morphogenesis processes) regulates the expression and 
hence function of these developmental regulatory genes, and what causes these profound 
morphological alterations here, is discussed below.
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5.3.1 Open Neural Tube Defects
The data indicates that a loss of BMP signalling in the anterior neuroectoderm results in 
a partial open neural tube (Fig. 5.1A-D). This result is consistent with many studies, 
which have implicated alterations of BMP signalling in alterations in morphogenesis of 
the nervous system. Previous studies have described either a failure or delay of the 
neural tube to close as a result of a loss of BMP signalling (Urn et al., 2005; Solloway 
and Robertson, 1999). There was a failure of the neural tube to close, as well as defects 
in eye and craniofacial development, resulting from a loss of BMP signalling by 
dnBmprl (<a and b) electroporations into the chick neural tube (Lim et al., 2005). They 
suggest that the reason for the neural tube closure defect could be due to neural crest 
depletion in the midline. Delayed closure of the neural tube has also been reported as a 
result of loss of BMP signalling (Solloway and Robertson, 1999). In mice lacking 
Bmp5 and Bmp7 there is a delayed closure of the rostral neural tube, hypoplasia of the 
telencephalic vesicles and reduced apoptosis in the telencephalic roof. The open neural 
folds of normal embryos initiate fusion at multiple sites, including the fore/midbrain 
boundary and anterior extremity of the forebrain (Geelen and Langman, 1977). 
Bmp5;Bmp7 double mutants also show closure defects from the hindbrain to anterior- 
most forebrain (Solloway and Robertson, 1999). By 10.5dpc mutants had initiated 
closure of these regions, however, the hindbrain roof plate was reduced in size. The 
growth of the lobes of the forebrain (telencephalon) is severely compromised in 
Bmp5;Bmp7 mutants. The phenotype correlates with the overlapping expression of 
Bmp5 and Bmp7 in the hindbrain and dorsal telencephalon. Both these studies suggest 
that a loss of BMP signalling could be the underlying cause of the open neural tube/
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brain phenotype. Other studies using transgenic mice overexpressing Bmprla or 
Bmprlb have indicated that constitutively active BMP signalling can cause an open 
neural tube phenotype (Panchision et al., 2001). These studies together indicate that it is 
the level of BMP signalling that is critical in neural tube closure, as both an increase and 
decrease in BMP signalling can cause an open neural tube. Thus, in a similar manner to 
the above studies the direct inhibition of BMP signalling within the anterior 
neuroectoderm in the Otx2-gal4 X UAS-flognog cross may inhibit BMP signalling 
throughout neurulation, resulting in neural tube closure being blocked or suppressed or 
delayed to varying degrees depending on the level of intercellular BMP signalling. The 
viability of Otx-2-gal4;UAS-flognog double transgenic tadpoles suggests that there may 
be a delayed closure. The reason why there is a transient open neural tube may be due 
to the knockdown approach via the Otx2 promoter. It may be interesting to perform 
histological analysis to uncover possible reasons for the open neural tube defects seen 
here.
Furthermore, other studies have implicated synergistic actions of BMP4, SHH 
and FGF8 in the rostral prosencephalon in regulating morphogenesis of the 
telencephalic and optic vesicles (Ohkubo et al., 2002) or found that inhibition of BMPs 
results in decreases in proliferation as a result of decreased Wnt (Chesnutt et al., 2004). 
Increasing BMP signalling by implantation of BMP2, BMP4 or BMP7 beads into the 
anterior neuropore of HH stage 10 chick embryos during neurulation results in a loss of 
Shh and Fgf8 expression, decreased proliferation, increased cell death, and hypoplasia 
of the telencephalic and optic vesicles (Ohkubo et al., 2002). However, decreased BMP 
signalling, through ectopic electroporation of Noggin in the telencephalon of stage 14
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chick embryo results in decreased proliferation and hypoplasia of the telencephalic and 
optic vesicles. Also, Emx2 expression is weakened and recedes caudally, and there is a 
maintanance of Shh and FgfS expression. They suggest that optimum growth and 
patterning of the telencephalon depends on the combined effects of BMP, SHH and FGF 
expression. Also, it has been found that inhibition of BMPs by Noggin decreases 
Wntl/3a expression in the roof plate and decreases proliferation. They show that it is 
Wnts that are responsible for the alterations in proliferation, as Wnts act as mitogens 
(Chesnutt et al., 2004). These studies indicate neural tissue growth is reduced by 
increases or decreases in BMP signalling, suggesting that growth malformation results 
from interactions between other signalling molecules. Thus, the absence of BMP 
signalling within the anterior neuroectoderm may affect several tissues involved in 
neural tube morphogenesis. As BMPs in co-ordination with SHH and FGF8 have being 
implicated in growth and morphogenesis of the telencephalic vesicles. It may be that 
there is a de-regulation of the balance between these signalling factors, hence resulting 
in the morphological alterations observed in the Otx-2gal4 X UAS-flognog cross. 
However, this is not known and further molecular characterisation may dissect out the 
underlying cause.
5.3.2 Alterations in Pax6 Expression in the Anterior Neural Tube
The loss of BMP signalling in the anterior neuroectoderm results in an altered shape or 
pattern, a reduced domain size, and closer and/or fused bi-lateral domains of Pax6 
expression in Otx2-gal4 X UAS-flognog cross embryos (Fig. 5.2).
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Explanations for these findings may include regulation of regionally restricted 
markers and morphogenesis as a result of alterations in BMP signalling from altered 
formation of the roof plate and/or a decreased BMP signalling gradient throughout early 
neural development. Studies diminishing BMP signalling in whole embryo or ablating 
the roof plate (hence blocking BMP signalling) have reported altered expression of 
dorsal telencephalon markers (Monuki et al., 2001; Cheng et al., 2006; Hanel et al., 
2006). A conditional allele of the toxin DTA driven from the Gdf7 locus has been used 
to ablate the roof plate in mouse embryos. This reduced Lhx2 expression in the cortical 
neuroepithelium and the normal graded pattern of Lhx2 was no longer apparent. There 
was also a reduction of the L/ix2-negative domain at the dorsal midline. Therefore, due 
to the non-cell-autonomous actions of the roof plate, this implicated BMP signalling in 
dorsal telencephalic development and patterning (Monuki et al., 2001). The phenotype 
was difficult to interpret due to severe open forebrain defects. In an attempt to further 
elucidate forebrain roof plate functions they modified the Gdf7-mediated ablation to 
generate embryos with a closed forebrain phenotype. In ACTBCre;Gdf7-DTA roof plate 
ablated mice (Currie et al., 2005), at El 1.5 to E12.5, Pax6 was expressed in its normal 
high ventral to low dorsal gradient in the cortex (Cheng et al., 2006), whereas there was 
a decrease and inversion of the normal high dorsal to low ventral expression for both 
Lhx2 and Emx2 markers, again implicating and extending the BMP signalling function 
in dorsal cortical patterning. They suggest that these roof plate patterning functions are 
mediated via a Bmp activity gradient which depends on the roof plate in a non-cell- 
autonomous manner. They also found that roof plate ablation results in both a 
flatteming and reduction of a BMP signalling gradient as opposed to a dimished
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gradient, as assessed by P-Smad-1 levels in dorsal telencephalic tissue sections. They 
suggest that some BMP signalling, particularly in the ventro-lateral domain, is also 
regulated by a nondorsal source of BMPs or other factors that promote nuclear P-Smadl 
accumulation, such as the ventral midline. It is known that the maximum that BMP 
signalling can act is 10 cell diameters away or is poorly diffusible from its source of 
expressing cells (Niehrs, 2001; Jones et al., 1996; Nikaido et al., 1999). Thus, the lack 
of alteration in Pax6 expression in ventro-lateral domains of the dorsal telencephalon 
may be due to being too far away from the BMP signalling source. However, this 
depends on the mechanism of the BMP signalling gradient. These studies implicate 
BMP signalling in alterations of regionally restricted telencephalon markers, however 
they analyse (dorsal) patterning defects at late stages of neural development. As, there 
were no alterations in Pax6 expression in the above studies, the alterations in Pax6 
expression in the Otx2-gal4 X UAS-flognog cross embryos are not likely to be due to 
similar mechanisms.
Further to these findings, other studies have indicated that early Bmp activity 
establishes a gradient of positional information throughout the entire neural plate. Bmp 
activity is required for establishing fates at the margin of the neural plate and patterning 
neurons at all D-V levels of the CNS (Barth et al., 1999). Analysis of zebrafish null 
mutant swirl/bmp2b- (swr-) revealed a neuralised embryo with an expansion of flh (a 
dorsal diencephalon marker) into ventral ectoderm, a loss of Emx-1 (a dorsal 
telencephalic gene) and expansion and radialised domain of Pax6 expression in the 
diencephalon and hindbrain. There is an absence of sensory neurons and an expansion 
of intemeuron populations. Furthermore, they find a loss of marginal neural plate
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expression of flh, emxl and fkd6 in noggin-injected embryos. In conclusion, they show 
that the underlying mechanism of the alterations is due to an early gradient of BMP- 
dependent positional information (medial and lateral extent of ectodermal gene 
expression domains) extending throughout the entire neural and non-neural ectoderm. 
Due to the early onset of the Otx2-gal4 transactivator, resulting in mis-expression of 
Flognog in the anterior neuroectoderm, consistent with the early BMP activity gradient 
affecting latero-medial cell fate (Barth et al., 1999), the roles of inhibition of a BMP 
signalling gradient during initial neural plate patterning and neurulation are likely to be 
the underlying cause of the alterations in Pax6 expression. As mentioned previously in 
the study by Hanel et al. (2006), loss of BMP signalling by GDF6 (Bmp 13) morpholino 
results in an altered expression domain of Pax6 in the retina. Furthermore, many studies 
have implicated a loss or gain of BMP signalling, by BMP4 and BMP7 mutant mice, 
dominant negative Bmprl, noggin overexpression or constitutively active Bmprl, in eye 
defects, such as microphthalmia (small eye), anophthalmia (no eye) or eye cell fate 
decisions (Alder and Belecky-Adams, 2002; Furuta and Hogan, 1998; Wawersik et al., 
1999; Lim et al., 2005). Dominant negative or constitutively active Bmprl 
electroporated into chick neural tube resulted in microphthalmia and anophthalmia, and 
furthermore constitutively active Bmprl resulted in a transformation of forebrain tissue 
to retinal tissue (Lim et al., 2005). In a similar manner to the neural tube defects they 
speculate that the level of BMP signalling in the eye is critical for the phenotype 
observed. Hence, the reasons for the altered shape of Pax6 expression could indicate an 
altered retinal expression resulting from altered positional information (Barth et al., 
1999) as a result of the loss of BMP signalling mediated via different BMPs (such as
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GDF6), which are expressed and function throughout early neurula development (Hanel 
et al., 2006).
Other data shows that an increase or decrease in BMP signalling results in a 
fusion of the cerebral hemispheres (Golden et al., 1999; Bachiller et al., 2000; Cheng et 
al., 2006; Panchision et al., 2001). Beads soaked in recombinant BMP4 or 5 were 
implanted into chick rostral neural tube and the resulting embryos displayed a single 
forebrain vesicle (holoprosencephaly HPE), as well as cyclopia and other craniofacial 
defects (Golden et al., 1999). Whereas, roof plate ablation in conditional ACTB- 
Cre;Gdf7-DTA mice resulted in failed separation of the cortical primordia at the dorsal 
midline, a HPE phenotype (Cheng et al., 2006), and transgenic mice expressing 
activated BMPR1A receptor mutant under the control of the Nestin promoter caused 
HPE due to specification of the entire forebrain to choroid plexus epithelium 
(Panchision et al., 2001). A disruption of ventral forebrain induction underlies most 
HPE cases, however, there are some cases in HPE where there is a dysgenesis of 
forebrain dorsal midline structures. Thus, HPE can result from defective midline 
induction, and hence the failure to separate the cerebral cortex and other bi-lateral 
forebrain structures. Importantly, Golden et al., 1999 suggests that interrupting dorso- 
ventral patterning independent of disruptions in ventral Shh signalling can cause a 
holoprosencephaly phenotype too. Although, they speculate that HPE in their study is a 
secondary consequence of the loss of basal telencephalon. Also, compound mutant mice 
for both Chordin and Noggin, display a HPE phenotype, indicating a requirement of 
Chordin and Noggin for forebrain development (Bachiller et al., 2000). These studies 
implicate either increases or decreases of BMP signalling in the HPE phenotype. Thus,
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the altered shape and closer bi-lateral expression domains seen here could be due to a 
secondary effect from altered midline induction (Panchision et al., 2001; Cheng et al., 
2006).
Also, other studies have indicated prechordal plate affects medial-lateral markers 
in the forebrain (Shimamura et al., 1997). A culture mouse explant from 3-somite stage 
embryos in which the axial mesendoderm was removed displayed a medially expanded 
and bi-laterally fused Pax6 expression domain. Conversely, in an explant whereby 
additional axial mesendoderm was transplanted to lateral neural plate, there was a 
reduced Pax6 expression domain around the site that the transplanted tissue was added. 
These results indicate that prechordal plate regulates ML patterning in prosencephalic 
neural plate explants.
Finally, the results indicated a smaller expression domain compared to siblings 
was observed in Otx2-gal4 X UAS-gfp cross embryos, implying that the transgene 
expression may contribute to the reduced size in Pax6 expression domain seen in the 
Otx2-gal4 X UAS-flognog cross embryos. Thus it is not clear whether the alterations in 
Pax6 expression in the Otx2-gal4 X UAS-flognog cross are as a result of a loss of BMP 
signalling in anterior neuroectoderm, and this transgene-mediated artifact needs to be 
taken into account for any further analysis of the phenotype.
To further investigate the reason for the alterations in Pax6 expression, one 
possibility was that there was an alteration in other anterior regionalised identity 
markers.
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5.3.3 Alterations in X-dll3 Expression in the Anterior Neural Tube/ Neural Tube 
Border
An expansion and fusion of X-dll3 expression domain in the anterior neural tube/ neural 
tube border in Otx2-gal4 X UAS-flognog cross embryos was observed (Fig. 5.3). The 
findings here suggest that a loss of BMP/Smad-1 signalling in the anterior 
neuroectoderm causes an expansion of prospective ventral telencephalon or 
diencephalon or olfactory placode tissue, indicated by X-dll3 expression (Papalopulu 
and Kintner, 1993; Eagleson and Harris, 1990).
The reason for the increase in expression domain of X-dll3 could be due to 
alterations in pattern (and cell fate) as a result of an altered gradient of BMP signalling 
from adjacent tissues (Hartley et al., 2001; Dale et al., 1997, 1999; Luo et al., 2001; 
Anderson et al., 2002; Barth et al., 1999). Alternatively, transgene-mediated expression 
may affect marker expression (Hartley et al., 2001). BMP4 over-expression by targeted 
mRNA injection into one dorsal cell of a 4- to 8- cell stage embryo produced a reduced 
level and circumference of X-dll3 expression in the boundary of the anterior neural plate 
(Hartley et al., 2001). This suggests that the reason for the down-regulation of neural 
gene expression by BMP4 misexpression is because antagonism of BMP signalling is 
needed for anterior neural development. However, in contrast, they found that BMP4 
misexpression after gastrulation from the Pax6 promoter using the Pax6-BMP4 
transgenic resulted in an up-regulation of X-dll3 expression. They suggest that the 
expression of this neural gene is maintained by the expression of localised inhibitors of 
BMP expression and signalling which are in the anterior neural plate. In line with this 
finding that BMP signalling modulation differentially alters X-dll3 expression, it has
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been found that a BMP morphogenetic gradient differentially regulates Dlx expression 
(Luo et al., 2001). In northern blot assays on animal caps from Xenopus embryos 
injected with Chordin RNA (a BMP antagonist), there is a concentration-dependent 
modification of Dlx5 expression (which corresponds to X-dll3). DlxS expression is 
stimulated by a low chordin dose, whereas it is inhibited by higher levels of chordin. 
This suggests that this finding is evidence to support the conclusion that BMP-based 
morphogenetic gradients can control the differential expression of Dlx homodomain 
genes, suggesting a possible mechanism for linking the BMP gradient to regionalised 
tissue specification.
It is also known that mesendodermal tissue is implicated in the induction and 
patterning of the forebrain (Reviewed by Kiecker and Niehrs, 2001). BMPs (Bmp4 and 
Bmp7) are expressed in the prechordal mesoderm tissue at neurula stages onwards 
underlying the rostral diencephalon (Dale et al., 1997, 1999; Hartley et al., 2001). 
Bmp7 has been shown to be required in conjunction with Shh for induction of ventral 
midline cells of the rostral diencephalon identity, for induction of a hypothalamic rather 
than a floorplate fate (Dale et al., 1997,1999). This indicates that BMPs are needed for 
induction of the ventral midline. In contrast, Chordin and Noggin from the prechordal 
plate have been implicated in promoting SHH function from the prechordal plate, and 
hence ventral forebrain identity (Anderson et al., 2002). Also, it has been found that 
inhibition of BMP/GDF ligands by Noggin and normal SHH signaling is also required 
for proper formation of ventral cell types (McMahon et al., 1998). The opposing 
functions may be attributed to different stages of development, as chordin, noggin and 
Bmp7 are expressed in these regions at different times.
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Thus, due to the persisting expression from the Xenopus Otx2 promoter in the 
prechordal mesoderm (Hirsch et al., 2002), Flognog over-expression in this region may 
therefore be the reason for the expansion in the ventral forebrain identity (Anderson et 
al., 2002). Moreover, this expansion in X-dll3 expression may be due to low Flognog 
transgene expression levels in these regions causing a graded BMP signal and 
consequently acting to specify and expand regionalized marker, X-dll3 (Luo et al.,
2001). However evidence for this explanation comes from in vitro animal cap assays, 
thus it is different to the in vivo/ whole-embryo system employed here and may not be 
the reason for the alterations. Furthermore, as mis-expression of Flognog in the Otx2- 
gal4 X UAS-flognog cross partially overlaps with X-dll3 expression in the 
neuroectoderm, these alterations in X-dll3 expression could be due to cell-autonomous 
or non cell-autonomous effects. In addition, the similarity of fusion in X-dll3 
expression to the fusion of Pax6 expression indicates that this fusion may be due to the 
same underlying cause, such as the effects of BMP signalling during neurulation and the 
secondary effects on brain morphogenesis. It may be that alterations in induction of the 
roof plate results in a HPE phenotype in the Otx2-gal4 X UAS-flognog cross, similar to 
the roof plate ablation studies (Cheng et al., 2006).
The morphological and molecular alterations in the Otx2-gal4 X UAS-flognog 
cross are evident in percentages from 9-19%. The reason for the low percentages 
displaying a phenotype is not due to a viability problem because cross embryos 
(including double transgenic embryos) were evident in Mendelian ratios. Instead, the 
numbers of embryos observed displaying alterations are consistent with previous studies 
whereby either a microcephalic or ventralised phenotype was observed in 13-16% of
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either Pax6-gal4 or CMV-gal4 cross to UAS-vent2 embryos (Hartley et al., 2002), and 
may be attributed to GAL4 variability (GALA expression) (Brand and Perrimon, 1993). 
This may also be the reason for variations in the severity of the alterations in 
morphology and molecular marker expression as well. For this reason, it may be a good 
idea to breed the effector lines to homozygosity to increase sample number of the binary 
transgenics in the cross to transactivator. To ascertain whether all the alterations seen 
are real, PCR analysis should be carried out to confirm that embryos displaying these 
effects are double transgenic.
It should be noted that mis-expression of transgenes can alter development and 
molecular patterning (Hartley et al., 2001). The mis-expression of BMP4 by the 
Xenopus Pax6 promoter suppressed anterior brain and eye formation in 36% of GFP 
expessing embryos. Moreover, upon analysis of patterning markers, most neural 
markers displayed a decrease in expression in a proportion of the GFP-expressing Pax6- 
GFP embryos, except X-dll3, which displayed slight decreases and increases in 
expression in the GFP expressing embryos. Thus, although I did not observe alterations 
in X-dll3 expression in the Otx2-gal4 X UAS-gfp cross, the sample number was small, 
and there is still as possibility that the alterations in X-dll3 expression may due to 
transgene-mediated over-expression.
To ascertain whether all these above reasons apply to the Otx2-gal4 X UAS- 
flognog cross, it will be interesting to do further characterisation of the phenotype, such 
as characterise the gross morphology of the phenotype by sectioning. This will 
determine if there is any transformation from one tissue type to another, or if there is a 
reduction or expansion in tissue. Also, to verify the molecular alterations observed here,
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it may be interesting to phenocopy the expansion in domain of X-dll3 expression, for 
example, by targeted Flognog mRNA injections into the anterior CNS region. 
Additionally, if the expansion in X-dll3 expression domain results from an expansion of 
ventral identity, it may be possible to rescue this effect with exogenous recombinant 
BMP4 or BMP2 (or BMP7). If the increase in X-dll3 expression is due to a change in 
cell fate, it may be interesting to analyse the expression of other identity markers 
(ventral markers, dorsal markers, as well as other tissue specificity markers) in this 
region. In addition, it may be interesting to determine whether the respective 
downstream regulators (i.e. bHLH proteins) and subsequently the neuron populations of 
Pax6 and X-dll3 domains are altered in the Otx2-gal4 X UAS-flognog cross. 
Furthermore, it may be interesting to determine whether there are alterations in the 
migration of cells from the ganglionic eminences into the cortex in the Otx2-gal4 X 
UAS-flognog cross (Chapouton et al., 1999). Other signalling pathways, such as 
Retinoid, Hedgehog and FGF signals are involved in (dorso-ventral) latero-medial (and 
anterior) patterning of the rostral CNS (Lupo et al., 2005), and this should be taken into 
account when assessing any phenotype in in vivo/ whole embryo models as well. How 
these diverse signalling pathways interact both temporally and spatially to generate the 
complex adult nervous system is not understood. The use of the Xenopus transgenic 
lines established here, together with other SLT lines, such as UAS-HIP (UAS-hedgehog 
interacting protein) may shed some light on these processes.
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5.3.4 Pax6-GalPR Hormone-inducible Transactivation of Transgene Expression 
There are some problems or issues to be aware of when using the GalPR based-system. 
Difficulties in controlling the level of expression and alterations in expression from a 
transgenic promoters’ normal expression has been previously demonstrated using 
(inducible) binary transactivation transgene-mediated expression, resulting in 
uncontrolled transgene expression, amplification of expression, or even alterations in 
development (Chae et al., 2002; Govindarajan et al., 2005; Gill and Ptashne, 1988; 
Argenton et al., 19%; Luan et al., 2006). Solubility problems have been reported for 
RU486, making it difficult to control the amount of RU486 that is delivered to the 
animal (Das and Brown, 2004). Additionally, RU486 antagonises endogenous 
hormones at high micromolar concentrations (Philbert et al., 1985; Henderson et al., 
1987), which can result in abnormal development. This indicates that caution must be 
taken to deliver the right amount of RU486. Furthermore, in the absence of RU486, 
basal transactivation of the promoter can occur by endogenous hormones, at tadpole and 
post-embryonic stages (Osterwalder et al., 2001; Chae et al., 2002; Das and Brown, 
2004). Also, strong transcriptional activators have been found to cause unspecific 
promoter squelching (Gill and Ptashne, 1988) resulting in retardation of embryogenesis 
(Argenton et al., 19%). In the mouse, it has been found that a GAL4/VP16 
transactivator itself is sufficient to alter ocular development, indicating a dose- 
dependent intolerance and toxicity from GAL4/VP16 (Govindarajan et al., 2005). As a 
result of this it was suggested that phenotypes of bi-genic embryos generated using this 
transactivator need to be interpreted with caution. Also, in crosses using the VP16 
activation domain (AD), target gene expression was observed outside the promoter
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driven area, and this was due to ectopic VP16 AD expression from an enhancer in the 
transgene construct (Luan et al., 2006). Hence, indicating that care must be taken to 
ensure the specificity of target gene expression is within promoter driven areas. 
Nevertheless, in RU486-treated Rx-GalPR Xenopus embryos there was a concentration- 
dependent (nanomolar range, 5-25nM) increase in transgene expression levels at low 
amounts of RU486 (below the amount required to antagonise progesterone) (Chae et al.,
2002). There were no apparent adverse effects on development from the hormone or the 
regulatory elements in GalPR, and no observable basal expression in the absence of 
RU486 using their assays.
Thus, although the concentration used to induce transactivation of Pax6-GalPR 
was relatively high for the system (Fig. 5.4, 5.5), it was below the RU486 amount (1- 
5pM) required to antagonise endogenous hormones (Philbert et al., 1985; Henderson et 
al., 1987) and no observable adverse effects on development or viability were observed 
in the Pax6-galPR X UAS-gfp cross. Although I did not notice developmental defects, 
further analysis of the system needs to be carried out to ensure this problem is not 
associated with the Pax6-GalPR transgenic.
The difference in reporter expression from endogenous Pax6 expression (Fig. 
5.5A, E) may be due to a time-lag in reporter expression (resulting in embryos at a later 
developmental stage with the earlier expression profile compared to the endogenous 
Pax6 expression profile). They may also result from altered or missing promoter 
elements in the Pax6 promoter fragment (Hartley et al, 2001).
Furthermore, although I did not fully characterise the system (including 
determining the time lag from addition of RU486 to functional target protein) it will be
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important to determine the spatial expression profile, kinetics and dose-responsiveness 
of the system to RU486 at a full concentration range down to low nanomolar range 0.1- 
25nM, for further use (Chae et al., 2002; Wang et al., 1994). Perhaps a time-course 
whole-mount in situ hybridisation analysis of GalPR expression, as well as GFP 
expression (in a reporter cross) could be carried out at a full RU486 concentration range. 
Once the Pax6-GalPR system is fully chracterised, it will allow spatial, temporal (or 
conditional) and quantitative control over gene expression in vivo in the dorsal 
forebrain, allowing many questions to be asked regarding the biological processes 
involved in forebrain patterning and other developmental processes. By using GalPR 
system, early effects can be avoided, which permits addressing the effects of transgenes 
in later embryonic development or adults. Furthermore, the strong transactivation by the 
Pax6-GalPR transactivator seen here (Fig. 5.4, 5.5), which may be due to the VP16 
activation domain in GalPR, may allow the expression of dominant negative variants, 
opening up avenues for loss of function studies using this GalPR-binary transactivation 
system. In addition, the GalPR system may be able to be adapted to other species, such 
as zebrafish. Most importantly, this Pax6-galPR transactivator can be used together 
with the UAS-flognog effector to analyse the effect of block or suppression of BMP 
signalling on dorsal telencephalon patterning.
5.3.5 Further Uses of the Binary Crosses
Firstly, using the inducible Pax6-GalPR X UAS-flognog cross, it is possible to analyse 
the effects of loss of BMP signalling before, during and after neural tube closure on 
dorsal telencephalic patterning. In addition, Pax6-GalPR driven Flognog expression in
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the alar (lateral) plate, adjacent to the high levels of BMPs in the dorsal midline, allows 
analysis of whether a global concentration gradient-dependent mechanism of BMP 
signalling is required to specify pattern of the dorsal telencephalon (pallium), in a 
similar manner to the spinal cord. In the spinal cord, the inductive interactions of TGF- 
p signals on neuronal patterning involve both qualitative and quantitative differences in 
signalling by TGFp-related factors and temporal changes in the response of neural 
progenitor cells (Liem et al., 1997). The main BMP ligands involved in dorsal 
telencephalic patterning include BMP2 and BMP4 (and BMP5 in chick) (Furuta et al., 
1997; Golden et al., 1999; Monuki et al., 2001). The use of the Pax6-GalPR X UAS- 
flognog cross will allow the dissection of the roles of BMP4 and BMP2 in this proposed 
model. Importantly, these experiments will allow assessment of patterning of the dorsal 
telencephalon independently from the early effects of BMP signalling. After 
characterisation of the kinetics of the Pax6-GalPR transactivator (including the time lag 
from addition of RU486 to functional gene product), in initial experiments, it is 
necessary to determine whether BMP signalling is blocked in the RU486-induced Pax6- 
GalPR X UAS-flognog cross. Again, a decrease in phospho-Smad-1 immunostaining 
may be used to indicate a decrease in BMP signalling. Once this is established, it may 
be interesting to determine whether BMP signalling is required for dorsal patterning of 
the telencephalon (i.e. the pallium, the dorsal telencephalon). In a cross of Pax6-GalPR 
to UAS-flognog, addition of RU486 at a pre-determined time-point to induce Flognog 
expression before, during and just after neural tube closure, may decrease BMP 
signalling in the developing telencephalon. Then, the effects of this decrease of BMP 
signalling on dorsal patterning of the pallium can be assessed by whole-mount in situ
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hybridisation for a panel of forebrain markers. These could include eomes and Tbrl, 
which both mark the whole of the pallium, and opl-1, a dorsal forebrain marker. To 
determine if there are any alterations in D-V patterning as a result of altered dorsal 
patterning, the pattern of ventral forebrain markers, such as X-dll3 and Nkx2.1 on cross 
embryos could be assessed.
Furthermore, phenotypes resulting from these binary crosses may be used as in 
vivo animal models of diseases, such as HPE or exencephaly to study the pathogenesis 
of these disorders.
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CHAPTER 6: GENERAL DISCUSSION
In conclusion, the utility of the GAL4/UAS binary system in Xenopus tropicalis has 
been demonstrated by analysis of the roles of BMP signalling during early neural 
development. Use of the transgenic “Ligand-trap” loss-of-function technique works to 
block BMP signalling and produce an expected phenotype in the Otx2-gal4 X UAS- 
flognog cross. The phenotype in the Otx2-gal4 X UAS-flognog cross and embryos from 
the Pax6-GalPR X UAS-flognog cross that are induced with RU486 are evident as viable 
double transgenic embryos. The viability of the double transgenics from these crosses 
illustrates the usefulness of the GAL4/UAS system to avoid lethality associated with 
early functions of BMPs. Here, the effects of mis-expression of Flognog, a ligand trap 
for BMPs, during early neural development have been demonstrated. The Pax6-GalPR 
transgenic was generated to be able to assess the initial question about the effects of 
BMP signalling during late CNS development, e.g. to analyse the late BMP signalling 
source hypothesised to be involved in patterning of the dorsal telencephalon.
6.1 Usefulness of the GAL4/UAS Transcriptional Binary Approach
Consistent with previous studies by Hartley et al. (2002), the binary approach tested 
here allows spatial and temporal manipulation of gene expression in vivo. Lines were 
identified that induced high enough levels of GAL4 to induce target gene expression in 
all presumed double transgenics (e.g. Figs. 3.3; 3.4; 4.5). However, phenotypes were 
displayed with variable severity (eg. Fig. 5.1), making them hard to interpret. In 
agreement with the system observations by Brand and Perrimon (1993), this variability 
could be attributed to GAL4 expression directed by the Otx2 promoter. Thus, although
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phenotypes can be observed, due to problems with phenotype variability resulting in low 
numbers displaying effects, the GAM binary system may not be an optimum approach 
for gene function analysis. However, the possibility to increase the level of transcription 
with the Pax6-GalPR transgenic line, may allow more embryos to display phenotypes in 
crosses of this inducible transactivator to a UAS effector.
6.2 Binary Transgenics to Analyse Late CNS Development
The use of the Pax6-GalPR X UAS-flognog cross will allow manipulation of gene 
function, and hence BMP signalling, at later stages of neural development, at least from 
after gastrulation and at later time points. This will be particularly useful because, 
primarily, it will allow the analysis of whether a gradient of BMP signalling is required 
for dorsal patterning of the telencephalon. Furthermore, as RU486 has been found to 
induce GalPR driven expression into late tadpole stages (Chae et al., 2002), even later 
roles of BMP signalling during late CNS organogenesis can be assessed. Thus, roles of 
BMP signalling in D-V patterning in forebrain development and other areas of forebrain 
development, which still remains unclear, could be elucidated.
6.3 Other Binary Cross Uses of the UAS-flognog Transgenic
Firstly, UAS-flognog lines have been made that can be used together with Otx2-gal4 
transactivator in a binary cross to down-regulate BMP signalling in the anterior 
neuroectoderm to investigate neural differentiation and patterning, and the utility of the 
binary approach.
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Recently, by using a Xenopus DNA microarray approach, over-expression of a 
dominant negative BMP receptor in ectodermal cells, has allowed the identification of 
new targets of BMP signalling (Shin et al., 2005). However, there are BMP target genes 
that are not known. Therefore, another potential use of the UAS-flognog line is in DNA 
microarrays to search for BMP signalling target genes. Since, it has been demonstrated 
that BMP signalling is down-regulated in the Otx2-gal4 X UAS-flognog cross (Fig. 4.7), 
it is feasible to seach for BMP signalling target genes in the anterior neuroectoderm 
using the Otx2-gal4 X UAS-flognog binary cross. Furthermore, the loss of BMP 
signalling by BMP2, BMP4 and GDF5-7 BMPs by Flognog may allow more targets of 
BMP signalling during early neural differentiation and patterning to be identified.
Furthermore, UAS-flognog can be used in crosses to other promoter-gal4 
transactivator lines to block BMP signalling in a tissue-specific manner to ask questions 
about other biological processes.
6.4 Use of Different Types of Stable Xenopus Lines to Analyse 
Development in other Tissues
Due to the many biological processes that BMP signalling is involved in (Hogan, 1996), 
crosses of the different tissue-specific transactivator lines generated here N-tubulin-gal4, 
N-tubulin-galPR (see Appendix II) and Rx-gal4 to the UAS-flognog line can be used to 
block BMP signalling in different tissues and unravel the role of BMP signalling in 
these tissues. For example, BMP has a role in D-V patterning of the eye (Koshiba- 
Takeeuchi et al., 2000; Sasagawa et al., 2002; Murali et al., 2005; Sakuta et al., 2001). 
BMP overexpression in the retina has a strong dorsalising effect (Koshiba-Takeeuchi et
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al., 2000; Sasagawa et al., 2002), while BMP inhibition ventralises the eye (Murali et 
al., 2005; Sakuta et al., 2001; Sasagawa et al., 2002). Others have found that Bmp 
receptor lb is required for axon guidance and cell survival in the developing retina (Liu 
et al. 2003). Therefore, use of Rx-gal4, N-tubulin-gal4 and N-tubulin-galPR 
transactivator crosses to UAS-flognog will be a valuable model to expand on the 
mechanisms of these processes and clarify the roles BMPs play in dorso-ventral 
patterning of these other tissues.
6.5 Limitations of Xenopus Transgenic Lines
Finally, although the trangenesis method used here together with the production of 
stable lines offers a valuable technique to analyse gene function, it is time- and space­
consuming to grow many lines. Transgenesis in other organisms, such as mouse or 
zebrafish cannot be used as an alternative model system because it produces mosaic 
animals. There have been some further advances in the Xenopus transgenesis technique 
to improve the integration efficiency of transgenes into the genome by using I-Scel 
meganuclease or <)>C31 integrase-mediated integration (Ogino et al., 2006; Allen and 
Weeks, 2005). These new techniques result in a high amount of founder embryos 
displaying non-mosaic transgene reporter expression, and allow founder transgenics to 
be used for reporter assays or misexpression experiments. Although this does not make 
the GAL4/UAS approach easier because GAL4/UAS depends on the use of two 
independent lines, it will allow quicker analysis of gene function in developmental 
processes.
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Another limitation using the binary approach together with the lines developed 
here is that the transgene expression pattern is constrained by the limited specificity of 
the available promoters, and this may not allow refined spatial manipulation of gene 
function. Recently, new ternary techniques have been implemented that place binary 
gene activation under the control of a third component. The combinatorial “Split Gal4” 
system can limit transgene expression to the intersection of two distinct, but overlapping 
expression patterns from two different promoters (Luan et al., 2006). The system takes 
advantage of the modular nature of the GAM transcription factor, and puts the DNA- 
binding domain and the activation domain of GAM under the control of different 
promoters. Consequently, only in cells co-expressing both domains of GAM can the 
two domains heterodimerise and become transcriptionally competent, thus activating 
expression from a UAS-target gene in tissues where expression from the two promoters 
overlap. Although, this system has been implemented in Drosophila, there is no reason 
it cannot be used in genetic model organisms, such as Xenopus, where it has been 
demonstrated here that similar transcriptional systems for controlled gene expression do 
exist.
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APPENDIX I: Characterisation of N-tubulin-GalPR
Hormone-Inducible Transactivator
1.1 Generating and Testing the N-tubulin-GalPR Transactivator
An N-tubulin-GalPR construct containing the Xenopus N-tubulin promoter (Richter at 
al., 1998) and GalPR, a hormone-inducible GAL4 (Wang et al., 1994) was made 
(Section 2.2.1). Subsequently, using transgenesis as described by Hirsch et al. (2002), 
N-tubulin-GalPR F0 transactivator transgenics were made. In one transgenesis 
experiment, there were 12/37 embryos containing GFP in the lens due to the y- 
crystallin-gfp reporter, indicating that the transgenesis rate was 32%. Of the 12 founder 
transgenic embryos identified, 11 contained GFP in both the lens, and one embryo 
displayed GFP in one of the lens, suggesting that it was a half transgenic. The N- 
tubulin-GalPR transgenic tadpoles were raised to adulthood (Section 2.1).
An N-tubulin-GalPR transactivator was tested for its transactivation potential by 
crossing to a homozygous UAS-gfp reporter transgenic line. The embryos from this 
cross were incubated in 0.5pM RU486 from the 4 to 8 cell stage. At tadpole stages, 
GFP was detected in the brain, spinal cord, and lens in N-tubulin-GalPR X UAS-gfp 
cross embryos (Fig. II A), that contained RFP in the somites from the CAR-RFP 
reporter from the effector transgene (Fig. II C). No GFP was detected in sibling N- 
tubulin-GalPR X UAS-gfp cross embryos (Fig. II B), that, again, contained RFP in the 
somites (Fig. II D). This result suggests that the N-tubulin-GalPR transactivator can 
transactivate GFP from a UAS-gfp reporter line in the presence of RU486.
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N-tubulin-GalPR X  UAS-gfp
0.5pm RU486
GFP No GFP
Figure II N-Tubulin-GalPR Hormone-inducible GAL4 Transactivator Activates 
GFP from a UAS-gfp reporter in the Presence of RU486
Images are either GFP (or RFP) fluorescence microscopy (A, B or C, D ) or brightfield 
(E, F) o f tadpoles from a cross o f N-tubulin-GalPR  transgenic founder X  UAS-gfp 
reporter frog, incubated in 0 .5 jliM  RU486. GFP is detected in primary neurons in the 
brain and spinal cord (and in the lens) (A) in an N-tubulin-GalPR  X UAS-gfp cross 
embryo incubated in 0.5pM  RU486 which contained RFP in the somites (C). The white 
arrow illustrates GFP in the anterior brain (A). No GFP was detected in a sibling N- 
tubulin-GalPR  X  UAS-gfp cross embryo (B), which contained RFP in the somites (D), 
and was also incubated in 0.5pM  RU486. E, F represent brightfield images o f A, C, and 
B, D respectively.
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1.2 Discussion
An N-tubulin-GalPR transactivator has been established that can be used to drive 
expression in the primary neurons, in a RU486-inducible manner. This will allow the 
functions of (pleiotropic) signalling molecules to be analysed by the ligand trap 
approach in these specific tissues at later stages in development, in an inducible manner 
(see sections 6.4 and 3.3.3).
Studies have reported that basal transactivation by endogenous hormones can be 
a problem at tadpole stages (Osterwalder et al., 2001; Chae et al., 2002; Das and 
Brown, 2004). It was not determined whether basal transactivation of UAS-gfp 
occurred. Also, the timing of gene expression in response to a dose-range of RU486 
was not carried out, so this should be established for further use of this system.
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